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Abstract
Photochemical internalisation (PCI) is a technique which enhances targeted drug
delivery using light in combination with a photosensitiser. It is a modification of
photodynamic therapy (PDT) which involves sub-lethal photodynamic treatment to
modify the intracellular distribution of co-administered drugs and other agents which
are sequestered in lyso/endosomes. In this study, PDT and PCI using a sulfonated
chlorin, Amphinex
TM (TPCS2a), in combination with two anti-cancer drugs, saporin or
bleomycin, have been investigated both in vitro and in vivo.
In vitro experiments initially examined the cell uptake, photostability and cellular
localisation of Amphinex using A431 human epidermoid carcinoma cells and HN5
human head and neck squamous cells. The cell killing effect after PDT and PCI in the
presence of saporin and bleomycin were assessed. The bioavailability and therapeutic
efficacy were also compared with another two PCI photosensitisers, TPPS2a and
AlPcS2a. The results indicate that PCI is able to induce the relocalisation of bleomycin
and saporin inside cells and thereby enhance cell death.
A new porphyrin-peptide bioconjugate of a cell penetrating peptide (CPP) and
tetraphenylporphine was investigated for PDT and PCI. It was found that CPP peptide
conjugation renders efficient cellular delivery of the tetraphenylporphine for use as a
PDT and PCI sensitiser.
The pharmacokinetics of Amphinex in normal and tumour-bearing rats was studied
using quantitative fluorescence microscopy and chemical extraction. In vivo Amphinex
PCI effects and the comparison with PDT were investigated in normal rat liver, colon
and a syngeneic rat fibrosarcoma tumour models. Amphinex PCI showed a significant
enhancement in inducing damage to normal tissues and tumour. The involvement of
apoptosis was also established using the TUNEL assay.
This thesis has demonstrated that Amphinex has favourable properties for PDT and PCI.
The consistent results from both in vitro and in vivo experiments indicate that
Amphinex has the potential for further clinical utilization.4
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SectionA: Background and Introduction21
Chapter 1: Photodynamic Therapy22
1.1 General Introduction and Early History
Photodynamic therapy (PDT) is a promising treatment which induces damage to the
target tissues by using photosensitive drugs with the activation of light. In the presence
of sufficient oxygen, cytotoxic agents can be produced upon illumination and initiate
the photodamage to tissues. Each component is essential and their combination can
achieve a site-specific treatment by the fact of the limited irradiation area.
Although it was only in the last century that PDT began to be used in oncology, the
attempt to combine light and certain chemicals to treat illness can be traced to thousands
of years ago. Dolmans et al. have summarised the early history of PDT in this review
[Dolmans et al., 2003]. In ancient Egypt, India and China, people have used light to deal
with several diseases such as psoriasis, rickets, vitiligo and skin cancer. The beginning
of modern ‘phototherapy’ is considered to be in 1903 when a Danish doctor, Niels
Finsen, was awarded the Nobel Prize for his work on phototherapy [Finsen, 1901]. Sun
light was proven to be beneficial for treating smallpox and cutaneous tuberculosis
lesions. In fact, evidence for the therapeutic effects triggered by the combination of
chemicals and light has been reported since the early 1900s. Using acridine or eosin
together with light exposure could cause the killing effect on microorganisms (infusoria)
or skin tumours [Raab, 1900;von Tappeiner and Jesionek, 1903]. A few years later, the
term ‘photodynamic action’ was first mentioned by von Tappeiner and Jesionek to
describe this photosensitised reaction in biological systems [von Tappeiner and
Jodlbauer, 1907]. Since then, more and more studies have been carried out and
haematoporphyrin, a compound with a porphyrin structure, was found to be one of the
most powerful photosensitising agents [Figge et al., 1948;Meyer-Betz, 1913].
The purification of haematoporphyrin was another step forward for PDT treatment.
Haematoporphyrin derivative (HpD) was isolated by Schwartz et al. [Schwartz et al.,
1955] and exhibited better tumour localisation properties [Lipson et al., 1961]. Another
breakthrough happened in 1975 when Dougherty and Kelly independently demonstrated
that the combination of HpD and red light could eradicate tumour growth using animal
tumour models [Dougherty et al., 1975;Kelly et al., 1975]. One year later, Kelly and his
co-workers began the first human trial with HpD PDT in bladder cancer [Kelly and
Snell, 1976]. The clinical application of PDT was soon expanded for treating many23
other early-stage cancers, and PDT with Photofrin
® (Porfimer sodium), a further
partially purified HpD, was first approved for treatment of bladder cancer in Canada in
1993. Until now, Photofrin
® is the most extensively studied photosensitiser, and has
been licensed for use in lung cancer, superficial gastric cancer, oesophageal
adenocarcinoma, cervical cancer, and bladder cancer among many countries [Brown et
al., 2004].
However, Photofrin
® is a mixture of monomers, dimers, and oligomers involving ester
and ether linkages [Byrne et al., 1990]. It is difficult to reproduce the same composition
and to identify the therapeutic effect attributed to individual constituents. Moreover, it
has a relatively low extinction coefficient in the red light region and the problem of
prolonged skin photosensitivity in patients. As a result, the need for new
photosensitisers has arisen and research has aimed for the development of sensitisers
with improved properties, e.g. chemically pure, with stronger absorbance at longer
wavelength, better tumour specificity and less skin photosensitivity etc. These
sensitisers are called second-generation photosensitisers [Moser J.G., 1998] whose basic
structures include porphyrins, chlorins, bacteriochlorins and phthalocyanines.
PDT has gone through an era of rapid development since the early approaches to human
cancer. The use of diode lasers certainly benefits PDT treatment in many aspects. This
intensive, coherent and monochoromatic light source provides efficient and reliable
light delivery. A combination with other fibre optic delivery systems also broadens the
approachable locations of human disease. To date, PDT has accumulated substantial
experiences either in preclinical experiments or clinical studies as a cancer therapy.
There several drugs originally developed for PDT which are now clinically approved, as
listed in Table 1.1: 5 in oncology, one for fluorescence diagnosis (Hexvix) and two for
non-malignant disorders. Several drugs are currently under clinical trial investigation.
PDT seems to be a profound modality which can deal with solid tumours appearing in
almost all anatomical sites. However, the lack of standard dosimetry and the difficulty
in establishing its optimum use have made PDT remain marginal [Brown et al.,
2004;Zhu and Finlay, 2008]. The inherent complexity of PDT mechanism is believed to
be one of the main reasons. PDT already involves light, photosensitiser and molecular24
Table 1.1 Approved PDT drugs for oncology, fluorescence diagnosis and benign disorder [Berg et al., 2005b;Brown et al., 2004;Juzeniene
et al., 2007].
Chemical name Tradename Time of approval Indications
Haematoporphyrin derivative
(HpD), porfimer sodium
Photofrin First approved in 1993;
now approved in a
number of countries
Lung cancer, superficial gastric cancer,
oesophageal adenocarcinoma, cervical
cancer, bladder cancer
Meta-tetrahydroxyphenyl
chlorin (m-THPC),
temoporfin
Foscan Approved in EU, Norway
and Iceland in 2001
Head and neck cancer
5-aminolevulinate (ALA) Levulan Approved in USA in
1999
Actinic keratosis of face and scalp
Methyl aminolevulinate Metvix Approved in EU and
Australia in 2001
Actinic keratosis, basal cell carcinoma
Oncology
Aluminium sulfonated
phthalocyanine (AlPcS)
Photosense Approved in Russia Head and neck cancer
Diagnosis Hexyl aminolevulinate Hexvix Approved in Sweden
(2004) and EU (2005)
Fluorescence diagnosis of bladder cancer
Non-
malignant
disease
Benzoporphyrin derivative
(BPD), Verteporfin
Visudyne Approved in 2001 in
more than 70 countries
Age-related macular degeneration25
oxygen. These components not only can change during treatment but also can influence
each other. The variations are also the causes of some conflicting treatment results.
Research has focused on the understanding of the fundamental mechanisms of PDT in a
view of chemistry, biology and physics. The development of nanotechnology, molecular
biology and the improvement of light sources and detection techniques can certainly
improve drug uptake and localisation, standardise treatment protocols and establish
optimal dosimetry.26
1.2 Mechanism of Actions - Photosensitisation
1.2.1 Photochemistry
The photocytotoxic effect of PDT is caused by a series of photochemical reactions
including the excitation of photosensitiser under light exposure and the interaction with
surroundings by energy transfer. Figure 1.1 illustrates the process of photosensitisation
using the Jablonski diagram. With the absorption of light (a), photosensitisers are
excited from the ground state (S0) to a higher energy state, singlet state (S1). The
photomolecules can thereafter decay to the ground state by emitting fluorescence (b) or
to the triplet state (
3S) via intersystem crossing (c). The energy transition from the
singlet state to triplet state is unusual because it requires a change of electron spins.
However, the fully conjugated double bond system (the macrocyclic structure) of
photosensitisers allows this exception. Moreover, because the transition to return to the
much lower ground state energy level from the triplet state is “quantum mechanically
forbidden”, photomolecules can remain in the triplet state with a longer lifetime than the
singlet state. Eventually sensitisers at triplet state will slowly relax back to the ground
state either via emitting phosphorescence (d) or internal conversion (g).
Figure 1.1 Jablonski diagram depicting the photophysical processes following
photosensitiser excitation, together with Type I and Type II mechanisms. S0:
photosensitiser in a ground state, S1: photosensitiser in a singlet excited state,
3S:
photosensitiser in a triplet excited state, R: substrate, S
-: reduced photosensitiser
molecule, R
+: oxidised substrate, O2
-: superoxide anion, O2
•: superoxide radical,
3O2:
triplet ground state oxygen,
1O2: singlet excited state oxygen, R(ox): oxidised substrate.
Ground state
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(a) excitation
(b) fluorescence
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1O2
f )
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Triplet state27
Excited triplet photosensitisers (
3S) can react with neighbouring substrates (R) and
generate reactive oxygen species (ROS) which lead to cytotoxic effects. This is known
as the type I mechanism. In an oxygen-rich environment,
3S can also transfers its energy
to the oxygen molecule (e) to an excited state called singlet oxygen (
1O2) which is
highly active and can directly oxidise surrounding substrates (f). This process is
classified as type II mechanism.
1.2.2 Singlet oxygen
Oxygen has a unique triplet ground state (
3O2) because its two unpaired electrons reside
in separate orbitals (Px* and Py*) in order to comply with the Pauli exclusion principle,
resulting in three possible configurations: both spin aligned up or down or one up and
one down (Figure 1.2). Two electrons can be paired together in the same orbital when
the spin of one electron is inverted during the interaction with excited photosensitisers.
The energy transfer produces singlet oxygen (
1O2) which is not stable and thus
extremely reactive.
Figure 1.2 Molecular orbital diagrams of the electron distribution in triplet and singlet
oxygen [MacDonald and Dougherty, 2001].
Although type I and type II mechanisms can take place simultaneously and the balance
is driven by the surrounding substrates, the concentration of oxygen, as well as the
sensitisers themselves, indirect or direct evidence from in vitro and in vivo experiments
have proved the importance of singlet oxygen during the photosensitisation process
[Juzenas and Moan, 2006;Niedre et al., 2002]. In fact, the significance of singlet oxygen
in PDT treatment was already acknowledged in the early stage of PDT treatment since28
1976 [Weishaupt et al., 1976]. Singlet oxygen was proposed responsible for the
cytotoxicity of PDT in tumour cells.
The lifetime of singlet oxygen in organic solvents can be up to tens of μs but it is only
2-3 μs in aqueous solutions [Egorov et al., 1989], and even lower in cells which means
that the reaction area inside cells is confined [Moan and Berg, 1991;Moan, 1990]. On
one hand, this character restricts the photodynamic damage to the nearby region where
sensitisers locate; on the other hand, it gives PDT a low probability to cause genome
toxicity [Evans et al., 1997] since cell nucleus is not a favourable accumulation site for
most of the photosensitisers [Moan, 1986].
1.2.3 Photosensitisers and the singlet-oxygen quantum yields
Photosensitisers are chemicals which can be activated by irradiation and then transfer
the energy to other molecules. This photo-sensitive character is attributed to their back
bone chemical structures. Figure 1.3 shows the structure of the most common
photosensitisers used for PDT: porphyrin, chlorin, bacteriochlorin and phthalocyanine.
Figure 1.3 Basic structures of porphyrin, chlorin, bacteriochlorin and phthalocyanine.
These compounds are usually planar and aromatic. The core structure is called
‘macrocycle’ which is composed of four pyrroles linked by azone bridges in the case of
phthalocyanine or by methine bridges for the others. They are all fully conjugated with
double bones (π-electrons). The extensive aromatic (i.e. π-conjugation) structure
enables photomolecules to absorb light in the visible spectrum region. The absorption
spectra among these compounds are similar with a strong peak at around 400 nm called
Soret band and other weaker bands between 600 nm and 800 nm called Q-bands.
Generally, red light is preferable for clinical use because blue light penetrates tissue less
efficiently and there is a large attenuation of the absorbance up to 580 nm by29
haemoglobins. The extended π-conjugation in these molecules results in lower
electronic repulsion and therefore lowers the energy of the molecular states involved. A
lower transition energy (ΔE) results in longer wavelength absorption according to the 
equation ΔE = hc/λ where the energy of light is inversely proportional to the wavelength
λ (h is Plank’s constant and c is the speed of light). Porphyrins have more π-electrons
than other photosensitisers because the others have reduced double bonds (chlorin has
one double bond reduced and bacteriochlorin and phthalocyanine have two double
bonds reduced). As a result, the maximum absorption of porphyrin is around 630 nm,
shorter than the peak absorption of chlorin at 650nm and phthalocyanine at 670 nm.
Several studies have demonstrated that the small changes in wavelength can lead to
improvements in the clinical outcomes such as the increase of penetration depth and the
consequent larger treatment volume [Lee et al., 1995;Pantelides et al., 1990]. Based on
this advantage, among the 2
nd generation sensitisers, chlorin and phthalocyanine are
believed to be two of the most efficient photosensitisers for in vivo and clinical
applications.
There have been many chemical approaches to increase the bioavailability of
photosensitisers by the co-ordination with metal irons in the centre or the substitution of
the peripheral pyrrole rings on the four methine carbons. These synthesised complexes
are meant to have better properties for PDT in many aspects such as improved solubility
and stability. For instance, the introduction of sulfonate groups to tetraphenylporphine
(TPPSn) and aluminium phthalocyanine (AlPcSn) reduces the tendency of
photosensitiser aggregation. Among those sulfonated sensitisers, disulfonated
tetraphenylporphine (TPPS2a) and aluminium phthalocyanine (AlPcS2a) have the
amphiphilicity which creates their cellular localisation to membranes because of the
hydrophobic and hydrophilic interfaces [Margaron et al., 1996]. This feature has been
exploited for photochemical internalisation (PCI) which achieves drug/gene delivery by
photosensitisation [Berg et al., 2003;Hogset et al., 2004] and is also the theme of this
thesis study. The details of PCI will be described later.
A good photosensitiser should not only exhibit high absorbance of light activation but
also yield a high quantity of singlet oxygen after the energy transfer through its triplet
state formation. This property is called singlet oxygen quantum yield (ΦΔ) which is
recognised as one of the main determinant of effectiveness of photosensitisers for PDT.
A direct method to measure the singlet oxygen is to detect the phosphorescence emitted30
at 1270 nm when singlet oxygen returns to the ground state. Measurements can be
carried out in water or organic solvents for longer lifetimes [Tanielian et al., 1996]. In
Chapter 5, this technique was also used to investigate a new porphyrin-peptide
conjugate for PDT and PCI.
Although the importance of singlet oxygen in PDT has been recognised since 1976
[Weishaupt et al., 1976], early attempts to directly measure the ΦΔ generated in vivo
were not successful due to insufficient detection sensitivity [Patterson et al., 1990]. It
was until the innovation of the near-infrared (NIR) photomultiplier tube by Hamamatsu
that direct measurement of the singlet oxygen production in vitro and in vivo became
feasible and reliable [Niedre et al., 2002]. Despite no human or clinical data being
available yet, directly examining the singlet oxygen luminescence has received
considerable attention as a metric for PDT dosimetry along with other traditional
approaches such as measuring the photobleaching of photosensitisers or the ground-
state oxygen concentration [Jarvi et al., 2006].
The whole photosensitisation process is an incorporation of the involved components:
light, drug and oxygen. The therapeutic outcomes rely on how their interactions work
within the biological system. For example, at a cellular scale, the site of the intracellular
localisation of photosensitisers determines the location where initial photodamage takes
place. In animals or human beings, more biological and physiological factors such as
the pharmacokinetics of sensitisers, the light delivery and the treatment responses
including cell death or triggered inflammatory reaction will certainly influence the
overall efficacy of PDT treatment. The following section will discuss PDT on the basis
of biology.31
1.3 The Biology of Photodynamic Therapy
1.3.1 In vitro studies
1.3.1.1 Cellular uptake and subcellular localisation of photosensitisers
Cellular uptake of photosensitisers has been intensively studied during the past two
decades. For instance, the relationship between the molecular structure of sensitisers
and their extent of cellular uptake has been investigated using zinc phthalocyanines
[Margaron et al., 1996] and porphyrins [Oenbrink et al., 1988] in artificial membranes
and cells. The structure, charge and hydrophobicity of the photosensitiser are the factors
that determine the cellular uptake, subcellular localisation and phototoxicity.
In general, longer incubation time and higher drug dose can result in higher drug
accumulation in cells. Additionally, cellular uptake of photosensitisers is under the
influence of various parameters such as the temperature, the pH value, and the serum
concentration [Bohmer and Morstyn, 1985]. In their study, it was found that HpD
exhibited higher cellular uptake in the medium with acidic pH and lower serum
concentration. Lower temperature also seemed to inhibit the uptake of HpD in cells.
Using the chemical nature of HpD- a complex mixture of porphyrins, Kessel also has
reported the different pathways involved in the uptake of photosensitisers [Kessel,
1981]. The hydrophobic components of HpD displayed a rapid accumulation but they
were readily washed off from cells, whereas the hydrophilic components of HpD
presented a gradual accumulation with stronger affinity to cells. In this regard, different
mechanisms may operate the cellular uptake of different sensitisers.
Many photosensitisers are believed to enter the cell through endocytotic pathway and
target endo/lysosomal vesicles [Geze et al., 1993]. Based on the molecular properties,
several mechanisms of the cell entry and the lysosomal targeting of hydrophobic
photosensitisers were suggested. Firstly, highly hydrophobic photosensitisers such as
protoporphyrin, photofrin II, and phthalocyanines display some solubility in medium
containing serum. After being solubilised by binding with lipoproteins, for example
LDLs, sensitisers could be carried by these lipid proteins and localised within the
lysosomes. Secondly, photosensitisers with negatively charged or very polar structures,
such as the sulfonates of tetraphenylporphine and aluminium phthalocyanine, could32
possibly bind to the cell membrane by anionic-ionic interaction. The third group of
molecules comprises naturally lysosomotropic photosensitisers, such as Nile Blue
derivatives which would localise within lysosomes eventually. In fact, hydrophobic
photosensitisers, such as hypericin and m-THPC, have been reported to be able to enter
cells through passive diffusion when using serum free medium, whereas, in the presence
of serum, these sensitisers will bond to the serum proteins and result in endocytotic
cellular uptake [Friberg et al., 2003;Siboni et al., 2002].
Subcellular localisation of photosensitisers is crucial for effective PDT since the main
cytotoxic agent,
1O2, has a short lifetime and diffusion distance. Organelles including
Golgi, endoplasmic reticulum, mitochondria, lysosomes and membranes have been
reported as intracellular target sites for various photosensitisers [MacDonald and
Dougherty, 2001].
An adequate accumulation of photosensitisers in cells is essential for effective PDT.
The type of photodamage triggered after illumination is clearly dependent on the
subcellular localisation of the employed photosensitisers. Therefore, it is important to
understand the uptake and intracellular localisation of interesting photosensitisers.
Many of the sensitisers were found to be localised at lysosomes. The lysosomal
localisation is the main feature of the photosensitisers used for photochemical
internalisation (PCI). Amphiphilicity is the reason for this phenomenon. Details of this
group of photosensitisers will be addressed in Chapter 2 and Chapter 4 in the
experimental sections.
1.3.1.2 Cell death induced by photodynamic therapy
In general, there are two types of cell death: necrosis and apoptosis. The term of
‘apoptosis’ was firstly described in 1972 as a tight-regulated process of cell suicide
which involves series of signalling pathways either intrinsic or extrinsic [Kerr et al.,
1972]. Cells which undergo apoptosis are morphologically distinguishable by the cell
shrinkage, chromatin condensation and the formation of apoptotic bodies. DNA
fragmentation is also one of the features that ‘DNA ladder’ can be found upon gel
electrophoresis. In vivo, apoptotic bodies are engulfed by phagocytes without the33
participation of tissue inflammation. Apoptosis happens naturally and is a regulated
process. The loss of regulatory ability (either inhibited or unrestrained) can lead to
diseases such as cancer or neurodegenerative disorders [Gorman et al., 1996;Guchelaar
et al., 1997]. Stresses from the outside environment such as chemicals, radiation or heat
can also induce apoptosis [Robertson and Orrenius, 2000;Verheij and Bartelink,
2000;Zhuang et al., 2000].
In contrast to apoptosis, necrosis is a more acute process which causes cytoplasmic
swelling, destruction of organelles and inflammation in vivo. After PDT treatment, it
was found that cells can die through necrosis or apoptosis or the combination of both
pathways, but lower dose of PDT is believed to be capable of inducing efficient
apoptosis in many cases [Oleinick and Evans, 1998]. Since the first report of PDT-
induced apoptosis [Agarwal et al., 1991], numerous investigations of the occurrence of
apoptosis have been carried out. The initiation of this process and the engaged
mechanisms differs depending on the photosensitiser, its subcellular localisation and
other circumstances. Figure 1.4 shows some of the PDT-induced apoptosis pathways
and the involved signalling molecules, particularly associated with mitochondria.
Mitochondria appear to be the central organelles in relation to most of the apoptotic
mechanisms. Sensitisers, such as Photofrin [Wilson et al., 1997] and Pc4 (Silicon
phthalocyanine) [Trivedi et al., 2000], were found to accumulate at various
compartments in mitochondria and evoke mitochondria-mediated apoptosis after
photosensitisation. As shown in Figure 1.4, the mechanism begins with the release of
cytochrome c oxidase into cytosol, assembles a complex with dATP, APAF-1
(apoptosis-activating factor-1) and pro-caspase 9 and generates active caspase 9, which
in turn cleaves pro-caspase 3 to form caspase 3. Caspases (cycteine protease acting on
aspartic acid), a family of proteases, are principle enzymes in the apoptosis process.
Among them, caspase 3 is the key protein which is responsible for the cleavage and
activation of other downstream caspases, leading cells to apoptosis. The release of
cytochrome c immediately after photoactivation has been reported in many studies
using mitochondria localised photosensitisers [Granville et al., 1998;Kessel and Luo,
1999]. The collapse of mitochondria membrane potential upon PDT was also observed
in the later study which might be due to the opening of a large channel called
permeability transition pore (PTP) complex. Opening of the PTP complex can change34
the concentration of ions (e.g. Ca
2+) and may associate with the release of cytochrome c
[Green and Reed, 1998].
Figure 1.4 Some PDT-associated apoptosis pathways
A separate pathway through the cell surface receptor FAS also has been reported in the
induction of apoptosis in response to PDT [Granville et al., 1998]. A delayed activation
of caspase 8 was found whose downstream proteins can also induce the release of
cytochrome c and lead to the consequent caspase 3 activation (Figure 1.4) [Granville et
al., 1999].
The critical influence of the subcellular localisation of photosensitisers on the apoptotic
mechanism has been demonstrated in a series studies conducted by Kessel and co-
workers [Kessel et al., 1997;Kessel and Luo, 1998;Luo and Kessel, 1997].
Photosensitisers which localise in mitochondria induced rapid apoptosis upon
illumination while sensitisers that bind to the plasma membrane or lysosomes displayed
non-apoptotic mechanisms and resulted in less efficient killing effects. In another study,
apoptosis was observed in the cells irradiated after 24hr incubation of Photofrin when
most of the drugs have been internalised, in contrast, necrosis was predominant in the
case of cells incubated with drugs for only 1 hr in which drugs were primarily in the cell
membrane [Dellinger, 1996].35
Further evidence was shown by Noodt et al. who compared the cell death mechanisms
induced after PDT with four sensitisers with different degrees of lipophilicity by
microscopic examination [Noodt et al., 1999]. After irradiation of sensitisers that
localised mainly at mitochondria, increasing number of apoptotic cells was detected
during the first 12 hr but apoptotic bodies were not observed. On the other hand,
apoptotic cells were not detected until after 12 hr but with the appearance of extensive
apoptotic bodies in the cases of using lysosome-localised photosensitisers. The results
imply that multiple mechanisms might be involved in the PDT-induced apoptosis.
Using Rose Bengal, a plasma membrane-localised photosensitiser, Zhuang et al. showed
that singlet oxygen was generated after the photosensitisation at the cell membrane and
stimulated the signalling for apoptosis via FAS receptor pathway [Zhuang et al., 1999].
This is also an example that the cellular localisation of sensitisers plays an important
role in the determination of apoptotic mechanisms induced after photoactivation.
There are still a number of other pathways and signalling molecules involved in the
regulation of cell death in response to PDT, such as Bcl-2 family proteins [He et al.,
1996;Kim et al., 1999] and lipid-derived second messengers ceramide [Separovic et al.,
1997;Separovic et al., 1998]. With the development of molecular biology techniques,
many convincing results have revealed the possible mechanisms participating in the
killing effects of PDT [Moor, 2000;Oleinick et al., 2002]. However, many details
remain unclear and require further investigations. It should be noted that some studies
have shown that cells could die after PDT treatment without undergoing apoptosis or
when some of the apoptotic pathways were blocked [Fisher et al., 1999;Xue et al.,
2007]. These results indicate that PDT may be beneficial for some tumours resistant to
certain apoptosis inducing chemotherapy or radiation therapy by providing a bypass
modality in vivo and in clinic practice. Although the in vivo data of cell death
mechanisms after PDT is limited, some studies have demonstrated that the situations in
vivo were in agreement with the ones in vitro [Colussi et al., 1999;Whitacre et al.,
2000;Whitacre et al., 2002].
Recently, another pathway was found to be associated with cell death after PDT
treatment. Cells lacking pro-caspase 3 can die after PDT by undergoing a non-apoptotic
or non-necrotic mechanism [Whitacre et al., 2002], known as autophagy. This process
was confirmed as the dominant cell death pathway when cells are incapable of36
undergoing normal apoptosis [Buytaert et al., 2006;Kessel et al., 2006]. Autophagy,
which literally means ‘self-eating’, is also a programmed cell death with the formation
of double-membrane vesicles called autophagosomes, encasing cellular constituents (e.g.
damaged organelles) [Tsujimoto and Shimizu, 2005]. It was initially discovered as a
survival response to nutrient depletion, but it can also provide a protective function
against several diseases and infections. When damage is extensive, damaged organelles
can be removed through the mechanism by the fusion of autophagosomes and
lysosomes/vacuoles, resulting in the lysis of the contents. As a consequence,
microscopic observation of autophagosomes (300-900 nm) is usually used as one of the
methods to characterise this mechanism. Several studies have demonstrated the
involvement of autophagy in response to PDT treatment [Kessel and Reiners, Jr.,
2007;Xue et al., 2008]. The later authors proposed that the release of calcium ion by the
damage of endoplasmic reticulum or mitochondria may initiate the pathway. Further
investigations still need to be carried out.
More discussion of the in vivo pharmacokinetics of photosensitisers and treatment
response to PDT will be shown in the next sections.37
1.3.2 In vivo studies
1.3.2.1 Pharmacokinetics of photosensitisers - accumulation, distribution and
clearance of photosensitisers in tissue/tumour
In PDT, the first generation photosensitisers haematoporphyrin derivative (HpD) and
Photofrin were both found to localise preferentially in tumours in the early stage when
discovered [Lipson et al., 1961] and have been well studied since then. As more and
more photosensitisers (so-called 2
nd and 3
rd generation photosensitisers) were identified,
detailed pharmacokinetics of sensitisers has been investigated and extensively reviewed
[Gomer, 1991;Jori, 1996;Kessel and Woodburn, 1993]. In summary, the biodistribution
patterns of photosensitisers are affected by the fundamental properties of sensitisers
themselves, the delivery system (the drug formulation and administration methods), and
the diverse physiological circumstances between different tissues or species etc. Among
them, the hydrophobicity of sensitisers is believed to be one of the major determinants
for the drug bioavailability.
Evidence has been reported of the association of hydrophobic porphyrin derivatives
(first generation photosensitisers) and plasma low-density lipoprotein (LDL) [Barel et
al., 1986;Jori and Reddi, 1993;Kessel, 1986]. This lipid-type transport system certainly
contributes to the enhanced tissue uptake of such photosensitising compounds.
Moreover, as many tumour cells and certain normal tissues including liver and kidney
contain more lipoprotein receptors on the cell surface, the LDL-mediated pathway
should favour the accumulation of these sensitisers in those tissues [Maziere et al.,
1991;Norata et al., 1984].
Other pathways were also suggested as a few 2
nd generation photosensitisers, NPe6
(mono-N-aspartyl chlorine e6), m-THPC (meso-tetraphenylporphyrin tetrasulfonate),
and AlPcS4 (Aluminium phthalocyanine tetrasulfonate), which are water-soluble but
exert great tumour localisation, were found in strong affinity for albumin [Kessel et al.,
1992;Kongshaug, 1992]. Thus, there should be multiple mechanisms for the in vivo
uptake of sensitisers in respect of their basic features.
Another aspect to be noted is that tissue accumulation results from both localisation and
retention. For instance, the initial concentration of Photofrin in malignant tissues was38
found to be low but elevated values for the ratio of tumour to normal was observed with
time, resulting in preferential retention [Bellnier et al., 1989]. Pottier et al. have reported
the influence of tissue and cellular pH value on the biodistribution of porphyrins [Pottier
and Kennedy, 1990]. Thomas and Peng have independently demonstrated that lowered
pH induced by multiple injection of glucose could facilitate HpD or Photofrin retention
in vivo [Peng et al., 1991;Thomas and Girotti, 1989]. Hyperglycemic tumours in
animals with decreased pH resulted in increased photosensitiser uptake and consequent
enhancement in tumour killing. In fact, the intracellular pH (pHi) was measured slightly
more basic than the extracellular pH (pHe) in tumour tissues [Gerweck and
Seetharaman, 1996]. It is proposed that the decreasing pHe in tumours would make
drugs lose their charges and diffuse freely into cells. Further more, the relatively basic
intracellular compartment would make drugs ionized again and trapped inside cells.
This mechanism might explain why the acidity of tumour favours the uptake of some
photosensitisers.
The administration methods would also affect the drug localisation substantially. In
order to ease the skin photosensitivity caused by HpD and achieve higher uptake of
drugs in tumours, Amano et al. injected drugs intratumourally (i.t.) into mouse bladder
tumours, comparing the effect of intraperitoneal injection (i.p.) [Amano et al., 1988].
Several studies also have compared the PDT effect of Photofrin following these two
administration modes using different animal tumour models [Brand et al., 1990;Gibson
et al., 1990a]. Although, the i.t. route can in some cases be better than i.p. as the former
resulted in higher photosensitiser accumulation in tumours and greater photodynamic
damage to tumours, the non-uniform intratumoural distribution using i.t. will be a
disadvantage.
Systemic delivery of photosensitisers is the most adopted administration routes for PDT
as drugs could be distributed to tissues with sufficient amount at times regardless of
their location (depth) in the body. Another approach, topical administration, is used
widely for PDT in superficial skin disorders. In particular, topical application of ALA
(5-aminolevulinic acid) or methyl-ALA has been successfully used for a variety of
neoplastic skin diseases [Donnelly et al., 2008]. It is because the drug can be given to
the areas of interest within a short interval and without undesirable cutaneous
photosensitivity caused by the prolonged drug accumulation from systemic injection. In39
fact, topical delivery of methyl-ALA has gained clinical approval for treating skin
cancer in Europe (Table 1.1).
2
nd generation of photosensitisers were introduced to overcome the drawbacks of HpD
and Photofrin including the problems of impurities, low absorbance at red spectral
region and prolonged skin photosensitivity. Over the past two decades, there have been
numerous pharmacokinetic studies of these sensitisers using different analytic methods
on various animal models or on humans. Researches also have focused on the
correlation of the biodistribution photosensitisers with their biological effects and
photodynamic activities [Barr et al., 1991].
For instance, m-THPC, one of the most powerful photosensitisers, has been intensively
studied in animals and humans in the aspects of the biodistribution and treatment
efficacy. Glanzmann et al. have compared the pharmacokinetics of m-THPC using LIFS
(light induced fluorescence spectroscopy) and its PDT effect in hamster cheek pouch
and human oral mucosa [Glanzmann et al., 2000]. The kinetic patterns were observed to
be similar in both normal tissues where the maximum uptake is between 3-6 days.
However, a quantitative difference was observed of the same drug dose (3 times higher
concentration in human mucosa) as well as the different photodynamic responses in
each tumour tissue. It should be noted the drug administration for hamsters was
intracardiac (i.c.) and it was i.v. for humans.
Another pharmacokinetic study using
14C-labelled m-THPC in transplanted
fibrosarcoma in rats was carried out by Jones and her colleagues [Jones et al., 2003].
There seemed to be three half-lives of m-THPC according to the plasma
pharmacokinetics and the peak drug concentration in tumours at 24hr after i.v. injection.
PDT treatments at 24hr post injection induced the most tumour growth delay which is
correlated to pharmacokinetic results. However, treatments at 2hr after injection also
achieved significant tumour growth inhibition. Taking the kinetic results and treatment
efficacy together, it is suggested that multiple mechanisms might be involved in m-
THPC PDT – vascular effect dominates the early-time treatment on tumour while the
majority of sensitisers were accumulated in the circulating system; direct cell killing
contributes the tumour eradication in the longer-term treatment while most of the
sensitiser was localised inside tumour cells.40
There also have been attempts of using polymer-sensitiser conjugates to improve the
bioavailability and delivery of many photosensitisers. Brasseur et al. examined the
pharmacokinetics of hydrophobic aluminium phthalocyanine and its water-soluble
polyethyleneglycol or polyvinylalcohol conjugates (AlPc-PEG or AlPc-PVA) by
chemical extraction in tumour bearing mice [Brasseur et al., 1999]. A higher retention
in the reticulo-endothelial system (liver and spleen) was found compared to other
organs in all compounds. AlPc-PVA exhibited the lowest drug level in the RE system,
the longest plasma half-life, and the highest concentration of tumour-to-skin ratio
among the three. AlPc alone reached the peak uptake in tumour at 6-24hr after i.v.
injection while AlPc-PVA was accumulated the most at 24hr and remained stable for 1
week.
This study demonstrates the influence of the conjugation with polymer on the
pharmacokinetics of photosensitisers. In fact, the incorporation of carriers (e.g.
dendrimers, micelles, liposomes and nanoparticles) with photosensitisers has been
exploited rapidly and become one of the major branches PDT development at present
[Sibani et al., 2008]. A common aim of these strategies is to perform enhanced
permeability and retention (EPR) effect, resulting in better diffusion and retention of
photosensitisers within tumours [Iyer et al., 2006]. Other approaches, linking
photosensitising compounds to targeted ligands such as antibodies or peptides, have
also been designed to achieve specificity [Schneider et al., 2006;van Dongen et al.,
2004]. In chapter 5 of this thesis, a porphyrin-peptide conjugate was synthesised to
benefit the cellular uptake. Another conjugate coupling photosensitiser with protein
toxin was also synthesised for photochemical internalisation. More details about
photosensitiser conjugates will be discussed in Chapter 5.
1.3.2.2 The anti-tumour effects of photodynamic therapy and the immune
responses
The killing effect of PDT is initiated by the cytotoxic species generated from the
photochemical reactions after illumination. The anti-tumour effects of PDT can be
categorised into three processes: direct cytotoxicity, vascular effect and immune
responses. These three factors are interdependent and together result in the overall
outcome while individual contribution is difficult to define [Nowis et al., 2005].41
The direct cell death following PDT in vivo shows similarity with the in vitro situation.
Necrosis or apoptosis can be induced through the photodamage. It is generally believed
that higher light dose or drug dose has the tendency to cause necrotic cell death.
Evidence for the switch from apoptosis to necrosis under increasing PDT doses has
been shown using several photosensitisers [Lavie et al., 1999;Vantieghem et al., 1998].
Strategies which manipulate the light fluence rate, the drug-light interval or other
parameters have established enhanced PDT efficacy in vivo [Gibson et al., 1990b;Sitnik
et al., 1998;Tsutsui et al., 2002]. In a study of ALA-PDT, low fluence rate (with
extended irradiation or drug delivery time) was found to induce selective killing effects
in rat brain tumour, i.e. apoptotic damage to tumour and no detectable damage to
surrounding normal tissue [Bisland et al., 2004].
As oxygen is the key factor in PDT, reduced oxygen consumption using fractionated
illumination or low fluence rate has been documented in improving treatment outcome
[Foster et al., 1991]. It is suggested that the dark interval of the fractionation permits
reoxygenation of tissue [Tsutsui et al., 2002]. Higher oxygen concentration was also
detected using lower fluence rate PDT in mouse tumour [Busch, 2006]. However, the
intratumoural oxygen level is not controlled by a single factor. The oxygen supplier, the
microcirculation of the tumour, plays a critical role in the final therapeutic efficacy of
PDT. In fact, the photodamage to the tumour vasculature is considered a marked
contributing effect in PDT.
Tumour growth is dependent on the blood supply, and therefore, approaches to achieve
vascular destruction have brought in new therapeutic opportunities for cancer therapy
[Siemann and Horsman, 2009]. In addition to the direct cell kill, the vascular effect of
PDT has been reported since early 1980s [Star et al., 1984]. By measuring the oxygen
level in tumour, Henderson et al. observed the ‘post PDT’ tumour hypoxia which
resulted in a profound tumour cure rate, and thus suggested the inactivation of tumour
cells is not limited to the direct PDT effect [Henderson and Fingar, 1987]. It was further
confirmed by Fingar et al. that an early photodynamic treatment (within minutes of
Photophrin injection) induced vascular damage [Fingar et al., 1992].
The response of the vascular devastation after PDT have been reported similar to the
inflammatory reactions after injury or infection [Korbelik, 1996]. The primary42
photodamage to the endothelial cells induce downstream chain events such as vessel
occlusion, the release of vasoactive molecules, leukocyte adhesion and blood flow stasis
and finally lead to ischemic death of tumour cells [Fingar, 1996]. As a result,
antivascular PDT has become an upcoming alternate PDT modality to induce cell death
by vessel constriction [Zilberstein et al., 2001]. Further studies, focusing on the
photodynamic effect in relation to the vascular perfusion and molecular extravasation,
also gave more information to understand the mechanism and optimised the treatment
conditions [He et al., 2008].
The immune response to PDT is another indirect anti-tumour effect which may act as a
secondary cytotoxic mechanism and lead to long-term tumour control. Several
researchers have demonstrated that the cure rate of PDT on tumour was lower in
immunosuppressed mice than in the mice with normal immunity [Canti et al.,
1994;Korbelik et al., 1996]. The resistance to tumour cell rechallenge was found in
normal animals but not in immunosuppressed ones who all survived after PDT.
Moreover, the curative effect was restored in the immunosuppressed mice after adoptive
transfer of T-lymphocytes (from normal mice). These results together pointed out the
existence and the importance of the immunity after PDT treatment.
Many studies have proved the recruitment of several immune cells and inflammatory
products after PDT. The increased level of cytokines, such as IL-1β, IL-6, IL-10, TNF-α
and GM-CSF (granulocyte macrophage colony stimulating factor), have been detected
in the serum of animals receiving PDT [Gollnick et al., 2003]. Some of them are
associated with the apoptotic killing effect on tumour cells and some are generated from
the direct photodamage to the immune cells. These advantages have been applied for
developing cancer vaccines – injecting PDT treated cultured cells or the lysates to
tumour-bearing mice [Gollnick et al., 2002;Korbelik and Sun, 2006]. These vaccines
were found to be able to induce a cytotoxic T-cell response and benefit for tumour
growth inhibition, regression and cures.
Common cancer therapies such as chemotherapy and radiation therapy are often
immunosuppressive but that is on condition when the doses are sufficient. Lower doses
of either treatments have been shown to stimulate the immune system [Crum,
1993;Lugade et al., 2005]. An ideal cancer treatment should not only have a direct
killing effect but also have some other impacts to deal with further possible tumour43
recurrence or metastasis. In this regard, PDT, being a remedy able to evoke immune
responses, may be more desirable for cancer treatment [Castano et al., 2006].
Photoimmunotherapy is a new approach which combines PDT and immunotherapy. It
can be a simple combination of PDT and immuno-enhancers to boost specific immune
responses [Golab et al., 2000]. The other branch is using photosensitiser-monoclonal
antibody conjugates to achieve selective tumour cell localisation and may be useful for
tumour detection [del Carmen et al., 2005;van Dongen et al., 2004]. PDT in
combination with different immunobiological approaches opens another era to improve
the overall therapeutic outcome [Kwitniewski et al., 2008].44
1.4 Current Clinical Achievements and Future
Since early 1980s, effective photodynamic effects have been reported in clinical trials
for treating cancers. Unlike the conventional chemotherapy, PDT is a site-specific
modality where the ablation of tumour is confined to the area exposed to irradiation.
Compared to surgery, PDT is non-invasive when treating superficial diseases, or only
minimal invasive by combining endoscopy or other fibre-optic systems for treating
internal cancers interstitially. The fact that PDT treatment can be repeated is one of the
advantages of PDT over radiotherapy where only a limited treatment regimen can be
tolerated [Brown et al., 2004]. The outstanding healing response which contributes good
cosmetic results, and the greatly reduced morbidity particularly benefits the application
of PDT in skin cancer and head and neck cancer [Hopper, 2000].
PDT is already a routine treatment in dermatological oncology. It has been 8-10 years
since the clinical approvals of ALA (US) and methyl-ALA (EU) under the indications
covering treatment of basal cell carcinoma and some pre-cancerous diseases, and m-
THPC for palliative reduction of tumour volume in head and neck cancer in the Europe
(Table 1.1). Since then, PDT has demonstrated promising results in treating these two
groups of diseases as most of the tumours are accessible to direct light illumination.
Nevertheless, there is room for improvements.
In skin cancer, non-laser light sources are usually considered more effective than lasers
due to the larger illumination area [Brancaleon and Moseley, 2002]. Small size and low
cost are other advantages. However, some disadvantages such as the small penetration
depth, as well as the insufficient power resulting in longer treatment time should be
taken into account. Long irradiation may cause hyperthermia which may be associated
with more pain and burning sensation. Skin photosensitivity is another problem that
needs to be improved. Researches regarding the efficacy and safety of PDT are required
and will help the applications to other fields of skin diseases.
Some major problems of PDT of head and neck cancers were pointed out in a review
article by Kübler [Kubler et al., 2001]. Concerning the limitation of the therapy depth,
PDT on oral dysplasia or small primary tumours was only sufficient for very superficial
diseases, especially using topically applied ALA PDT [Kubler et al., 1998]. In the case45
of squamous cell carcinoma of oropharynx, this malignant tumour tends to spread into
the regional lymph nodes of the neck; therefore, there is a risk of lymph node metastasis
if patients are only treated by PDT. Up to date, surgery and radiation are still the first
choice of therapies for advanced head and neck tumours. But, these tumours are able to
be treated with image guided, interstitial PDT [Jager et al., 2005]. Improving the light
penetration depth and reducing skin sensitivity etc are tasks for PDT treatment on head
and neck cancers in the future.
PDT also has been used in many other diseases in the regions including brain, lung,
gastroenterology and genitorurology and has accumulated a substantial number of
promising results. Although PDT has been used widely in clinic, it has not been a
mainstream therapy in oncology. As mentioned before, there is a need for standard
evaluation of the efficacy of clinical PDT. In tumour ablation for instance, the extent of
acute tumour necrosis, the duration and rate of this response, and the length of the
tumour-free period can be considered as parameters to determine the clinical response
or biological endpoint [Huang et al., 2008]. With the development of more selective and
effective drugs, inexpensive and convenient light sources, and more understanding of
the biology of PDT, the future prospects of PDT remain encouraging.46
1.5 Combination Strategies and Photochemical Internalisation
Strategies combining PDT with other therapies have been exploited for enhancing the
overall therapeutic effect. Combination with established clinical treatments such as
chemotherapy [Canti et al., 1998], radiation therapy [Luksiene et al., 1999],
hyperthermia [Henderson et al., 1985] or immunotherapy [Kwitniewski et al., 2008],
have shown as good as or better results compared with single treatments are applied
alone. This attraction of such combination strategies is that each modality will treat the
diseased lesion using a different mechanism which would be expected to result in a
more effective overall treatment and enable lower doses to be used. For example, the
reduction of the dose of anti-cancer drugs can lower their toxicity to normal tissues. It
is important also to distinguish between combinations which are merely additive in
effect compared to synergistic combinations, where the combined effect is greater than
the effect obtained by applying each modality separately.
PDT in combination with chemotherapy will be discussed in this section which is
relevant to the following chapter on the use of Photochemical Internalisation (PCI) to
enhance the delivery of anti-cancer drugs by photosensitisation, which is the theme of
this thesis. An early attempt was made using HpD-PDT, together with the well known
chemotherapy agents cisplatin and doxorubicin, to treat transplanted tumours in nude
mice [Nahabedian et al., 1988]. No enhancement was found in the case of PDT in
combination with cisplatin whereas the combination with doxorubicin resulted in
enhanced anti-tumour effect. The authors suggested the increased activity of
doxorubicin (compared to drug alone) may be due to the photochemical treatment.
Another study using the same cytotoxic drugs but with AlS2Pc PDT was carried out by
Canti et al. to treat two murine tumours [Canti et al., 1998]. Treatments with non-
therapeutic toxin doses were ineffective, whereas additive toxicity was observed in
combination with PDT.
Mitomycin C is another chemotherapeutic agent which also has been used in PDT-
chemotherapy in vivo. Combination treatments with PDT using Photofrin, m-THPC, or
bateriochlorin showed a significant tumour growth delay, even when the light dose was
considerably reduced in most of the cases [Baas et al., 1994;van Geel et al., 1995].
Moreover, according to the results of these studies, the administration timing of anti-47
cancer drugs to achieve the greatest tumour responses varied when different PDT
regimens were used. This finding indicates that the anti-tumour effects derived from
PDT and chemotherapy are not independent, and optimising the combined treatment in
terms of the administration interval and sequence is important.
The influence of the combination schedule was also found when using cisplatin and
doxorubicin [Kirveliene et al., 2006;Uehara et al., 2006]. Zuluaga and Lange proposed
several considerations based on the pharmacological mechanism of the anti-neoplastic
drugs and their impacts on photodynamic therapy: for example chemotherapy agents
can interfere in the cell replication and the subsequent cellular uptake of
photosensitisers [Zuluaga and Lange, 2008].
Different techniques such as the introduction of a copolymer to link either toxins or
sensitisers [Peterson et al., 2003] and the use of bioreductive anti-cancer agents
[Bremner et al., 1992] also have demonstrated significant inhibition in tumour growth.
The copolymer conjugates in the former study not only increased the tumour
accumulation of the toxins but also prolonged the retention time which enabled multiple
PDT irradiations, resulting in a better therapeutic outcome. In the later study, the PDT-
induced tumour hypoxia created a favourable environment for the bioreductive anti-
cancer drugs, leading to an increased tumour cure rate.
In contrast to conventional combination strategies outline above, PCI is a technology
which is designed to enhance drug delivery using light in combination with a
photosensitiser. Although the approach is similar to the combination treatment of PDT
and chemotherapy, the role of photochemical reaction is to promote the drug delivery to
its intracellular targets. The cell killing effect therefore results predominantly from the
drug not the photochemical treatment, as will be discussed in more detail in the
following chapter.48
Chapter 2: Photochemical Internalisation49
2.1 General Background
PDT is considered to be a site-specific cancer therapy because the therapeutic effects
only take place in the area exposed to light. With the rapid expansion of PDT, many
new drugs either chemically or endogenously synthesized have been developed and
exploited in various ways. Among them, there is a group of photosensitisers with a
unique intracellular distribution pattern observed under fluorescence microscopy.
These photosensitisers enter cells through endocytosis and localize at the membrane of
endocytotic vesicles instead of being diffusely localised in the cytosol. Upon irradiation,
the generated cytotoxic agents destroy the endosomal membrane and release the content
inside these organelles (eg. lysosomal enzymes) [Berg and Moan, 1994;Moan et al.,
1994]. Moreover, the redistribution of these sensitisers (i.e. an increase of fluorescence
intensity and the change of distribution phenomenon to become diffuse) was also
observed. This particular lysosomal photosensitisation and the membrane disruption
accompanying the release of content led to the concept of photochemical internalization
(PCI) – a novel photochemical technology for inducing the release of macromolecules
from endocytotic vesicles [Berg et al., 1999].
Macromolecules generally refer to oligonucleotides, peptides, proteins and polymers
whose sizes are normally larger than 1k Dalton. They can serve as alternatives to
traditional drugs (e.g. low molecular weight chemotherapeutics) but their
bioavailabilities are usually limited [Bareford and Swaan, 2007]. First of all, the cell
membrane is normally impermeable to the above large molecular complexes, whereas
small molecules such as glucose, ions or amino acids can quickly diffuse into cells.
Secondly, even though macromolecules still can enter cells through various active
internalisation mechanisms called endocytosis, escaping from endocytotic vesicles to
reach the intracellular targets is another problem [Lloyd, 2000].
Lysosomes are known to be the destination of all substances taken up by cells through
endocytosis. Their characteristics of storage were discovered by de Duve, one of the
pioneers who related lysosomes and drug action together [de Duve, 1969]. Many
approaches have been established to improve the uptake of macromolecular therapeutics
[Juliano et al., 2001]. There is also growing awareness of a need to develop drug50
delivery systems which can efficiently release therapeutics accumulated in endosomes
and lysosomes.
The fact that macromolecules retain in intracellular vesicles and remain inactive is not
ultimately a hindrance. If their biological effects can be manipulated by a delivery
system, these macromolecular drugs will be superior to traditional chemotherapeutics in
terms of specificity. In this regard, PCI which causes the rupture of endo/lysosomal
membranes during photosensitisation can provide a site-specifically light-induced
delivery of macromolecules.
As shown in Figure 2.1, after being taken up by cells, photosensitisers (S) for PCI are
localised at the membranes of endo/lysosomes together with the delivered molecules (G)
trapped inside the endocytotic vesicles. Upon illumination, photochemical reactions are
induced which cause the membrane destruction and consequent macromolecule release.
Figure 2.1 The principle of photochemical internalization (PCI) [Hogset et al., 2004]. S:
Photosensitiser; G: molecules to be delivered.
It should be noted that the whole PCI process is dynamic and therefore the efficacy is
highly dependent on the timing of drug (both sensitisers and macromolecules)
administration and light exposure. The illumination should be carried out when
sensitisers are sufficiently localised at the biomembranes and the macromolecules have
been internalised in endocytotic vesicles but before being degraded by the lysosomal
enzymes. As a result, understanding the kinetics of the endocytosis of both sensitisers
and macromolecules is very important.
The aim of PCI is to relocalise the therapeutics - escape from the barrier of
endo/lysosomal membrane and ability to reach their targets. In other words, the
principal considerations are the drug delivery effects and the cytotoxicity from51
macromolecules after PCI. Therefore, the light and sensitiser doses required for PCI is
much lower than the ones for PDT treatment whose ultimate goal is to kill the whole
cell. Moreover, because the therapeutics used for PCI are normally potent drugs but not
bioavailable without efficient delivery system, the drug dose can be reduced to
extremely small (compared to its LD50 dose) using PCI technology. For these reasons,
synergistic effects are expected for PCI strategy where individual treatment (i.e. PDT
and drug alone) exhibits minor effect but an enhanced killing effect can be achieved
when these macromolecules are activated after photosensitisation.
This is different from most of the combination therapies which combine PDT with
another treatment modality (e.g. hyperthermia, radiation therapy, antibody therapy or
chemotherapy). Although a synergistic response can be obtained if one mechanism
influences the other, additive effects are often the results of these combined strategies
where treatments are working independently.
PCI has been established to enhance the intracellular delivery of a large variety of
macromolecules including peptides, protein toxins and genes (either through viral or
non-viral vectors) [Hogset et al., 2004]. It has been shown to be effective for releasing
these therapeutics both in vitro and in vivo [Berg et al., 2006]. However, some details of
PCI remain to be investigated such as the exact mechanism of membrane rupture at
molecular scale and the optimisation of PCI in terms of the balance of photochemical
treatment and drug toxicity.
The later sections in this chapter will discuss the principle, applications, current results
and future of PCI.52
2.2 Mechanism of PCI Action
2.2.1 Photosensitisers for PCI
2.2.1.1 Entry into the cell – Endocytotic pathway
As mentioned before, essential small molecules such as sugars, amino acids or ions can
enter cells through the membrane protein pumps or channels whereas macromolecules
must be carried into cells through a process termed endocytosis which involves the
formation of membrane-bound vesicles derived from the plasma membrane.
Endocytosis is known as a common way for the uptake of extracellular substances. It
can be divided in two broad catagories: phagocytosis and pinocytosis. They both play a
crucial role in the communication between cells and their environment which involves
almost all the cell physiology conditions [Conner and Schmid, 2003]. Unlike
phagocytosis which is restricted to specialized mammalian cells (e.g. macrophages,
monocytes and neutrophils), pinocytosis, known as fluid-phase uptake, occurs in all
cells and transports molecules by forming vesicles coated with a protein layer
surrounding the membrane. In pinocytosis, some solutes bind to cell membrane non-
specifically, but most of the pinocytic pathways involve specific high-affinity receptors.
In those cases, substances are concentrated into specialized endocytotic transport
vesicles and taken up into cells more efficiently. There are at least 4 mechanisms of
receptor involved endocytosis: macropinocytosis, clathrin-mediated endocytosis,
caveolae-mediated endocytosis and clathrin- and caveolae-independent endocytosis.
The particular pathway that should be followed for entering cells is well regulated and
driven by the cargo molecules themselves.
It has been well documented that many photosensitisers enter the cell through
pinocytosis pathway and target endo/lysosomal vesicles, especially hydrophobic
photosensitisers [Geze et al., 1993]. However, it is not expected that all endo/lysosome-
localised photosensitisers are suitable to be used for PCI. The selection of PCI
sensitisers is based on the property of ‘membrane’ localisation at these endocytotic
vesicles.
The reason for this requisition is simply to limit the photochemical destruction to the
membrane and therefore minimise the possible photo-damage to the delivered53
macromolecules in the lumen compartment. As the reactive oxygen species, particularly
singlet oxygen, generated from photochemical reactions have a short diffusion distance
(10-20 nm) [Moan and Berg, 1991;Niedre et al., 2005], amphiphilic sensitisers are
desirable to fulfil this certain criteria.
2.2.1.2 Subcellular localisation
To date, meso-tetraphenylporphine (TPPS2a) and aluminium phthalocyanine disulfonate
(AlPcS2a) are the most efficient photosensitisers for PCI with two sulfonate groups on
adjacent phthalate/phenyl rings (Figure 2.2). After being taken up by cells through
endocytosis, these sensitisers localise specifically at the membrane of endo/lysomes,
with a hydrophobic part inserted into the membranes and a hydrophilic part free inside
the vesicle matrix. This amphiphilic feature ensures their membrane localisation and
inhibits further penetration (Figure 2.3).
Figure 2.2 The structures and molecular weights of three PCI photosensitisers – (from
the left) TPPS2a, AlPcS2a and Amphinex (TPCS2a).
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Figure 2.3 Schematic proposed localisation of sulfonated sensitisers in endocytic
vesicles. (Modified from [Berg et al., 2005b])
Evidence has been shown that the exact lysosomal membrane localisation is crucial to
an efficient PCI effect [Prasmickaite et al., 2001]. To study the impact of intracellular
localisation of photosensitisers for PCI, several photosensitisers were tested for their
ability to induce macromolecule delivery - polylysine-mediated gene transfection. This
study showed that photosensitisers which are localized at the endo/lysosomal membrane
(e.g. AlPcS2a and TPPS2a) have the greatest effects on the transfection of plasmid
encoding EGFP (enhanced green fluorescent protein). In contrast, transfection was not
significantly stimulated after photoactivation of non-lysosomally localised
photosensitisers (e.g. 3THPP, 5-ALA). Moreover, other hydrophilic sensitisers, such as
TPPS4 and Nile blue A, which localise within endocytotic vesicles displayed only weak
or negligible EGFP expression after light treatment. As a result, the physical property of
photosensitisers determines their intracellular localisations and amphiphilic sensitisers
are the best photosensitising compounds for PCI applications.
Amphiphilic sensitisers also exhibit some advantageous photodynamic properties [Allen
et al., 2002]. The cell uptake of amphiphilic photosensitisers was detected as good as
hydrophobic ones but the tendency to aggregate was lower. This is an important feature
as dimerised photosensitisers are less effective in inducing photochemical reactions.
The absorbance spectrum also should be considered in clinical practice since near
infrared is preferable for deeper tissue penetration of light. It has been mentioned in
section 1.2.3 that phthalocyanines have a porphyrin based macrocycle with four benzo
rings on the pyrrol units (Figure 1.3), which results in a strong absorption in the far-red
region of spectrum ( > 670nm) [Spikes, 1986]. In this regard, AlPcS2a may be preferable
endosome/lysosomes
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to TPPS2a for in vivo or in clinic utilisation. In fact, AlPcS2a is so far the only
photosensitiser used for in vivo PCI studies.
Amphinex (tetraphenylchlorin disulfonate, TPCS2a) is a new chlorin-based amphiphilic
photosensitiser (PCI Biotech, Norway) which is designed for PCI (Figure 2.2). The
chemical synthesis of Amphinex is rather simpler than AlPcS2a and it is proposed to be
as efficient as the well known chlorin sensitiser, m-THPC, regarding the photodynamic
ability. The investigation of PCI using Amphinex in vitro and in vivo will be shown in
the experimental sections of this thesis.
2.2.2 Light Induced Drug Delivery
Figure 2.1 depicts the principal mechanism of photochemical internalisation. It contains
three processes: the uptake of photosensitiser and macromolecules, the illumination and
induced membrane rupture, and finally the release of macromolecules. After diffusing
into the cytosol, macromolecules can thereby perform their pharmacological action
when reaching their targets. As PCI also utilises the same photochemical reactions as
PDT, the fundamental requirements, such as the presence of oxygen and sufficient
photosensitisers, are also essential to PCI. The key step is the photochemically induced
membrane rupture.
Although a wealth of published studies have demonstrated that PCI can release a variety
of macromolecules from endosomes and lysosomes to cytosol, the detailed mechanism
of membrane break is not fully understood. Some results from other photosensitisers
indicate a possible mechanism of membrane destruction that the generated reactive
oxygen species damage the membrane proteins rather than oxidation of membrane
lipids of mitochondria and erythrocyte [Belzacq et al., 2001;Zavodnik et al., 2002].
However, whether this is also the case of PCI awaits further investigations.
The role of different endocytotic vesicles for PCI-directed gene transfection has been
studied by Prasmickaite and her co-workers [Prasmickaite et al., 2000]. Using different
strategies to perturb the endocytotic uptake of DNA-polymer complexes, the results
showed that plasmid can also be released from early endosomes.56
In contrast to the conventional concept of PCI that irradiation should be carried out
when the internalisation of macromolecules and photosensitisers has been completed,
another strategy called ‘light before’ PCI has been found to be as effective as or even
better than ‘light after PCI’ in some cases in vitro [Prasmickaite et al., 2002]. The
possible mechanism is shown in Figure 2.4. Photochemical treatment is performed after
photosensitisers have been localised at the membrane of endocytotic vesicles. When
cells are incubated with molecules to be delivered, the molecules will be taken up
through endocytosis as well and the vesicles may fuse with the ones damaged by light
treatment, resulting in the release of molecules.
Figure 2.4 Possible mechanism for ‘light before’ PCI. Modified from [Hogset et al.,
2004]. S: Photosensitiser; G: molecules to be delivered.
It is suggested that, following this ‘light before’ procedure, macromolecules can leak
out immediately once the endocytotic vesicles with delivered macromolecules are fused
to photochemically destructed ones. Several advantages are proposed, firstly, that the
possible photochemical effects on the therapeutics should therefore be diminished as
those drugs are delivered after illumination. Secondly, it may be more practical in
animal models or in clinic in the case when PCI is in combination with surgery. After
surgical removal of tumours, light treatment can be carried out for residual disease,
followed by the administration of therapeutics. This will be difficult for ‘light after’ PCI
because the period of several hours between drug application and irradiation is not
appropriate during surgery.
However, no differences were observed regarding the results between both strategies
when delivering transgene [Prasmickaite et al., 2002]. Therapeutics dependence is57
clearly an assumption. It is not unexpected that PCI effects were also found to be cell
line dependent [Hogset et al., 2004]. The uptake of photosensitisers and
macromolecules varies between cell lines and so does the light sensitivity. In fact, these
are all the factors which relate to the optimisation of PCI treatment conditions. Despite
the unclear mechanism, the significant release of large particles such as viral vectors
indicates that PCI provides a remarkable drug delivery platform. A successful PCI
should be well planned and the photochemical reaction has to be efficient, precise and
well timed, in respect to the incorporated therapeutics.58
2.3 PCI Applications
2.3.1 Macromolecular delivery
2.3.1.1 Type I ribosome inactivating proteins
The studies of PCI-induced delivery of protein have mainly focused on ribosome-
inactivating proteins (RIPs), a group of protein toxins which inhibit protein synthesis by
damaging ribosomes catalytically. RIPs are usually divided into two groups (Figure
2.5A): Type II RIPs consist of an enzymatically active A chain (30 k Dalton, approx.)
linked to a B chain (35 k Dalton, approx.) which contains a binding domain. Type I
RIPs, however, which only consist of the A chain, are hardly taken up by cells.
Figure 2.5 A: Schematic representation of ribosome-inactivating proteins (RIPs) [Stirpe,
2004]. B: Rat 28S rRNA loop and the site of depurination by RIPs. The red circle is the
A4324 adenine resi due, the target of RIPs.
The toxicity of RIP toxins was discovered in the early 1970s when it was found that
protein synthesis can be inhibited by ricin, one of the type II RIPs, in cells and cell-free
systems [Montanaro et al., 1973;Montanaro et al., 1975]. The inhibition of the binding
of elongation factor 2 (EF-2) to ribosomes by this plant toxin was identified. The
detailed enzymatic activity was later confirmed by Endo and colleagues who showed
that the toxin exhibits a removal of a single adenine residue (A4324 in rat liver rRNA)
from a universally conserved loop at the top of a stem in 28S rRNA (Figure 2.5) [Endo59
et al., 1987]. This phenomenon was extended to all RIPs, which all have similar activity
[Stirpe et al., 1988].
The absence of a B chain with a binding domain indeed limits the entry of type I RIPs
into cells and justifies their very low toxicity to cells and to animals compared to type II
RIPs, with LD50 for mice of 40-75 mg/kg [Battelli, 2004]. However, if they are
delivered into cells, they can induce efficient inhibition of protein synthesis. Several
strategies have been employed to improve the cellular delivery of type I RIPs including
enclosing them in drug carriers (reviewed in [Barbieri et al., 1993]), subjecting cells to
shock waves [Delius and Adams, 1999] and conjugating to antibodies [Thorpe et al.,
1985]. These protein toxins are ideal model proteins to evaluate and demonstrate PCI
effects.
Gelonin and saporin are two type I RIP toxins which are mostly used in PCI strategy.
The effect of PCI-induced delivery of gelonin has been investigated using several
photosensitisers in 16 cell lines of various origins [Berg et al., 1996]. The best results
were found using TPPS2a PCI of gelonin in NHIK 3025 cells where protein synthesis
was significantly reduced by more than a factor of 300 compared to each treatment
alone [Berg et al., 1999]. Co-localisation of fluorescent probe-labelled gelonin and
photosensitiser, AlPcS2a, and the re-localisation of both molecules were observed by
fluorescence microscopy [Selbo et al., 2000a].
Saporin is another type I RIP which exerts much higher toxicity than gelonin [Bolognesi
et al., 2000]. As a result, it is believed that saporin has the potential to affect protein
synthesis and thereby induce cell death in use of PCI more efficiently. Lai et al.
investigated the PCI effect using AlPcS2a in combination of saporin in vitro [Lai et al.,
2008]. In addition, the introduction of polyamidoamine (PAMAM) dendrimer to saporin
showed an increased cellular uptake and cytotoxicity using PCI. Interestingly, after PCI,
the distribution of PAMAM-saporin conjugates was observed to be a nuclear-
localisation which was different from the granular distribution in the cytosol before
illumination.
To increase the uptake and specificity of protein toxins, antibody-conjugated gelonin
and saporin have been developed for PCI. Details will be discussed in the section on
targeted macromolecules.60
2.3.1.2 Bleomycin
Bleomycins are a family of water-soluble glycopeptidic antibiotics with at least four
functional domains mediating DNA breakage, ion binding and O2 activation (Figure 2.6)
[Hecht, 2000]. Since first isolated by Umezawa in 1966, bleomycins have been used in
combination with several anti-cancer agents for a number of cancer chemotherapies,
notably squamous cell carcinomas and malignant lymphomas [Sikic et al., 1985].
Figure 2.6 Structure of bleomycin [Hecht, 2000]. Molecular weight:1400.
With a very high cytotoxicity, as few as 500 bleomycin molecules translocated to
cytosol are sufficient to kill a cell in combination with electroporation in vitro
[Poddevin et al., 1991;Pron et al., 1999]. However, due to its hydrophilic property,
bleomycin penetrates membrane structures poorly and therefore accumulates in
endocytic vesicles. The sensitivity of tumour cells to this drug is accordingly variable.
Although many fundamental properties of bleomycin are still unknown, its therapeutic
potential could be activated if delivered and exported sufficiently into cytosol.
PCI has demonstrated enhanced cell growth inhibition in combination with bleomycin
in vitro [Berg et al., 2005a]. As bleomycin is a current chemotherapy drug, in vivo
studies of PCI of bleomycin using AlPcS2a also have been carried out in xenograft mice
models. Details of PCI of bleomycin using animal models will be discussed in the in
vivo section.61
2.3.1.3 Targeted macromolecules - Immunotoxins
The targeting strategy was developed due to the demand of specific and efficient drug
delivery system, especially in in vivo studies. Immunotoxins are one of the designs
which link antibodies with specific binding function to therapeutics. Protein toxins are
usually used for this conjugation approach and the conjugates should meet several
criteria to be used in clinical practice for cancer treatment: a high toxicity, a linker
modification and survival from the endocytotic process [Johannes and Decaudin, 2005].
Because the number of receptors presenting on the cell surface is usually less than 10
5
molecules per cell, it is important to have very high toxicity to kill targeted cells
efficiently. To combine the antibody and the toxin, a linker is sometimes required to
synthesize immunotoxins. Moreover, most toxins enter the cell through the endocytotic
pathway. Therefore, the toxin must be able to survive from the acidic compartments of
endo/lysosomes and the proteolytic process.
Immunotoxin therapy has been developed to treat cancer by linking tumor-targeting
ligands or antibodies to toxins, which are mainly bacteria or plant protein toxins. The
aims of combining targeting ligands are to achieve tumour specificity and a favourable
biodistribution between normal and tumour tissues. Since cooperation of PCI and RIPs
has inactivated protein synthesis efficiently, the use of immunotoxins- monoclonal
antibody conjugated type I RIP is believed to be able to increase the drug uptake and
specificity.
The first studies of PCI in combination with immuno-RIP conjugates were introduced
by Selbo et al. coupling of monoclonal IgG1 antibody MOC31 with gelonin [Selbo et al.,
2000b;Selbo et al., 2001a]. This conjugation enables gelonin to directly bind to
epithelial glycoprotein-2 (EGP-2) which is expressed on most carcinoma cells, resulting
in increased uptake of the conjugates. The cell viability was significantly reduced using
TPPS2a, AlPcS2a and ALA PCI compared to immunotoxins alone. Moreover, the results
also show that there was no difference between immunotoxin and toxin alone in the
case of using PCI in EGP-2 negative cell line. The specificity might be very useful for
in vivo application.
Epidermal growth factor receptor (EGFR) targeting is one of the most common
strategies to achieve specific cancer therapies. EGFR is involved in regulating cell62
proliferation, metastasis, angiogenesis and is over-expressed in a variety of tumour cell
lines [El-Rayes and LoRusso, 2004]. The EGFR inhibitor, C225, has been used as an
anti-cancer drug in Phase-I to Phase-III trials for several malignant diseases, most
notably colorectal and head and neck cancer.
It may therefore be a good combination employing EGFR targeting system to PCI.
Weyergang et al. established an EGF-saporin affinity toxin (biotin-straptavidin linkage)
to investigate the PCI effects using EGFR over-expressing and EGFR-negative cell
lines [Weyergang et al., 2006]. PCI of EGF-saporin enhanced the cytotoxicity about
1000-fold in NuTu-19 cells. Researchers from the same group later demonstrated
increased cytotoxicity by using PCI in combination with saporin-C255 complex (via the
same linking method) in EGFR-positive cells [Yip et al., 2007]. The efficacy and
selectivity of this combination of PCI and EGFR targeting system indicate it can be of
benefit for cancer therapies in clinic.
2.3.1.4 Multidrug resistance
Since PCI has been employed for enhancing the cellular uptake of drugs which have
difficulties in entering the cell, it is predicted that PCI might be able to reverse the
multiple drug resistance (MDR) of chemotherapy agents. Two main mechanisms for
MDR are the overexpression of p-glycoprotein (p-gp) efflux pumps and the entrapment
of anticancer drugs in endosome/lysosomes. The former leads to the extrusion of drugs
from cytosol and the later induces the degradation of drugs by lysosomal enzymes
[Gottesman et al., 2002]. As a result, weak base chemotherapeutics such as doxorubicin
are often trapped in endocytotic vesicles due to the increased acidification of these
intracellular compartments. In this respect, PCI might have the potential to deal with
multiple drug resistance, which is a serious problem affecting many chemotherapy
drugs.
It was firstly established by Lou et al. that successful reversal of drug resistance can be
induced by PCI [Lou et al., 2006]. After TPPS2a PCI treatment (doxorubicin was
administered after irradiation), doxorubicin was observed in the nuclei of MCF-7/ADR
cells (a breast cancer cell line which is resistant to doxorubicin) and the drug dose
required for 50% inhibition of cell survival was reduced to 10 times lower.63
Another study using similar concepts also indicated the PCI effects on the improvement
of drug resistance. The cytotoxicity of mitoxantrone (a chemotherapy agent) against its
drug resistant cancer cells sensitised with hypericin (a photosensitiser) was enhanced
after illumination [Adigbli et al., 2007]. The mobilisation of mitoxantrone to cell nuclei
was also found after light exposure.
As mentioned before, there are many different phenotypes of drug resistance and some
mechanisms may not be affected by PCI treatment. Selbo et al. reported that TPPS2a
PCI has no influence in reducing the level of resistance to doxorubicin for MES-
SA/Dx5 cells, a MDR cell line [Selbo et al., 2006]. However, PCI of gelonin
successfully reduced the cell survival. The results suggest that PCI may not be able to
adjust the drug sensitivity for some MDR cells, but it still can be useful as a cancer
treatment when in combination with other macromolecules.
2.3.1.5 Other macromolecules
PCI also has been employed to release some peptides or small proteins efficiently. It
was reported that more than 60% of endocytosed horseradish peroxidase (HRP) can be
released into cytosol by using TPPS2a PCI. Similar findings were also obtained when it
was shown that fluorescein-labelled ras peptide (p21
ras), a cancer-specific peptide was
co-localised granularly with AlPcS2a in cells but became diffuse in cytosol after light
exposure [Berg et al., 1999].
Oligonucleotides are a group of macromolecules with recognised therapeutic potential.
Some of these molecules exhibit antisense effects, resulting in the replication of
uncorrected DNA sequence or site-specific gene silencing from the host cell. Peptide
nuclei acids (PNAs) are examples for the former action which are DNA mimics with a
pseudopeptide backbone [Pooga et al., 2001]. Small interfering RNA (siRNA)
molecules are the examples for the later mechanism which are able to control gene
expression through the process of RNA interference [Dykxhoorn et al., 2003]. The
inefficient cellular uptake is the major obstacle for both therapeutic agents [Koppelhus
et al., 2002]. As a result, several strategies, including PCI, have been explored to
enhance the drug delivery.64
Recent studies have clearly shown that PCI represents an efficient delivery system for
naked PNA conjugated with the catalytic component of human telomerase reverse
transcriptase (hTERT-PNA) [Folini et al., 2003] and various cell penetrating peptides
(CPPs-PNA) [Shiraishi and Nielsen, 2006]. As for siRNA molecules, substantial gene
silencing was induced by PCI-mediated gene transfection of siRNA molecules against
S100A4, a protein associated with the invasive and metastatic phenotype of cancer cells
[Boe et al., 2007]. These promising in vitro results open the future applications using
PCI technology for activating the biological antisense effects of oligonecleotides on
animals or humans.65
2.3.2 Gene delivery
The basic principle of gene therapy is that insertion of corrective genetic material into
cells alleviates the symptoms of disease. However, there are some obstacles, and
consequently few successes in gene therapy. The three main problems of gene therapy
are the lack of efficient delivery systems, the lack of sustained expression, and the host
immune reactions in vivo [Verma and Somia, 1997]. PCI, as a novel technology for
releasing macromolecules from endosomes to cytosol, could provide efficient delivery
for gene therapy.
Recent studies have shown encouraging results in gene transfection via either viral or
non-viral vectors. AlPcS2a based PCI-induced EGFP/polylysine complex delivery was
tested and the transfection efficiency reached above 50% of surviving cells [Hogset et
al., 2000]. PCI using different photosensitisers has also been examined to induce EGFP
transfection and a light dependent transfect efficacy was found [Prasmickaite et al.,
2001].
In addition, various delivery agents have been evaluated in PCI mediated gene
transfection. It was found that PCI enhanced transfection using polycationic vectors (e.g.
polylysine or polyethylenimine (PEI)), but cationic lipid vector-mediated transfection
(e.g. DOTAP (dioleoyltrimethylammoniumpropane) was inhibited [Prasmickaite et al.,
2000]. One possible explanation suggested was that the photochemical treatment might
perturb the dissociation of DNA/DOTAP complex and cause DNA inactivation.
Although the exact reason is still unknown, this finding warrants further mechanistic
study of both PCI and gene delivery.
PCI mediated delivery requires administration of both photosensitisers and candidate
drugs or genes. There is a new design devised a complex composed of a core DNA
packaged with cationic peptides and enveloped in the anionic dendrimer phthalocyanine
(DPc) [Nishiyama et al., 2005].
The concept was to reduce the administration of photosensitisers and drugs into one and
was thought to be more suitable for in vivo application due to the integration of
photosentisers and DNA/polymer complex. The preliminary results showed lowered66
photocytotoxicity and increased cell viability compared to AlPcS2a mediated PCI in
gene transfection. This study is also the first success in PCI-mediated gene delivery in
vivo with transgene expression in conjunctival tissues of rats.
Gene delivery through viral vectors is usually regarded as a very efficient process
because of the natural occurrence of virus infections [Anderson, 1998]. However, after
being taken up into cells through endocytosis (mostly) [Greber et al., 1993], virus-DNA
complex may still be trapped inside the endocytotic system in cases of some virus
vectors or in certain cell lines [Hansen et al., 2000].
PCI-mediated gene transfection by adenoviral vectors was firstly introduced by Hogset
et al. using β-galactosidase-encoding adenovirus [Hogset et al., 2002]. Pronounced
transduction efficiency was obtained and the amount of virus dose was significantly
lowered to achieve the same results using PCI compared with conventional adenovirus
transfection (no illumination).
A later study investigated the transfection efficacy of PCI-induced transduction of
polycation-complex adenovirus using several cell lines [Bonsted et al., 2004]. The
efficacy was found to be cell type dependent but positive transgene expression were
observed in all cell lines including cells with low or without the receptors to adenovirus
on the cell surface.
Altogether, PCI has the potential of being a useful technology for in vitro and in vivo
gene delivery and gene therapy but optimization of PCI-mediated gene delivery is still
needed.67
2.3.3 In vivo PCI for cancer treatment
For in vivo PCI, most of the studies were performed in tumour using nude mice
transplantation xenograft models; AlPcS2a is the only photosensitiser employed so far.
The first in vivo PCI study was carried out using AlPcS2a PCI of gelonin in a
transplanted human colon adenocarcinoma model [Selbo et al., 2001b]. PCI treatments
delayed the tumour growth and resulted in complete remission in 6 out of 9 animals
whereas only one of six animals in the PDT group achieved complete remission. A
different strategy in which gelonin was administered after light treatment also
demonstrated inhibition in tumour growth comparable to the result using gelonin before
light [Berg et al., 2006].
Dietze et al continued the previous study but using the human fibrous histocytoma
xenograft model in nude mice [Dietze et al., 2005]. AlPcS2a was observed well
distributed in tumour cells with a roughly constant concentration at the time of surgery
(48hrs after intraperitoneal (i.p.) injection). Gelonin also could be detected in tumour at
the time of light treatment (6hrs after intratumoural (i.t.) injection) although the level in
tumour was found decreasing with time after drug administration. 50% of the animals
receiving the AlPcS2a PCI of gelonin treatment remained tumour free after more than
100 days where the complete response was only found in 10% in the PDT group. The
histological results showed that PCI could induce deeper damage than PDT in this
tumour treatment.
Bleomycin also has been used for in vivo PCI in four different xenograft tumours in
nude mice [Berg et al., 2005a;Norum et al., 2009a]. A synergistic delay in the tumour
growth was found in all models after PCI of bleomycin. The tumour re-growth in the
peripheral zone was inhibited by PCI treatment according to histological analysis of the
samples 7 days after surgery. A further study also indicated that PCI treatment could act
as an adjunct to surgery, resulting in the delay of tumour growth in a human
fibrosarcoma model [Norum et al., 2009b]. This finding suggests that PCI might be
suitable for treating residual tumour cells after inadequate surgical resection from the
clinical point of view.68
2.4 Future and Clinical Application
PCI is attracting interest as a novel technology for improving macromolecular drug
delivery to cells. The key advantage of PCI is the site specificity due to the light-
dependent activation of a photosensitiser which is co-administered with the
macromolecule. The photochemical effect only takes place in areas under light exposure.
Additionally, PCI has the potential to approach different cancer treatments when in
combination with different therapeutic agents since various macromolecules have been
shown to be released by PCI and their size can range from small peptides to genetic
materials. Combination with specific ligand targeted drugs may therefore improve the
specificity of PCI treatment in vivo by directing drugs to antigen presenting tumour cells
through receptor-mediated endocytosis.
As described previously, synergistic effects are obtained in PCI treatment because both
the PDT dose (the dose of light and photosensitisers) and drug dose are reduced. The
killing effect originating from the photochemical reaction is beneficial to cancer therapy
where the final goal is to kill the malignant cells, whereas it might be a disadvantage for
gene therapy. The possibility of the damage to the internalized DNA following
photochemical treatments might cause DNA mutations or further dysfunction which
could affect normal gene expression.
Toward this point, optimization of the treatment conditions should therefore be
emphasized again. The ‘light before’ method of PCI might also provide an alternative
approach to minimise the potential photodamage to delivered DNA complexes. The
detailed mechanisms behind PCI also need further investigations since PCI involves the
participation of delivered therapeutic agents which makes the whole procedure more
complicated compared with PDT.
Collectively, PCI is a promising technology to improve a cytosolic delivery of
macromolecules in vitro and in vivo. It is important to point out that PCI is in the stage
of its first clinical trial using Amphinex PCI in combination with bleomycin for head
and neck cancers in University College London Hospital. As a cancer treatment, the
challenges will be the same as what PDT faces: the benefit of its therapeutic effects69
against the conventional well-established therapies, such as chemotherapy, radiation
therapy and surgery. The fact that PCI seems flexible for delivering a variety of anti-
cancer drugs broadens the future applications of PCI in clinic to deal with different
cancers.70
Chapter 3:Aims of Thesis71
Aims of Thesis
This thesis firstly aims to investigate the in vitro PCI effect using TPCS2a (Amphinex),
a new amphiphilic chlorin based photosensitiser, in comparison to two other
photosensitisers, TPPS2a and AlPcS2a, with A431 and HN5 cells. The cellular uptake,
subcellular localisation/relocalisation after irradiation, phototoxicity and the ability of
inducing PCI effect in combination with two anti-cancer drugs, saporin and bleomycin
will be examined. The photostability and photosensitising process will be also assessed
by looking at the intracellular photobleaching properties and photomodification upon
exposure to light.
The next objective is to investigate the PCI effect in vivo starting with the
biodistribution of Amphinex in healthy rats. The drug uptake in several organs at
different time points after administration will be examined using quantitative
fluorescence microscopy. The absorption spectrum of Amphinex will also be measured
in rat liver using an optical pharmacokinetic system. The in vivo optical properties of
Amphinex can be informative for optimising the wavelength of the light source suitable
for activating Amphinex in vivo.
The next aim is to investigate the PCI effect with Amphinex in normal rat tissues and a
transplanted tumour model. Experiments begin with the Amphinex PCI treatments in
combination with saporin and bleomycin on normal rat liver/colon. The interplay
between the dose of Amphinex and the light fluence, as well as the influence from the
doses of toxins and their administration time points on the therapeutic efficacy will be
examined by histological examination of the size of necrosis induced after treatments.
Studies will later focus on the treatments on tumours using a syngeneic transplanted rat
fibrosarcoma model. Further experiments will also be carried out to look at the PCI
mechanisms in vivo.
Finally, the possibility of using new photosensitiser bioconjugates will be studied in an
additional chapter to investigate the use of bioconjugation strategies for PCI
applications.72
Section B: In Vitro Studies73
Chapter 4: PCI Treatment In Vitro74
4.1 Introduction
Photochemical internalisation (PCI) has been developed as a technology to improve
drug delivery to cells since the late 90s. Studies involved different photosensitisers, cell
lines and in combination with a variety of anti-cancer drugs have been documented for
the last years, particularly from the group from Norwegian Radium Hospital in Oslo.
Høgset reviewed PCI-mediated drug and gene delivery in 2004 and concluded that PCI
can induce the rupture of vesicles containing the co-administered therapeutic
macromolecules and thereby display significant reduction of cell viability [Hogset et al.,
2004].
As mentioned in Chapter 2, PCI has been shown to work well with anti-cancer drugs
from different categories including small peptides and protein toxins. The drugs
considered to be used in PCI strategy either have difficulties in entering cells or they are
sequestered in lyso/endosomes after cell uptake and would be degraded eventually. In
other words, PCI induces the relocalisation of those drugs inside the cell and thereby
enhance cell death. Among these anti-cancer drugs, bleomycin and a group of plant
toxins, type I ribosome-inactivating protein, have drawn researchers’ attention in
particular. As discussed in Chapter 2, these drugs would be ideal anti-cancer agents if
delivered and exported sufficiently into cytosol. However, due to the nature of these
molecules (i.e. the hydrophilicity of bleomycin; the lack of a binding domain of type I
RIPs), their therapeutic potential are inactivated if without any modifications. Based on
these facts, these two drugs should thus be candidates to demonstrate the PCI
technology.
To date, the most efficient photosensitisers for PCI are meso-tetraphenylporphine
(TPPS2a) and aluminium phthalocyanine disulfonate (AlPcS2a), which have two
sulfonate groups on adjacent phthalate/phenyl rings. This amphiphilic structure with
both a hydrophobic part and a hydrophilic part enables molecules to insert into
biomembranes and inhibit further penetration. A new chlorin based photosensitiser with
two adjacent sulfonated groups known as Amphinex
TM, (TPCS2a, tetraphenylchlorin
disulfonate), has been developed by PCI Biotech which was also investigated through
out this thesis study.75
PCI could work as a cancer treatment by acting a technology for drug delivery. PCI can
deal with different cancer diseases when in combination with different drugs. Head and
neck cancer is a good model for PDT treatment because it is easily accessible for
treatment and follow-up. The good cosmetic outcome is one of the major advantages of
PDT on head and neck cancers. As organ structures are complicated and delicate which
should be well-preserved after any treatments for tumour removal, the benefit of PDT
has made this site-specific treatment superior to other conventional regimens such as
surgery in some cases. However, some advanced tumours of the larynx and the
requirement for deeper light penetration in order to tackle potential lymph node
metastasis in the case of SCC of the oropharynx are the problems that PDT has to
overcome in the future [Kubler et al., 2001]. From this point of view, because PCI
involves not only the sub-lethal photodynamic treatment but also the therapeutic effects
caused by the combined drugs, PCI can induce more intensive damage to target tissues
and thus has the potential to tackle head and neck cancers.
The in vitro experiments in this thesis were carried out using A431 human epidermoid
carcinoma cells and HN5 human head and neck squamous cell carcinoma cells. Since
both cell lines express high levels of the epidermal growth factor receptors, they are
good models for cancer associated signalling pathway studies. Considering the possible
introduction of targeting strategy into PCI technology in the future, as well as the future
clinic applications on head and neck cancers, these two cell lines were chosen in this
thesis study to investigate the PCI effect in vitro.
The following chapter will, therefore, assess the PCI approaches at the cellular level by
examining the intracellular uptake, photostability (4.3) and photodynamic modification
(4.5) of photosensitisers, conducting imaging studies of photosensitisers in cells (4.4),
measuring the cell kill effect after photodynamic treatment (4.7), and also the
cytotoxicity achieved by photochemical internalisation in the presence of two anti-
cancer drugs, saporin and bleomycin (4.8).76
4.2 Materials and Methods
Chemicals and drugs
AlPcS2a was supplied as a powder (Frontier Scientific, USA) and was dissolved in water
as the stock solution (1mg/ml). The sulfonate groups are adjacently substituted on the
macrocycle. In many previous studies the AlPcS2a preparation contained both adjacently
and oppositely substituted isomers, therefore the preparation used here represents an
improvement on those studies. TPPS2a dissolved in dimethyl sulfoxide (0.35 mg/ml)
and Amphinex in Cremophor (10 mg/ml) were kindly donated by PCI Biotech
(Norway). The structures and molecular weight of these three photosensitisers are
shown in Figure 2.2 in Chapter 2. The stock solutions (20 μg/ml) for TPPS2a and
Amphinex were prepared after serial dilutions in water. Sensitiser solutions (in water)
were finally added into cell culture medium to make desired concentration for
experiments (personal communication with Prof Berg, Norwegian Radium Hospital).
Saporin was purchased from Sigma-Aldrich (UK). The stock solution of saporin
(1mg/ml) was prepared by dissolving the drug power in sterile water. Saporin stock
solution was then diluted to 10μg/ml (330nM) and the aliquotes was kept at -20ºC until
use. Bleomycin (Kyowa Hakko, Mayne) was provided as powder (15 IU per vial
according to the U.S. standard equivalent to 15,000 IU according to the European
Pharmacopeia. 5.1), and was dissolved in 0.5ml 0.9% NaCl (30 IU/ml). The stock
solution of bleomycin was prepared at a concentration of 0.14 IU/ml after serial
dilutions with 0.9% NaCl. Alexa Fluor
®488 was purchased as a protein labelling kit
from Molecular Probes (UK).
Cell line and cultivation
A431 human squamous carcinoma cell line was purchased from ECACC (UK) and
cultured in Minimal Essential Medium which was supplemented with 10% fetal bovine
serum (FBS) (Sigma, UK), 100μM nonessential amino acid, 2mM Glutamine (GIBCO
BRL, UK) and 500μg/ml Gentamycin (GIBCO BRL, UK). The HN5 human squamous
cell carcinoma cells were obtained from Prof. MJ O’Hare (Ludwig Institute for Cancer
Research, London, UK). Cells were cultured in Dulbecco’s Modified Eagle’s medium
containing 10% FBS (Sigma, UK), 100μM nonessential amino acid, 2mM Glutamine
(GIBCO BRL, UK) and 500μg/ml Gentamicin (GIBCO BRL, UK). All cells were
incubated at 37 °C in a humidified atmosphere containing 5% CO2.77
Synthesis of Saporin-AlexaFluor488 conjugates
The linkage of saporin and Alexafluor488 followed the protocol provided by the
supplier Molecular Probes. Briefly, saporin was dissolved by adding 1M sodium
bicarbonate to the protein concentration of 2 mg/ml. The protein solution was then
transferred to the vial of reactive AlexaFluor488 dye containing a magnetic stirrer bar.
After 1 hour (or more) stirring at room temperature, the reaction mixture was carefully
loaded to a column filled with resin. An elution buffer was then added slowly to the
column. The absorbance of the protein conjugates was measure at 280nm (for proteins)
and 494nm (for the dye) in a cuvette with a 1cm pathlength. The protein concentration
was calculated followed the equation:
Protein concentration (M) =
24000
)] 11 . 0 ( [ 494 280 ctor dilutionfa A A   
where 24000 cm
-1M
-1 is the molar extinction coefficient of saporin and 0.11 is a
correction factor to account for absorption of the dye at 280nm.
Moles dye per mole protein=
) ( _ 71000
_ 494
M ion concentrat protein
factor dilution A


where 71,000 cm
-1M
-1 is the approximate molar extinction coefficient of Alexa
Fluor
®488 dye at 494nm.
Light irradiation equipment
The light source for excitation of TPPS2a and Amphinex for the in vitro experiments
was a blue lamp, LumiSource
® (PCI Biotech, Norway), emitting light uniformly from
four fluorescence tubes in the spectral region 375-450nm. The fluence rate was 7 mW
cm
-2(Figure 4.1).
Figure 4.1 LumiSource
®. It consists of a bank of 4 fluorescence tubes. Plates are
covered with light-impermeable material during exposure from the plate base.78
AlPcS2a was activated with laser excitation at 670nm (Hamamatsu Photonics, Japan).
Irradiation from below is required because cells are cultured in well plates with the lid
in place. This method was used because condensation tends to collect on the inside
surface of the lid which would scatter light delivered from above the plate. A 400
micron diameter fibre terminated with a microlens was used to deliver a uniform beam
of light for irradiating the whole of a 96 well-plate. The setup of laser irradiation
equipment for well-plate experiments (i.e. photobleaching, phototoxicity and PCI with
anti-cancer drugs) is shown in Figure 4.2. The fluence rate was 0.88 mWcm
-2 measured
on the bottom of plates.
Figure 4.2 Laser devices setup of AlPcS2a PCI for well-plate experiments
The 670nm laser was also used for activating AlPcS2a on stage in the microscopic
imaging study of light-induced AlPcS2a redistribution. As shown in Figure 4.3, the light
was delivered from above using a 400 micron diameter fibre terminated with a
microlens. A uniform beam of light produced an irradiation area with about 1cm
diameter which covered the whole round coverslip. The fluence rate was 19.1 mWcm
-2
measured on the platform of microscope.79
670nm laser
slides cover slips
Irradiation area
20X
670nm laser
slides cover slips
Irradiation area
20X
Figure 4.3 Laser setup for activating AlPcS2a on stage. The laser fibre is pointed out by
the inset white arrow.
Spectroscopic measurements
The absorption spectrum measurement was carried out on a Perkin-Elmer Lambda 25
UV/Vis spectrometer (Perkin-Elmer, UK) using a 1 cm path length quartz cell. The
absorption spectrum of Amphinex was measured with samples prepared from the stock
solution diluted to 5 μg/ml in water. The fluorescence spectrum of Amphinex was
examined in aqueous solution (diluted in distilled water to the concentration of 0.5
μg/ml) and also within A431 cells using a LS50B Perkin-Elmer spectrofluorimeter
(Perkin-Elmer, UK). Cells were incubated with 0.1 μg/ml Amphinex for 18 hrs and the
medium was replaced with clear medium before fluorescence measurement.
Cellular uptake and photostability detection by fluorescence spectrometer
A431 cells were plated onto 96-well plate at 2-2.5x10
4 cells/well overnight and then
incubated with TPPS2a or Amphinex in different concentrations for 18 hours. Thrice
washing of cells and a 4-hour further incubation with fresh medium was the
recommended protocol to avoid photosensitiser molecules remaining bound on the
plasma membranes which might affect fluorescence measurements or photosensitisation
[Selbo et al., 2000a]. Then the medium was replaced with clear medium (no phenol red;
no serum), and cellular uptake of photosensitisers was excited at 420nm and detected at
655nm using a LS50B Perkin-Elmer Spectrofluorimeter (Perkin-Elmer, UK). For
photobleaching experiments, the fluorescence was detected using the spectrometer after
different light dose irradiation by LumiSource
® (PCI Biotech, Norway). Photobleaching
curves were constructed from normalised fluorescence intensities against irradiation
time. The fluorescence measurement itself did not induce any measurable80
photobleaching. Each data point of the experiments was carried out by using 96-well
plates in triplicate as the average of 6 wells.
Observation of the intracellular distribution of photosensitisers and the redistribution
after illumination using fluorescence microscopy
Cells were seeded on glass coverslips in 6-well plates overnight and were then
incubated with 2.5μg/ml TPPS2a or AlPcS2a and 0.1μg/ml Amphinex for 18 hours,
washed three times with fresh medium and then incubated for further 4 hours. After that,
DMEM medium with neither serum nor phenol red was replaced for microscopy study.
The subcellular distribution was observed using fluorescence microscopy. A 633nm
laser was used to activate AlPcS2a and a 532nm laser was for TPPS2a and Amphinex.
The first fluorescence imaging system was used in cells with AlPcS2a, using a slow-scan
liquid nitrogen cooled charge-coupled device (CCD) camera (Model 1, Wright
Instrument Ltd, UK) and a combination of bandpass (Omega Optical Inc.USA) and
longpass (Schott RG55) filters to record the images. The studies of TPPS2a and
Amphinex were carried out with an upgraded fluorescence imaging system using a
Peltier-cooled charge-coupled device (CCD) camera (Princeton Instruments Ltd., UK).
Co-localisation studies using fluorescence microscopy or confocal microscopy
In order to identify the subcellular distribution of photosensitisers and saporin, cells
treated with either photosensitisers or Alexa488-labelled saporin were exposed to
lysosomal probes before imaging analysis. A431 or HN5 cells overnight seeded onto
glass bottom dishes FluoroDish
TM (WPI, UK) were incubated with 0.1 μg/ml Amphinex
or 300nM Alexa488-labelled saporin for 18 hours. After thorough washing and further
incubating with fresh medium for 4 hours, LysoTracker Green or LysoTracker Red
(Molecular Probes, UK) was added to medium (final concentration 100nM) for 30min
for lysosomes labelling. Following incubation, clear medium with neither serum nor
phenol red was replaced for live-imaging. Experiments were initially conducted using
fluorescence microscope attached a CCD camera. Confocal imaging was later carried
out by confocal microcopy using a laser-scanning confocal microscope (FLUOVIEW
FV1000, 60x magnification, NA 1.20, Olympus, Japan).81
Co-localisation of Alexa488-labelled saporin and Amphinex and their redistribution
after irradiation on stage by confocal microscopy
HN5 cells seeded onto FluoroDish were co-incubated with 0.1μg/ml Amphinex and 300
nM Alexa488-labelled saporin for 18 hours. After thorough washing and incubation
with fresh medium for at least 4 hours, clear medium was replaced for live-imaging by
confocal microscopy. Light treatment was carried out on stage using the 405nm laser of
the microscope.
Observation and detection of photodynamic modification
HN5 cells were plated onto FluoroDish overnight and incubated with either 10 μg/ml
AlPcS2a or 0.1 μg/ml Amphinex for 18 hours. Cells were washed three times and
incubated with fresh medium for a further 4 hours. Clear medium was replaced before
imaging studies.
A 670nm laser (Hamamatsu Photonics Ltd, UK) was used for the irradiation of AlPcS2a.
The laser setup is shown in Figure 4.3 as described before. A uniform beam of light was
produced with a microlens to give an irradiation area of about 1.9 cm
2 which covered
the glass bottom of the dish. The fluence rate was 10.9 mWcm
-2 measured on the
platform of microscope. For activating Amphinex and for fluorescence microscopy, a
green 543 nm laser module was used (Edmund Optics Inc., UK). The laser irradiation
power measured on the platform of the microscope was 50 mWcm
-2. In each case the
exposure time used to record the fluorescence image was short (3 s) in comparison to
the light exposures needed to induce the photomodification process. Thus there was
negligible perturbation induced by the fluorescence measurement itself on the overall
fluorescence dynamics.
The irradiation was switched on and off sequentially and the fluorescent images were
captured at pre-set times using a Peltier-cooled charge-coupled device (CCD) camera
(Princeton Instruments, UK). Fluorescence intensities at set times were analyzed by
ImageJ, a Java-based image processing software developed by NIH.
Phototoxicity of TPPS2a, AlPcS2a and Amphinex in A431 cells and HN5 cells
The phototoxicity of TPPS2a, AlPcS2a and Amphinex in A431 and HN5 cells was
examined and compared. The PCI effect in combination with anti-cancer drugs, saporin
and bleomycin, was further investigated using these two cell lines.82
Cells were seeded at 5000 cells/well in 96-well plates overnight. After 18 hour
incubation with either TPPS2a, AlPcS2a or Amphinex, cells were washed off trice and
incubated further 4 hours with fresh full medium. Irradiation was carried out up to 5 or
10 min for photosensitisers at a range of concentrations (TPPS2a: 0-0.2 μg/ml; AlPcS2a:
0-10 μg/ml; Amphinex: 0-0.5μg/ml in A431 cells and 0-0.2μg/ml in HN5 cells). The
light source for TPPS2a and Amphinex was LumiSource
® (PCI Biotech, Norway) and
AlPcS2a was activated by a 670nm laser. The cell viability was measured by means of
standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 48
hours after light treatment. Cultured medium was replaced with fresh medium
containing MTT (1mg/ml) (Sigma, UK) and the plates were returned to the CO2
incubator for 2 hours. The mitochondrial dehydrogenase in the remaining live cells
converts MTT to fomazan crystals with purple colour in the base of each well. After
removing the medium, dimethyl sulfoxide (DMSO) (Sigma-Aldrich, UK) was added to
dissolve the crystal. The plates were shaken for 20 min and then the absorbance was
then read at 570nm by an MRXII Microtiter
® Plate Reader (Dynex Technologies, Inc.,
USA). Each data point of the experiments was carried out by using 96-well plates in
triplicate as the average of 6 wells.
PCI treatment schedules
This treatment schedule was based on previous PCI studies by Berg and co-workers in
other cell lines. To summarise, the photosensitiser was incubated with the cells for 18
hours and then washed off thoroughly (3 times) so as to minimise plasma membrane
levels of the photosensitiser so that the PDT effect of the photosensitiser is maximised
in the intracellular organelle membranes. The 18-hour incubation was chosen by Berg et
al. based on the optimum endo/lysosomal localisation; however, in this work
independent confirmation was also carried out for the sensitisers used.
For PCI experiments, saporin was co-incubated with the photosensitiser whereas
bleomycin was added after the photosensitiser was washed off. The reasons for the
different incubation conditions are discussed later in this section. Light irradiation was
carried out at the 22 hour timepoint in each case. The cell viability of the cells treated
with saporin was measured by the MTT assay 2 days after light treatment and up to 4
days for cells treated with bleomycin, as discussed later.83
The detail of PCI treatment schedule is shown below in Figures 4.4 A and B.
Figure 4.4 PCI treatment schedules. A: PCI of saporin. B: PCI of bleomycin. PS:
photosensitiser; SAP: saporin; BLM: bleomycin.
Statistical analysis
Results are presented as mean ± standard deviation (SD). Significant differences were
assessed by one tailed Student’s t-test analysis. P ≤ 0.05 was considered statistically
significant.
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4.3 Comparison of Cellular Uptake and Photostability of TPPS2a and
Amphinex
4.3.1 Introduction
The therapeutic effect of PDT or the initiation of PCI comes from the photochemical
reactions that take place following light absorption by the photosensitiser. This process
involves the production of cytotoxic reactive oxygen species that induce oxidative
biological damage and cell death. The other factors determining the efficacy of the
treatment are the rate at which the photosensitiser is taken up by cells and then delivered
into endo-lysosomes, which are related to the intracellular accumulation. However
another factor to consider is the photostability of the photosensitiser once inside the
cells since photodegradation (or photobleaching) would reduce the amount of
photosensitiser present for PCI treatment. Therefore measuring the uptake and the
photostability of sensitisers within cells are the key starting points to estimate their
potential efficacy on photodynamic therapy or photochemical internalisation.
TPPS2a, AlPcS2a and TPCS2a (Amphinex) are photosensitisers used in PCI which are
water-soluble second generation photosensitisers, as summarised in Chapter 2. Unlike
the first generation photosensitisers such as Photofrin
®, AlPcS2a and TPCS2a have many
improved chemical and biological properties, for instance, the stronger absorption at
longer wavelengths. Moreover, amphiphilicity is another common feature among these
three PCI sensitisers.
In general lipophilic, hydrophobic photosensitisers display higher cell uptake than
hydrophilic ones because they can partition more easily to the cell membrane and thus
enter the cell. However, hydrophobic photosensitisers also tend to aggregate in solution,
thereby decreasing their photoactivity because of the excited state self-quenching
effects induced by dimerization [Berg et al., 1990;Moan et al., 1992]. Amphiphilic
photosensitisers with both hydrophilic and hydrophobic characteristics within the same
molecule, on the other hand, exhibit favourable physical and pharmacokinetic properties
for PDT [Allen et al., 2002]. Chemical synthesis of adjacent sulfonated
tetraphenylporphines, phthalocyanines, and tetraphenylchlorins is one of the most
common ways to make amphiphilic photosensitisers which are particularly effective for85
PCI owing to the membrane localisation [Kunz et al., 2007], as previously outlined in
Chapter 2.
Photobleaching refers to the process of photochemically induced destruction or
photodegradation in which the molecular structure of the molecule is degraded
following light absorption. Photostability can be estimated by measuring the bleaching
of absorption or fluorescence after light exposure. Each fluorophore has its own
photobleaching characteristics depending on its photophysicochemical properties and
the rate at which it reacts with reactive oxygen species. Photobleaching can also take
place under anaerobic conditions but in most cases is studied under air-saturated
conditions. The mechanisms of photobleaching have been reviewed by Bonnett and
Martinez [Bonnett and Martinez, 2001]. In the case of porphyrin-type photosensitisers,
it is believed that photobleaching takes place mainly by destruction of the porphyrin
macrocycle or ring following reaction with reactive oxygen species such as singlet
oxygen, resulting in smaller molecular fragments that do not absorb in the visible range.
The term ‘photomodification’ is often used in the same context but generally refers to
other photoinduced processes which result in the chromophore being retained in a
modified form. For example, the production of a photoactive photoproduct, or the
photoinduced monomerisation of weakly fluorescent fluorophore aggregates. The
influence of this process will also be considered in following sections.
The situation will be more complex for treatments in vivo than in vitro because of the
heterogenous environment, but in practical terms, it is essential to study both
accumulation and photostability of photosensitisers in order to establish the dosimetry
of PDT and PCI treatments in clinic.
In this section, we will only focus on the sensitisers used in PCI. The cellular uptake of
TPPS2a, and Amphinex and their photobleaching induced after irradiation were
determined and compared in A431 cell line using spectrofluorimetry. Detailed
photodynamic modification of AlPcS2a and Amphinex in HN5 cells demonstrated by
fluorescence microscopy will be discussed in section 4.5.86
4.3.1.1 Results
Spectroscopic studies of Amphinex
The spectroscopic properties of both TPPS2a and AlPcS2a have both been well studied.
However since Amphinex is a newly available photosensitiser, spectroscopic properties
of Amphinex were assessed then prior to the cellular studies in aqueous solution. One
advantage of Amphinex over AlPcS2a is that there are only three regioisomers present
(personal communication with K. Berg) whereas there are far numerous regioisomers
present in commercially available preparations of AlPcS2a.
Figure 4.5 shows the absorbance of 5 μg/ml Amphinex diluted in distilled water. The
peak absorption of Soret absorption band was found at 418 nm. The weaker series of Q
bands were measured at 520 nm, 546 nm, 595 nm and 649 nm (Figure 4.5, inset). Peak
absorption in the red is at 649 nm. A slight red-shift of this peak is observed in tissue as
described later in Chapter 6. Its molar extinction coefficient in water can therefore be
estimated as ε418nm = 1.6 x 10
5 M
-1cm
-1 which is similar to the value for m-THPC (in
ethanol) as ε418nm = 1.9 x 10
5 M
-1cm
-1(measured in our laboratory).
Figure 4.5 Absorption spectrum of 5 μg/ml Amphinex diluted in distilled water. Inset:
the Q band region from 450 nm to 700 nm.
The fluorescence spectra of 0.5 μg/ml Amphinex diluted in distilled water are shown in
Figure 4.6A. Two peaks of fluorescence emission were detected at 655 nm and 718 nm
when excited at 415nm; the maximum excitation was at 413 nm (λemission 655 nm). The
fluorescence spectra of Amphinex were also measured within A431 cells sensitised with87
0.1 μg/ml Amphinex for 18 hrs (Figure 4.6B). Medium was washed off and replaced
with clear medium for fluorescence measurement. Two peaks of fluorescence emission
were detected at 655 nm and 725 nm when excited at 420 nm; the maximum excitation
was at 421 nm (λemission 655 nm).
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Figure 4.6 Fluorescence emission and excitation spectra of Amphinex detected in
distilled water (A) and within cells (B). A: The spectra in aqueous solution were
measured with the concentration of 0.5 μg/ml diluted in distilled water (λexcitation 414 nm
and λemission 655 nm). B: The signal was detected within A431 cells sensitised with
Amphinex (0.1 μg/ml) for 18hrs. The spectrum was corrected for the variation of
detector sensitivity with wavelength.88
Cellular uptake of TPPS2a and Amphinex in A431 cells
The cellular uptake of photosensitisers was determined by measuring the fluorescence
intensity in cells following an 18 hour incubation. A431 cell monolayers were incubated
with increasing concentrations of sensitisers and following washing the fluorescence
from the cells was measured using fibre-optic spectrofluorimeter with the
detection/excitation fibre placed above each well in a 96 well plate. A concentration
dependent cellular uptake was found in using TPPS2a and Amphinex. As shown in
Figure 4.7 and 4.8, the fluorescence intensity linearly increased against different
concentrations (R
2>0.99) and no saturation was observed. The fluorescence intensity is
not comparable between two photosensitisers as experiments were carried out on
different days with different cell confluency. However, a similar uptake pattern was
found in using both sensitisers when comparing to the fluorescence signals between
concentrations of 0.1μg/ml and 0.5μg/ml. The fluorescence intensity using Amphinex
increased linearly, ie the intensity increased by a factor of 5 higher when a 5 times
higher concentration was used. Likewise using TPPS2a a near-linear dependence
between fluorescence intensity and sensitiser concentration was observed. Since this
detection technique measures fluorescence from whole cells the possibility of
fluorescence quenching effects (e.g. due to self-quenching induced by dimerization)
cannot be ruled out, but the fact that a near linear increase with concentration is
observed would be consistent with relatively little interference from dimerization effects
in this concentration range.
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Figure 4.7 Cellular uptake of TPPS2a in A431 cells using spectrofluorimetry. Cells were
incubated with TPPS2a with various concentrations for 18 hrs previously. Fluorescence89
measurements were carried out when cells were incubated with clear medium. Detailed
procedures can be found in the section of Materials and Methods.
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Figure 4.8 Cellular uptake of Amphinex in A431 cells using spectrofluorimetry. Cells
were incubated with Amphinex with various concentrations for 18 hrs previously.
Fluorescence measurements were carried out when cells were incubated with clear
medium. Detailed procedures can be found in the section of Materials and Methods.
Photo-induced changes in fluorescence of TPPS2ain cells
All photosensitising dyes are susceptible to photodegradation, which is also known as
photobleaching, and this process can limit the efficacy of the photosensitiser. In order to
evaluate the relevance of this process to PCI, the changes in fluorescence of TPPS2a in
cells were studied using fluorescence spectroscopy following different light exposures
with blue light. The results are presented in Figure 4.9. The fluorescence intensity in the
cells treated with higher photosensitiser concentrations (0.2 and 0.5 μg/ml) increased
upon light exposure, displayed the maximum fluorescence intensity after a light dose of
4.2 J/cm
2 and decreased afterwards. The cells incubated with lower concentration of
TPPS2a (0.05 and 0.1 μg/ml) had a reduction of fluorescence signal at the beginning of
illumination. The fluorescence intensity then went up upon irradiation, followed by a
photobleaching after the light dose of 4.2 J/cm
2. In the cell-free system, it was observed
that the fluorescence intensity kept declining during the process of light irradiation and
dropped to approximately 50% of its initial value after a light dose of 2.1 J/cm
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Figure 4.9 Normalised changes in fluorescence of TPPS2a in A431 cells as a function of
fluence. Cells were incubated with TPPS2a with various concentrations for 18 hrs
previously. Fluorescence measurements were carried out when cells were incubated
with clear medium. Detailed procedures can be found in the section of Materials and
Methods.
Photo-induced changes in fluorescence of Amphinexin cells
Similar experiments were carried out but using Amphinex as the photosensitiser (Figure
4.10). In contrast to TPPS2a, the fluorescence signals detected within A431 cells were
continuously falling but with a slower photobleaching rate after expose to light
regardless of the Amphinex concentration. The fluorescence decayed less than 5% after
1.26 J/cm
2 (3 min irradiation) and remained above 90% after 4.2 J/cm
2 (10 min
irradiation). At the longest irradiation time point (i.e. 12.6 J/cm
2, in this experiment),
80% of the original fluorescence intensity was still detectable in the cells with higher
concentrations. There was only a loss of about 13% of fluorescence in the cells treated
with 0.05μg/ml Amphinex. Unlike the case of using TPPS2a, there is less variation in the
photobleaching rate between cells incubated with different concentrations of Amphinex.91
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Figure 4.10 Normalised changes in fluorescence of Amphinex in A431 cells as a
function of fluence. Cells were incubated with Amphinex with various concentrations
for 18 hrs previously. Fluorescence measurements were carried out when cells were
incubated with clear medium. Detailed procedures can be found in the section of
Materials and Methods.92
4.4 Subcellular Distribution of Photosensitisers, Co-localisation with
Organelles and Redistribution after Illumination
4.4.1 Introduction
As addressed in Chapter 2, photosensitisers used in PCI should enter cells via
pinocytosis and possibly follow clathrin-mediated pathway because of their amphiphilic
structures. It is believed that photosensitisers would be directed to further stages along
the endo-lysosomal system and ended in late endosomes or lysosomes, the major
compartments of material degradation. Because photochemical internalisation takes
place during this trafficking process, it is important to investigate the cellular
distribution and the possible co-localisation with other intracellular organelles.
There are many approaches to demonstrate intracellular lysosomal localisation of
photosensitisers. In 1989, Moan and his colleagues used differential ultracentrifugation
and electron microscopy to look at the intracellular localisation of photosensitisers
[Moan et al., 1989]. In another of their studies, the release of the lysosomal enzymes (i.e.
β-N-acetyl-D-glucosaminidase and cathepsin) was detected after treating TPPSn-
sensitised NHIK 3025 carcinoma cells with light. This funding indicated a lysosomal
disruption caused by illumination and lysosomes are surely photochemical targets [Berg
and Moan, 1994]. Similar results were obtained in the experiment using AlPcS4 or
AlPcS2; moreover, the cellular distribution of sensitisers were found identical to the
lysosomotropic dye acridine orange (AO) by a co-staining method using fluorescence
microscopy [Moan et al., 1994].
Using inhibitors or generating a cold environment to stop or slow down the metabolism
of cells is also a way to examine the relationship between photosensitisers and
endolysosomal vesicles. Prasmickaite reported the role of endosomes in gene
transfection by conducting pulse-chase experiments, lowering the temperature to inhibit
endocytosis, or using endocytosis inhibitors [Prasmickaite et al., 2000]. The outcome
indicated that early endosomes are involved in this light-dependent transfection.
Since many photosensitisers are reasonably fluorescent in the red region, nowadays, co-
staining cells with chemically synthesized specific organelles probes is a common way93
to trace the cellular uptake and identify the subcellular distribution of photosensitisers.
By carefully choosing dyes with suitable absorption and emission spectra, the imaging
results from fluorescence microscopy or confocal microscopy can demonstrate the
cellular location of photosensitisers. Therefore, in this section, the subcellular
distributions of the photosensitisers and their redistribution after light exposure will be
examined using fluorescence microscopy. A lysosomal probe emitting fluorescence in
the range around 515 nm will be used to demonstrate the co-localisation studies. Cells
co-incubated with Amphinex and a synthesized green fluorescent probe-labelled saporin
will be analyzed by fluorescence microscopy. Another experiment co-staining
lysosomal probes to cells treated with this fluorescence labelled protein will also be
carried out to present the subcellular distribution of the protein toxin.
4.4.2 Results
Subcellular distribution of TPPS2a, AlPcS2a and Amphinex and their redistribution
after illumination
After treating with 2.5μg/ml AlPcS2a for 18 hours, intracellular distribution of AlPcS2a
was observed in A431 cells by fluorescence microscopy. Following 670nm laser
irradiation on stage, the distribution of AlPcS2a became diffuse accompanied by an
increase in intensity, and thereafter photobleaching with a decrease of the fluorescence
signal (Figure 4.11). Peak fluorescence levels were observed after 40sec exposure in
both cases, and thereafter declined due to photobleaching. The same phenomenon was
also observed using a lower dose of AlPcS2a (0.5μg/ml) (data not shown). This transient
increase in fluorescence phenomenon is studied in more detail in section 4.5.
Figure 4.11 Fluorescence studies of AlPcS2a light-induced relocalisation in A431 cells
using fluorescence microscopy. Cells were treated with 2.5 μg/ml AlPcS2a for 18 hours.
The light exposure was up to 160s.94
A431 cells were incubated with 2.5μg/ml TPPS2a or 0.1μg/ml Amphinex for 18hrs. A
granular cellular distribution was found in both cases by fluorescence microscopy
(Figure 4.12A and 4.13A). The distribution of photosensitisers became diffuse
following 5 min light exposure on stage or by the blue lamp respectively (Figure 4.12B
and 4.13B). After light exposure, a distinct fluorescence in the cell membrane was also
observed. Further experiments using confocal microscopy are needed to clarify whether
this is the result of photo-induced relocalisation of photosensitiser or is due to the
limitation of CCD fluorescence microscopy in which images are taken from the whole
thickness cells.
Figure 4.12 Cellular distribution of TPPS2a in A431 cells and the redistribution after 5
min irradiation on stage images by fluorescence microscopy. Cells were incubated with
2.5 μg/ml TPPS2a for 18 hours.
Figure 4.13 Cellular distribution of Amphinex in A431 cells and the redistribution after
5 min irradiation by blue lamp using fluorescence microscopy. Cells were incubated
with 0.1 μg/ml Amphinex for 18 hours.
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Synthesis of saporin-AlexaFluor488 conjugates
The final concentration of saporin-AlexaFluor488 conjugates was 41 μM and the ratio
was 1.5 moles dye per more of protein. Comparing the spectrum of AlexaFluor488 to
the conjugate, there is only a slight blue shift in the emission spectrum after the
conjugation (Figure 4.14). The saporin conjugate was then used in co-localisation
experiments.
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Figure 4.14 Normalised emission spectra of AlexaFluor488 (pink line) and saporin-
AlexaFluor488 conjugates (black line) using 488 nm excitation.
Co-localisation of Amphinex/TPPS2a and Alexa488-labelled saporin in A431 cells
using fluorescence microscopy
Photosensitisers (Amphinex or TPPS2a) and Alexa488-labelled saporin were co-
incubated in A431 cells for 18hrs. Their subcellular distributions without light exposure
were observed using fluorescence microscopy. Fluorescence imaging results
demonstrated good intracellular co-localisation of either photosensitisers with
Alexa488-labelled saporin in A431 cells (Figure 4.15). The yellow colour in the overlay
image (Figure 4.15C) indicates that a significant amount of Amphinex was localised in
lysosomes after 18 hours cellular uptake.
Due to the rotation of the CCD camera after changing filters manually for detecting
different fluorescent probes, the merged fluorescent image of TPPS2a and LysoTracker
Green is not in exactly the same alignment(data not shown) and therefore an overlay
image is not available in this experiment (Figure 4.15D and 4.15E). However, a well-96
matched cellular distribution was still observed by comparing the individual fluorescent
image (inset arrows).
Figure 4.15 Amphinex or TPPS2a co-localised with Alexa488-labelled saporin in A431
cells by fluorescence microscopy. A: Amphinex; B&E: Alexa488-labelled saporin; C:
Merged image of A and B; D: TPPS2a. Cells were co-incubated with Amphinex (0.1
μg/ml)/TPPS2a (2.5 μg/ml) and Alexa488-labelled saporin (300 nM) for 18 hours.
Identification of the subcellular distribution of Amphinex and Alexa488-labelled
saporin using lysosome probes in HN5 cells by confocal microscopy
In order to identify the subcellular distribution of Amphinex and saporin, HN5 cells
were treated with 0.1 μg/ml Amphinex or 300 nM Alexa488-labelled saporin for 18hrs
and then incubated with 100 nM LysoTracker Green or LysoTracker Red for 30 mins
before imaging using confocal microscopy. As shown in Figure 4.16, Amphinex (red)
and LysoTracker Green (green) were well co-localised (yellow) in HN5 cells. Similar
results were found in cells treated with green fluorescent saporin and LysoTracker Red
(Figure 4.17). The merged yellow colour showed that saporin were localised at
lysosomes after cell uptake.
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Figure 4.16 Co-localisation of Amphinex and LysoTracker Green in HN5 cells by
confocal microscopy. Red: Amphinex; green: LysoTracker Green; yellow: merged
image. Cells were incubated with 0.1 μg/ml Amphinex for 18 hours. LysoTracker Green
(100 nM) was applied to cells 30min prior to imaging.
Figure 4.17 Co-localisation of Alexa488-labelled saporin and LysoTracker Red in HN5
cells by confocal microscopy. Green: Alexa488-labelled saporin; red: LysoTracker Red;
yellow: merged image. Cells were incubated with 300 nM Alexa488-labelled saporin
for 18 hours. LysoTracker Red (100 nM) was applied to cells 30min prior to imaging.
Imaging the PCI action in vitro - Co-localisation of Alexa488-labelled saporin and
Amphinex and their redistribution after irradiation on stage in HN5 cells by confocal
microscopy
The PCI action in vitro was observed using this live-imaging confocal microscopy
system. HN5 cells were co-incubated with 0.1 μg/ml Amphinex and 300 nM Alexa488-
labelled saporin for 18 hours. The results are shown in Figure 4.18. The images taken
before light exhibit good intracellular co-localisation of Amphinex and saporin in HN5
cells (Merged-before light). A 90-second light treatment was carried out on stage using
the microscopic 405nm laser through the objective. After 90 seconds irradiation,
Amphinex became diffuse accompanied by a decreased fluorescence intensity (AMX-98
90 sec light) which is consistent to previous studies. Minor changes in the distribution
of saporin were found after the 90-second light exposure (SAP-90 sec light, arrow).
Light treatment was not carried on as blebbing cells were observed (data not available).
Long-term changes of the intracellular distribution of saporin were continuously
monitored after irradiation. Images taken 7 min after light exposure show that the
distribution of saporin has changed but not radically (SAP-7 min after light, white
arrow). There is not much difference in the fluorescence intensity of Amphinex since no
further irradiation was applied.
Figure 4.18 Co-localisation of Alexa488-labelled saporin and Amphinex and their
redistribution after irradiation on stage in HN5 cells by confocal microscopy. Green:
Alexa488-labelled saporin; red: Amphinex; yellow: merged images. Light source:
405nm laser of the confocal microscope. Cells were co-incubated with Amphinex (0.1
μg/ml) and Alexa488-labelled saporin (300 nM) for 18 hours.99
4.5 Fluorescence Imaging of Photodynamic Modification and
Bleaching of AlPcS2a and Amphinex in HN5 cells
4.5.1 Introduction
The term ‘photomodification’ is often used in the same context as photobleaching or
photodegradation but generally refers to other photoinduced processes such as the
photoinduced monomerisation of weakly fluorescent fluorophore aggregates, or the
production of a photoactive photoproduct, as previously discussed in section 4.3. The
fluorescence of photosensitisers makes it feasible to determine their concentration by
measuring the fluorescence intensity. However, it is known that photosensitisers tend to
aggregate at higher concentrations which can result in self-quenching of the
fluorescence signal in its dimeric or in higher aggregated forms. In the case of
disulfonated aluminum phthalocyanine (AlS2Pc) only the monomer is fluorescent, as
shown in several studies [Kunz et al., 2007]. For example, decreasing fluorescence and
triplet quantum yields were found when the concentration of AlS2Pc was increasing
[Dhami et al., 1997].
Previous studies have demonstrated the photodynamic modification of AlS2Pc
fluorescence using a macrophage cell line by fluorescence microscopy [Kunz et al.,
2007]. The AlS2Pc fluorescence intensity was increased after a short irradiation period
(1 min). It was found to continue to rise for more then 10 minutes in the absence of
irradiation. Photobleaching, corresponding to the decay in fluorescence signal, was then
observed after the second longer irradiation at 15 min. Moreover, an oxygen
dependence was found when cells were incubated in deoxygenated solution, with the
observation of slow photobleaching instead of transient increased fluorescence intensity.
The fluorescence quantum yield of a photosensitiser can be affected by its aggregation
state, as well as its primary photophysics [Boyle and Dolphin, 1996]. Since sulfonated
phthalocyanines can be complex mixtures, chemically well-characterised AlPcS2a
obtained from Frontier Scientific Inc., with the sulphonate groups on adjacent phthalate
rings, will be used instead to investigate the photomodification properties in this section.
The photomodification properties of the new chlorin based Amphinex was studied in
comparison to AlS2Pc using quantitative fluorescence microscopy both to image and100
measure fluorescence levels in cells following light exposure.
4.5.2 Results
The fluorescence intensities of AlPcS2a from four random HN5 cells in the field were
measured over the experiment (Figure 4.19 images). A transient increase was found
during the first 3min irradiation period (Figure 4.19 graph). As shown in the images,
AlPcS2a was granularly distributed inside cells but became diffuse after 2min light
exposure. After switching off the laser, the fluorescence signals continued to increase 2
min after but remained the same level afterwards. The second irradiation was performed
at the 13 min time-point for 1 min and the effect of photobeaching was observed
onwards. The laser was switched on again at 30min for 1 min and the fluorescence
signal continued to decrease. The effect of the excitation light used for fluorescence
detection was negligible on the photobleaching observed. Similar results using A431
cells were found using different concentrations of AlPcS2a as shown in Figure 4.11
where the relocalisation of AlPcS2a occurred in parallel to a transient increase in
fluorescence.
Different results were found in the studies using Amphinex. The fluorescence intensity
started decreasing and continued falling after several light-on-light-off procedures
(Figure 4.20 graph). As shown in the pictures in Figure 4.20, the cellular distribution of
Amphinex became diffuse after light exposure but only with incremental changes of the
fluorescence intensity.101
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Figure 4.19 Photoinduced changes in integrated intracellular AlPcS2a fluorescence
intensities measured in HN5 cells at set times. Cells were incubated with 10 μg/ml
AlPcS2a for 18 hours and irradiated using a 670 nm laser. Images: AlPcS2a fluorescence
images of cells before and 2 min after light exposure. Four cells were randomly chosen
for fluorescence intensities analysis. Graph: Monitoring the changes of fluorescence
intensity after several short irradiations (on: laser on; off: laser off, shown by arrows).
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Figure 4.20 Photoinduced changes in integrated intracellular Amphinex fluorescence
intensities measured in HN5 cells at set times. Cells were incubated with 0.1 μg/ml
Amphinex for 18 hours and irradiated using a 543 nm laser. Images: Amphinex
fluorescence images of cells before and 2 min after light exposure. Five cells were
randomly chosen for fluorescence intensity analysis. Graph: Monitoring the changes of
fluorescence intensities after several short irradiations (on: laser on; off: laser off,
shown by arrows).
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4.6 Discussion
4.6.1 Comparison of cellular uptake and photostability of TPPS2a and Amphinex
Cellular uptake is the process by which photosensitising molecules are incorporated and
accumulated by living cells. The cell uptake of sulfonated alumimum phthalocyanines
and meso-tetraphenylporphines has been investigated by comparing their different
degrees of sulfonation [Berg et al., 1989b;Berg et al., 1990;Paquette et al., 1988]. The
results showed that the derivatives bearing a reduced number of sulfonate groups
exhibit better cell uptake and higher phototoxicity. This is consistent with the effect of
sulfonate groups on decreasing the lipophilicity of the photoseisitising compounds.
However, high hydrophobicity of photosensitisers will increase their tendency to
aggregate and thereby reduce the photosensiticing activity. This might explain the
observation that AlPcS1 was found to be less toxic than AlPcS2[Berg et al., 1989a]. As
a consequence, sensitisers with two sulfonate groups seem the most effective among
sulfonated photosensitising agents for the use in PDT or PCI.
In this study, we found both TPPS2a and Amphinex displayed similar cellular uptake in
A431 cells, as might be expected since the molecular structures are virtually identical.
The drug concentrations used were the same as employed in the PCI studies described
in the following section. A linear regression analysis of the results for fluorescence
intensity versus increasing drug doses indicated a constant cellular uptake rate in a drug
concentration dependent manner. No plateau was found for both drugs dose up to
0.5μg/ml. Higher doses could be applied to check for any plateauing of the cellular
uptake, but there is the potential problem of increased toxicity induced when using
higher concentration of photosensitisers which should be taken into account.
It is essential to determine the cell uptake and photobleaching in cells in order to
evaluate the effectiveness of photosensitisers. Researchers so far have not successfully
established in vitro mathematical kinetic models for the cellular uptake and
photobleaching of different photosensitisers yet. Measuring photobleaching properties
is important when carrying out PDT or PCI since it is possible that the light doses used
would significantly affect the mean cellular levels of the photosensitiser. It is also
important that a very low excitation light dose is used when using fluorescence
detection so that there is minimal perturbation to the fluorescence measurements of104
photobleaching or photomodification [Bastogne et al., 2007]. In this great care was
taken to use low light doses combined with sensitive detection techniques. Measuring
the changes of fluorescence intensity of photosensitisers during or after expose to light
by spectrofluorimetry may not be ideal but is still the most straight-forward method to
observe the photobleaching/photomodification processes in cells.
Photobleaching is the chemical destruction of fluorophores induced by light activation.
TPPS2a and Amphinex display somewhat different photobleaching properties in A431
cells although their cell uptake and light absorption properties are comparable. The
same blue light source for cell illumination was used in each case and fluorescence was
detected using exactly the same excitation/detection setup. Fluorescence intensity was
found increased at the beginning of irradiation and decreased after longer light exposure
when using higher concentrations of TPPS2a (0.2 and 0.5 μg/ml). Using lower TPPS2a
concentrations (0.1 and 0.05 μg/ml), the fluorescence signal within cells was decreased
first upon illumination, then increased and decreased again after longer exposure time.
In contrast to TPPS2a, photobleaching of Amphinex was observed with continuously
decreasing fluorescence intensity when irradiation started regardless the concentrations
used (0.05-0.5 μg/ml). However, Amphinex bleached slowly in A431 cells and
therefore displayed a higher fluorescence signal (80% of the original intensity) after
longer light exposure in comparison with TPPS2a. The results indicate that Amphinex is
more photostable than TPPS2a in cells following light exposure.
The results here also give information about the suitable window of the light dose used
for activating photosensitisers for PCI. The fluorescence intensity was similar to the
original intensity after 10 min irradiation and remained within 90% of the original
intensity in the case of TPPS2a and Amphinex respectively. Since the light dose used for
PCI experiments in the following section described are within the range of light doses
used here it can be inferred the effect of photobleaching on the PCI results is minimal.
4.6.2 Subcellular distribution of photosensitisers, co-localisation with organelles
and redistribution after illumination
As mentioned before, amphiphilic photosensitisers are believed to display more ideal
physical and pharmacokinetic properties compared to hydrophilic or hydrophobic105
sensitisers [Allen et al., 2002]. Synthesis is carried out by chemical modification of the
photosensitiser with two ionic sulfonate groups on adjacent sites of the periphery of the
macrocycle. This polarity from the structure favours lipid membrane penetration and
therefore makes amphiphilic sensitisers particularly suitable to be used in PCI which
required a co-accumulation of sensitiers and anti-cancer drugs.
The optical properties of three photosensitisers (AlPcS2a, TPPS2a and Amphinex) in
vitro were examined in this section. Experiments including their intracellular
distribution, redistribution after light, and the co-localisation with lysosomes and co-
administered protein toxin were carried out using two squamous cell carcinoma cell
lines, A431 and HN5 cells.
In general, all photosensitisers displayed a granular cellular distribution after cell uptake.
Moreover, a light-induced redistribution was observed after light exposure using either
a blue lamp for Amphinex and TPPS2a (Soret band absorption) or 670 nm laser
irradiation for AlPcS2a. As shown in Figure 4.11, the AlPcS2a fluorescence pattern
inside cells was changed to a more diffuse distribution after a 20s light exposure. The
increased intensity after the first 40s irradiation is believed to be caused by the
monomerization of the sensitiser following disruption of intracellular vesicles [Kunz et
al., 2007], which was also observed in the photomodfication studies (Figure 4.19). The
diffuse pattern following light exposure is consistent with the process of photodynamic
reactions which induces the rupture of endo-lysosomes membranes. This significant
change also indicated that PCI could achieve sufficient release of macromolecules by
using a very low light dose.
Since most of the hydrophobic or lipophilic sensitisers were found to favour lysosomes
as their final targets after cell uptake [Geze et al., 1993], photosensitisers used in PCI
strategy were assumed to follow this endocytotic pathway because of their amphiphilic
properties. As a result, experiments imaging the intracellular distribution of
photosensitisers together with LysoTracker Green labelled lysosomes were carried out
to study further whether this particular subcellular distribution is indeed related to the
distribution of lysosomes. According to the results of the co-localisation experiments,
most of the red fluorescence produced from Amphinex is co-localised to lysosomes
which are labelled with LysoTracker Green fluorescence (Figure 4.16).106
PCI is a technology to release the co-administered anticancer agent retained within
endo/lysosomal compartments after taken up via endocytosis by shining the light. The
PCI effect in combination with different anticancer drugs has been well documented by
analysing the cell viability after treatments but only few studies presented the PCI
action by fluorescence microscopic studies. A conjugation strategy was used by Selbo
and his colleagues who coupled a green fluorescence probe to gelonin and imaged its
changes of cellular localisation after PCI in a melanoma cell line using epi-fluorescence
microscopy [Selbo et al., 2000a]. In this study, we synthesized Alexa488-labelled
saporin and carried out fluorescence imaging using an inverted confocal microscope
with cells seeded in a glass-bottom dish for live and higher resolution image analysis.
Therefore, we were able to examine the subcellular localisation of saporin and monitor
the PCI action in sensitised cells by visualising photosensitiser and fluorescence
labelled saporin at the same time.
The fluorescence spectrum of the saporin-Alexa488 complex was measured in
comparison with AlexaFluor488 alone (Figure 4.14). The maximum emission is almost
the same after conjugation but the possibility of perturbing the enzymatic activity of
saporin after conjugation to Alexa488 should be considered. A relatively high
concentration was used in these studies and some cell morphological changes were
noted with more cells detaching from the base (Figure 4.17 and 4.18). As shown in the
figures, the overlapping fluorescence images indicate the lysosomal localisation of
Alexa488-labelled saporin and its co-localisation with photosensitisers. The PCI effect
was visualised in the cells co-incubated with Amphinex and labelled saporin after
expose to 90s at 405nm by the confocal laser microscope (Figure 4.18). Cells were also
found to exhibit blebbing at this time point. A slow re-localisation of saporin was then
observed 7 min after irradiation accompanying the redistribution of Amphinex with a
diffuse pattern of distribution evident with lower fluorescence intensity.
This section has demonstrated the subcellular distribution of TPPS2a, AlPcS2a and
Amphinex by co-staining cells with lysosomal probes. Also, the re-localisation of these
sensitisers was observed after light exposure. The PCI effect, the light-induced re-
localisation of saporin, was visualised using Alexa488-labelled saporin in sensitised
HN5 cells after irradiation on stage. Further studies to elucidate the photochemical
reaction and to investigate the PCI effect in combination with anticancer agents will be
illustrated in the following sections.107
4.6.3 Fluorescence imaging of photodynamic modification of AlPcS2a and
Amphinex in HN5 cells
Previous work done by Kunz and colleagues investigated photodynamic modification
processes by imaging the fluorescence of disulfonated aluminium phthalocyanine in a
macrophage cell line [Kunz et al., 2007]. The aim of the experiments here was the same
but using purer AlPcS2a from a commercial source to carry out a comparison with
Amphinex in HN5 squamous carcinoma cells. The drug concentrations and incubation
times used were similar to those employed in the PCI studies.
AlPcS2a and Amphinex are both amphiphilic photosensitisers with a phthalocyanine and
chlorin macrocycle respectively. Both of them exhibit efficient cell uptake in HN5 cells
according to the results in previous sections. Using AlPcS2a, similar results to the
previous study were obtained where the fluorescence inside cells increased after a short
irradiation, increased slightly and retained the intensity in the absence of light. The
second irradiation was carried out when the fluorescence remained constant for 10 min
after the first irradiation (Figure 4.19). Unlike the previous study by Kunz [Kunz et al.,
2007], smaller light doses were used initially in order to resolve the induced
fluorescence increase more clearly. However, it still resulted in a decline of
fluorescence signal due to photobleaching. Amphinex, on the other hand, exhibited a
different photomodification pattern in this experimental setting. No increase of
fluorescence intensity was found after the first irradiation. Nevertheless, photobleaching
was observed from the beginning when cells were exposed to light. Of course different
light sources were used for each photosensitiser so it is difficult to compare the relative
light doses absorbed by the cells for each photosensitiser. However it is clear that the
fluorescence dynamics observed from the start of illumination are different
The aggregation of photosensitisers at high concentrations may explain the increase of
AlPcS2a fluorescence after the first short illumination. Dimeric or aggregated AlPcS2a
could be naturally formed when concentration is high which would result in self-
quenching of the fluorescence signal [Berg et al., 1990;Moan et al., 1992]. This
conclusion is supported by time-resolved fluorescence lifetime studies in cells
[Kelbauskas and Dietel, 2002]. With light activation, lysosomal rupture occurs which
results in release and dilution of the dimers which are then converted to monomers and
this monomerisation results in an increase of fluorescence intensity which was observed108
and detected in the early stage of photochemical reactions. In the previous study by
Kunz, the transient increase of fluorescence intensity was only found when cells were
treated with higher concentration of AlS2Pc (10μM) for longer incubation time. Similar
results were obtained in this study using 10μg/ml AlPcS2a in HN5 cells for 18 hours. In
contrast, cells were treated with a much lower dose of 0.1μg/ml Amphinex for 18 hours.
This was partly because Amphinex was easier to detect probably as result of more
efficient cellular uptake and the fact that a much lower concentration of Amphinex can
be used for PCI compared to AlPcS2a.
The photomodification imaging studies using AlPcS2a also showed a transient increase
in fluorescence which was ascribed to dimer monomerization. The fluorescence
dynamics of TPPS2a in cells during irradiation therefore parallels to the intracellular
photomodification of AlPcS2a, but are different from Amphinex where only slow
photobleaching was observed. The results obtained using Amphinex are also consistent
with the earlier photobleaching study (Section 4.4) in a different cell line (A431) using
fluorescence spectroscopy of cell monolayers. The fluorescence intensity of TPPS2a
(higher concentrations) in cells increased initially and then decreased during
illumination, whereas, the signal from Amphinex declined throughout the light exposure
process (Figure 4.9 and 4.10). Therefore it appears that Amphinex under these
incubation conditions (the same as employed for PCI) only undergoes slight
photobleaching without any noticeable photomodfication processes such as light-
induced monomerization.
Taking the results together from Sections 4.3 and 4.5, Amphinex has appears to exhibit
distinct photobleaching properties from TPPS2a and AlPcS2a. It should be noted
however that whereas the same concentrations of TPPS2a and Amphinex were used (0.1
μg/ml) a much higher concentration of AlPcS2a was used which would favour
dimerization. The lack of any transient fluorescence increase when using Amphinex
could indicate that this compound undergoes less dimerization in cell membranes,
which may be of benefit to its photoactivity. Resistance to aggregation may be a
consequence of its tetraphenyl chlorin structure but further experiments comparing
different photosensitisers in a range of doses should be conducted to unravel the exact
mechanisms.109
We did not attempt to investigate the role of oxygen in the photodynamic modification
of photosensitisers here, but, oxygen dependence is an essential characteristic of
photodynamic reactions. Considering the oxygen supply, cells were seeded in chamber
slides instead of using conventional coverslips for microscopic observation. For the
later photomodification studies glass-bottom ‘FluoroDishes’ which also enable live cell
imaging were used to guarantee a sufficient oxygen supply. Therefore in all these
studies the oxygen supply should not have been a limiting factor.110
4.7 Determination of the Optimal Treatment Conditions of PCI -
Analysis of the Phototoxicity Induced after PDT
4.7.1 Introduction
The overall cytotoxicity of PCI using a cytotoxic agent is combination of the phototoxic
effect of PDT from the photosensitiser and the enhanced toxicity from the released
cytotoxic agent. However, the ‘photodynamic dose’ (the product of the light dose and
photosensitiser dose) employed in PCI for inducing breakdown of the membranes of
intracellular organelles is much less than that required for PDT treatment itself which
aims to kill the whole cell. In other words, only a sub-lethal PDT dose is required for
the PCI strategy. The aim of this study was to establish the optimum combination of
light dose and photosensitiser dose for PCI treatment in cells for sub-lethal treatment.
Based on studies carried out previously by Berg and co-workers to deliver several
therapeutic agents with the size ranging from peptides, protein toxins to genetic
materials [Berg et al., 1999], it was found that the efficacy of PCI was clearly dependent
on the light dose which in turn is related to the PDT dose. For instance, in the study
using AlPcS2a PCI to deliver pEGFP-N1/p(Lys) DNA complex, the maximum
transfection was achieved at light doses which killed about 50% of the cells with the
photosensitiser alone [Hogset et al., 2000].
Optimal PCI treatment conditions may vary when combining different sensitisers and
therapeutic agents using different cell lines. It is essential therefore to study the PDT
effect prior to subsequent PCI experiments in order to make sure that a sub-lethal PDT
dose is employed in the PCI studies. This section will, therefore, investigate the PDT-
induced phototoxicity induced by TPPS2a, AlPcS2a and Amphinex in A431 and HN5
cells. From these data the sub-lethal phototoxic threshold (i.e. 50% cell death)
combination of light and photosensitiser can then be established. The abbreviation
‘PDT50’will be used to describe the sub-lethal photodynamic dose that kills 50% of the
cells.111
4.7.2 Results
Phototoxicity of TPPS2a and AlPcS2ain A431 cells
The phototoxicity induced by TPPS2a and AlPcS2a was investigated in a range of drug
concentrations under different light exposure time with A431 cells. Cell viability was
dependent on light does and drug dose in both cases (Figure 4.21 and 4.22). The PDT50
caused by TPPS2a with A431 cells was at the concentration of 0.1 μg/ml and 3 min light
exposure. Determination of treatments conditions corresponding to the PDT50 is
important when selecting the optimum treatment parameters for PCI where a sub-lethal
PDT effect is the aim. Using a 5 μg/ml concentration and 3 min light treatment 50% cell
death of A431 cells was induced after AlPcS2a PDT. After 10min irradiation, less than
4% cells were viable when incubated with AlPcS2a for all drug concentrations in this
experimental condition.
A negligible dark toxicity was measured in the cells treated with TPPS2a. Compared to
TPPS2a, AlPcS2a induced some dark toxicity, but the cell viability was still more than
50% after the 18 hour-incubation of 10μg/ml AlPcS2a.
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Figure 4.21 Phototoxicity of TPPS2a in A431 cells. Cells were incubated with TPPS2a
with a range of concentrations for 18 hrs. Cells were irradiated using a blue lamp for up
to 5 min. Cell viability was examined by the MTT assay 48hrs after irradiation.112
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Figure 4.22 Phototoxicity of AlPcS2a in A431 cells. Cells were incubated with AlPcS2a
with a range of concentrations for 18 hrs. Cells were irradiated using a 670nm laser for
up to 10 min. Cell viability was examined by the MTT assay 48hrs after irradiation.
Phototoxicity of Amphinex in A431 and HN5 cells
The phototoxicity induced by Amphinex was investigated in a range of drug
concentrations under different light exposure with A431 cells and HN5 cells. Light dose
and drug dose dependent cell killing was found in both cell lines (Figure 4.23 and 4.24).
Moreover, the phototoxicity of Amphinex in A431 and HN5 cells was very much
similar. It was reduced to about a quarter using 0.1μg/ml Amphinex after 3 min light
treatment. The PDT50 for both cell lines was achieved with a combination of 0.1 μg/ml
Amphinex and 1-3min irradiation or 0.05 μg/ml drug and 3-5 min light exposure.
The cytotoxicity produced by Amphinex was very low without light exposure. It was
only 15% and 6.5% in A431 or HN5 cells respectively when the drug concentration was
0.05 μg/ml. The cell viability was 86% in HN5 cells which were observed to be less
sensitive to Amphinex compared to A431 cells.113
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Figure 4.23 Phototoxicity of Amphinex in A431 cells. Cells were incubated with
Amphinex with a range of concentrations for 18 hrs. Cells were irradiated using a blue
lamp for up to 5 min. Cell viability was examined by the MTT assay 48hrs after
irradiation.
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Figure 4.24 Phototoxicity of Amphinex in HN5 cells. Cells were incubated with
Amphinex with a range of concentrations for 18 hrs. Cells were irradiated using a blue
lamp for up to 5 min. Cell viability was examined by the MTT assay 48hrs after
irradiation.114
4.7.3 Discussion
PDT efficacy differs when used photosensitisers, light doses and cell lines are not the
same. Effective PDT relies on an efficient cell uptake of photosensitisers and also an
appropriate light source to induce the photodynamic reactions. The results in this
section clearly show the drug dose and light dose dependence of PDT treatments –
higher drug concentration or longer light exposure result in less cell survival.
Cells were treated with either sensitiser for 18 hours to make sure there is sufficient
amount of drug taken up by cells. Due to the very low drug concentration window, the
dark toxicity produced from either photosensitiser was relatively low in comparison
with the treatments involving light exposure. This low dark toxicity therefore indicates
the significant cell kill effects produced after irradiation were mainly from the
photodynamic reaction.
In the experiments using TPPS2a or AlPcS2a in A431 cells, AlPcS2a induced a more
appreciable enhancement of the PDT effect than TPPS2a; however, TPPS2a is effective
at a much lower concentration. This may be due to the more efficient excitation of
TPPS2a by the blue lamp - the light dose delivered by the blue lamp is 1.26 Jcm
-2 and is
0.16 Jcm
-2 by the 670nm laser (for excitation of AlPcS2a ) after 3 min irradiation. The
absorption of the two drugs at these respective wavelengths is similar.
Using the same blue lamp, Amphinex displayed a more effective PDT toxicity than
TPPS2a on A431 cells. After 3 min irradiation, the cell viability was reduced to a half
using 0.1μg/ml TPPS2a PDT but was less than one third using 0.1μg/ml Amphinex PDT.
Exactly the same Amphinex PDT experiments were carried out but using HN5 cells.
The cell kill effect was found similar to the results using A431 cells.
Many studies have indicated that the sub-lethal dose of PDT is the optimal condition for
PCI treatments [Selbo et al., 2000a;Weyergang et al., 2006]. The results of this section
show that either TPPS2a, AlPcS2a or Amphinex could induce efficient PDT effect using
very low drug concentration in A431 or HN5 cells. Marked cell kill effects were found
after several minutes’ light exposure. The findings, therefore, make an assumption that
effective PCI effects using these three photosensitisers could be achieved if under
appropriate combinations of therapeutic agents.115
4.8 Photochemical Internalisation of Anti-Cancer Drugs
4.8.1 Introduction
The concept of photochemical internalisation (PCI) is based on the therapeutic effects
of sequestered macromolecules and other bioactive agents through their release from
vesicular compartments after the membrane-associated PDT treatment. The PCI effect
is therefore a combination result of PDT effect and the drug toxicity. PCI has been used
to relocate various types of macromolecules inside cells. These have been reviewed in
more detail in Chapter 2 but among them, PCI in combination type I ribosome-
inactivating proteins has been the most well-studied, in particular gelonin. Gelonin was
the first type I RIP used in PCI which has exhibited synergistic cytotoxicity under this
combined modality in many studies [Berg et al., 1996;Berg et al., 1999;Selbo et al.,
2000a]. Further approaches using antibody-coupled gelonin displayed enhanced
cytotoxicity in PCI strategy due to the increased cellular uptake of gelonin [Selbo et al.,
2000b;Selbo et al., 2001a]. Saporin, one of the anti-cancer drugs used in the PCI studies
in this thesis, is also a type I ribosome-inactivating protein but exerts much higher
toxicity compared with gelonin [Bolognesi et al., 2000]. In two recent papers, PCI of
saporin linked with epidermal growth factor (EGF) or the antibody against EGF
receptor induced increased killing effects on EGFR positive cancer cells [Weyergang et
al., 2006;Yip et al., 2007].
Another anti-cancer drug used in this thesis study is bleomycin. Bleomycins are a
family of water-soluble glycopeptidic antibiotics which have been used in combination
with several chemotherapy agents for cancer treatments in clinic [Sikic et al., 1985].
Bleomycin has been tested for whether its therapeutic effect could be improved by PCI
in vitro using hamster lung fibroblasts and a human colon cancer cell line [Berg et al.,
2005a]. Further details are given in Chapter 2. Although these two cell lines have
different sensibilities to bleomycin, the synergistic inhibition of cell growth after PCI
treatments was found in both cell lines treated with bleomycin.
Amphinex is a new photosensitiser designed for PCI technology. The aim of the studies
in this section is to investigate the PCI effect using Amphinex by combinations with
saporin or bleomycin in A431 human epidermoid carcinoma cells and HN5 human head116
and neck squamous cell carcinoma cells. There are no published studies to date on
Amphinex either for PDT or PCI in cells. The results of present study will be compared
with TPPS2a and AlPcS2a which are so far the most common two PCI photosensitisers
whose properties are better understood.
4.8.2 Results
Cytotoxicity of bleomycin and saporin in A431 and HN5 cells
The cytotoxicity induced by two anti-cancer drugs, saporin and bleomycin, with and
without light exposure was examined prior to the combination with PDT treatment. In
control cells without any applied drug but with exposure no change in viability was
noted. Saporin produced similar toxicity in A431cells and HN5 cells either with light or
without light treatment (Figure 4.25). The cell kill effect induced by bleomycin was also
measured in both cell lines (Figure 4.26). The suitable drug dose for further PCI
application is chosen when sub-lethal cell killing was induced. Therefore, up to 50 nM
of saporin and 0.0007-0.007 IU/ml of bleomycin would be used to investigate the PCI
effect in comparison with PDT treatment and in the presence of anti-cancer drugs only.
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Figure 4.25 Cytotoxicity of saporin in A431 and HN5 cells with or without light
exposure. Cells were incubated with saporin with a range of concentrations for 18 hrs.
Cells were irradiated using a blue lamp for 5 min. Cell viability was examined by the
MTT assay 48hrs after irradiation.117
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Figure 4.26 Cytotoxicity of bleomycin in A431 and HN5 cells with or without light
exposure. Cells were incubated with bleomycin with a range of concentrations for 4 hrs.
Cells were irradiated using a blue lamp for 5 min. Cell viability was examined by the
MTT assay 4 days after irradiation.
Cytotoxicity of TPPS2a and AlPcS2a PCI combing saporin in A431 cells
The PCI effect combining saporin or bleomycin in A431 cells was investigated using
TPPS2a and AlPcS2a with approximately the PDT50 doses. Light exposures of 3 minutes
were employed in each case, and incubation times of toxins are given in section 4.2.
Control measurements for light plus photosensitiser alone (i.e. PDT alone) are shown by
the intercept values for zero concentrations of the cytotoxin. In each case the toxicity
induced by PDT alone was about 50% (the exact values are shown in Table 4.1 in the
Discussion at the end of this section). Enhanced cell killing was observed in
combination with saporin or bleomycin after either TPPS2a or AlPcS2a PCI treatment
(Figure 4.27-29). Figure 4.27 shows the effect of TPPS2a and AlPcS2a PCI in
combination with saporin (0 to 5 nM) after 3 min light exposure. Cells treated with 0.1
μg/ml TPPS2a and 3 min irradiation exhibited about 50 percent survival. The cell
survival by treatment with saporin alone was above 55 percent in this range of
concentration but the cell viability was reduced to less than one fifth using 5 nM saporin
in TPPS2a-treated cells after 3 min light treatment (p < 0.001).118
Comparable results were obtained using AlPcS2a PCI in combination with saporin.
About 60 percent cells could survive from the PDT treatment with 5μg/ml AlPcS2a and
3 min light exposure. The cell viability was reduced to 6 percent in combination with
0.5 nM saporin after irradiation (p < 0.001) and was only 5 percent in the presence of
1nM saporin (p < 0.001).
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Figure 4.27 TPPS2a and AlPcS2a PCI of saporin in A431 cells after 3min light exposure.
Cells were coincubated with TPPS2a (0.1 μg/ml) /AlPcS2a (5 μg/ml) and saporin (up to
10 nM) for 18 hrs. Cells were irradiated for 5 min using a blue lamp for activating
TPPS2a and a 670 nm laser for AlPcS2a. Cell viability was examined by the MTT assay
48hrs after irradiation.
Cytotoxicity of TPPS2a and AlPcS2a PCI combing bleomycin in A431 cells
An interesting finding was observed in the PCI treatments combing bleomycin;
therefore, separate graphs are used to present the results. As shown in Figure 4.28 and
4.29, there is not much difference in the cell viabilities between cells treated with PCI
upon shorter irradiation time and cells treated with bleomycin alone or with
photosensitisers in the dark. Significantly enhanced cytotoxic effects induced by PCI
were only found when longer light exposure was carried out using 5min irradiation for
TPPS2a PCI and 10min light exposure for AlPcS2a PCI. These data are further analysed
later in this section.119
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Figure 4.28 TPPS2a PCI of bleomycin in A431 cells. Cells were incubated with TPPS2a
(0.1μg/ml) for 18hrs. Bleomycin (up to 0.007 IU/ml) was applied to cells 4 hrs before
irradiation using a blue lamp. Cells were exposed to light for 150s or 300s. MTT assay
was carried out to measure the cell viability 4 days after irradiation.
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Figure 4.29 AlPcS2a PCI of bleomycin in A431 cells. Cells were incubated with
AlPcS2a (1μg/ml) for 18hrs. Bleomycin (up to 0.007 IU/ml) was applied to cells 4 hrs
before irradiation using a 670 nm laser. Cells were exposed to light for up to 10 min.
MTT assay was carried out to measure the cell viability 4 days after irradiation.
Cytotoxicity of Amphinex PCI combing saporin and bleomycin in HN5 cells
This study was carried out after completion of the studies using TPPS2a and AlPcS2a
(which were already available) since Amphinex only became available later in the120
course of the project. By then a clinical trial of head and neck cancers using PCI was
being considered therefore it was thought to be important to assess Amphinex PCI in a
human head and neck cancer cell line. The human HN5 squamous cell carcinoma cell
line derived from a head and neck tumour was available in our department, therefore
experiments were conducted in this cell line. The Amphinex PCI effect on HN5 cells in
combination with saporin and bleomycin was evaluated using the PDT50 photosensitiser
and light dose combination.
Control measurements for the cytotoxic effects of saporin and bleomycin alone without
light are given by the intercept values for zero light exposure. Enhanced cell killing was
observed using 10-50 nM saporin concentrations. With saporin (25nM) and Amphinex
(0.1μg/ml) PCI, the cell viability was significantly reduced by a factor of 29 after 3 min
light exposure compared to saporin treatment alone (Figure 4.30). The results presented
here were plotted as the cell viability versus light exposure because more light doses
were used and fewer toxin doses were employed. This method of plotting the data was
adopted from the PCI studies carried out by Berg et al. in which the PCI effect in
relation to the illumination time can be seen clearly. Results of the later study in
Chapter 5 using bioconjugates for PCI strategy are also presented in the same way.
Enhanced cell killing effects also could be found using bleomycin with Amphinex PCI.
The survival rate became less than a half after 3 min light treatment if compared to the
PDT group, whereas the cell viability remained steady irrespective of a longer
irradiation time (5 min) (Figure 4.31).121
0.01
0.1
1
0 1 2 3 4 5
Light exposure time (min.)
R
e
l
a
t
i
v
e
v
i
a
b
i
l
i
t
y AMX 0.1μg/ml
Saporin 10nM
Saporin 25nM
Saporin 50nM
AMX + 10nM Saporin
AMX + 25nM Saporin
AMX + 50nM Saporin
Figure 4.30 Amphinex PCI of saporin in HN5 cells as a function of light dose using
different concentrations of saporin. Cells were coincubated with Amphinex (0.1 μg/ml)
and saporin (up to 50 nM) for 18hrs. Irradiation was carried out up to 5 min using a blue
lamp. Cell viability was examined by the MTT assay 48 hrs after exposure to light.
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Figure 4.31 Amphinex PCI of bleomycin in HN5 cells as a function of light dose using
different concentrations of bleomycin. Cells were incubated with Amphinex (0.1 μg/ml)
for 18hrs and bleomycin (up to 0.007 IU/ml) for 4 hrs. Irradiation was carried out up to
5 min using a blue lamp. Cell viability was examined by the MTT assay 4 days after
exposure to light.122
4.8.3 Discussion
PCI is a technology which involves sub-lethal treatment of PDT to modify the
intracellular distribution of co-administered drugs and other agents sequestered in
lyso/endosomes [Berg et al., 1999;Hogset et al., 2004]. This section investigated
whether an enhanced delivery of saporin and bleomycin to their intracellular target sites,
and in turn their therapeutic efficacy, could be achieved by photochemical
internalisation.
After receiving either TPPS2a, AlPcS2a or Amphinex PCI treatment using the saporin
and light does which induced 50% cell death, cell viability was reduced significantly (p
< 0.001). Synergistic effects were found combining saporin in all PCI treatments.
Synergistic cell killing corresponds to a loss of cell viability greater than the additive
effects arising solely from toxin toxicity and PDT toxicity.
Table 4.1 summarises the optimal parameters of the PCI treatments which achieved
enhanced cytotoxicity combining saporin or bleomycin in this section. The calculated
additive effect is the multiplication of the toxicity observed from toxins (A) alone and
from sub-lethal PDT alone (B) (A, B stand for the values of relative viability (e.g. A =
0.5 for 50% viability etc.). The PCI effect (C) represents the measured viability from the
overall combination of light, photosensitiser and toxin. The ratio (A x B) / C can
therefore indicate whether a synergistic enhancement or a purely additive effect is
obtained from the treatment: i.e. a value of 1 would therefore correspond to purely
additive effects whereas a value greater than one would correspond to a synergistic
effect and a value less than one would correspond to an antagonistic effect.
The greatest synergistic enhancement was achieved by Amphinex PCI of saporin in
HN5 cells in which the cell viability was reduced by a factor of 16 compared to the
additive toxicity from sub-lethal PDT and saporin under the same light exposure.
AlPcS2a PCI of saporin and bleomycin in A431 cells also reduced the cell viability by a
factor of 7 and 2.6 respectively compared to the combination effect from PDT and
toxins. The PCI effect using TPPS2aenhanced the toxicity in A431 cells by a factor of 2
in combination with both toxins. In contrast, Amphinex PCI of bleomycin in HN5 cells
only induced moderate toxicity in which the overall effect was about the sum of
Amphinex PDT and bleomycin.123
Table 4.1 Optimisation of PCI. Cell survival (%) after TPPS2a/AlPcS2a /Amphinex PCI
in combination with saporin/bleomycin with A431 cells or HN5 cells. The errors are
presented as ± SD. The synergistic effect is presented as the ratio of the calculated
additive effect (A x B) and measured PCI effect (C). The comparison of the PCI effect
and toxicity from toxins alone is shown as the ratio A/C. PS: Photosensitiser; SAP:
saporin; BLM: bleomycin. * with light but no photosensitiser
In fact, the variable PCI effects in combination with bleomycin using different cell lines
and sensitisers reflect some aspects found in these series of experiments where the
experimental protocol was the same as the PCI treatments using saporin. First of all,
bleomycin was found to be relatively more toxic than saporin; since not many cells
Cells A431
AlPcS2a Photosensitiser TPPS2a 0.1 μg/ml
5 μg/ml 1 μg/ml
SAP
5 nM
(3min light)
BLM
0.007 IU/ml
(5min light)
SAP
5 nM
(3min light)
BLM
0.007 IU/ml
(10min light)
Toxins only (A)*
(dose and light
exposure time)
54.0±8.6 50.1±4.7 54.0±8.6 46.6±0.3
PDT only (B)
(no toxins)
51.6±2.8 42.2±5.1 59.6±8.6 74.4±4.6
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PCI (C)
(with same light dose)
15.7±1.8 10.8±2.9 4.6±0.9 13.1±1.9
Ratio of effect of
PCI over toxin only (A/C)
3.4 4.6 11.7 3.6
Synergistic effect
- ratio of (A x B)/C
1.8 2.0 7.0 2.6
Cells HN5
Photosensitiser Amphinex 0.1 μg/ml
SAP 25nM
(3min light)
BLM 0.007 IU/ml
(3min light)
Toxins only (A)
(dose and light
exposure time)* 47.1±6.3 44.3±7.3
PDT only (B)
(no toxins)
55.5±9.6 35.5±6.6
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%
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PCI (C)
(with same light dose)
1.6±0.5 13.1±2.6
Ratio of effect of
PCI over toxin only (A/C)
29 3.4
Synergistic effect
- ratio of (A x B)/C
16 1.2124
could survive after 18 hrs drug incubation with bleomycin. Therefore, a shorter drug
incubation time where cells were only treated with bleomycin for 4 hours before
irradiation was employed through out all experiments, as shown Figure 4.4. Secondly, it
also has to be noted that the end time point of cell viability measurement differs from
that in the saporin experiment either. The survival of bleomycin-treated cells was
measured 4 days after light treatments. This is because no distinct PCI effect was
observed when the cell survival was measured 2 days after irradiation (data not shown).
This effect was also pointed out by the pioneering paper which evaluated the potential
of AlPcS2a based-PCI of bleomycin [Berg et al., 2005a]. Using other measurements to
examine the cell viability instead of changing the experiment termination time could
also be options. The MTT assay is the most common method to determinate the cell
viability but will not be suitable for every circumstance especially when experiments
may have influence on cell mitochondria. The protein synthesis assay which measures
the total protein amount which would be appropriate for saporin or the clonogenic assay
and gives a measure of the long-term cell survival are other possibilities although time-
consuming.
Nevertheless, a modified protocol which extended the exposure time but reduced the
dose of photosensitisers seemed to work better in combination with bleomycin since
more efficient PCI effects (i.e. significant cell killing; p<0.05) were only observed when
longer irradiation treatments were carried out. A summary is shown in Figure 4.32. The
results indicate that the optimal PDT condition for photoactivating bleomycin may not
be at the PDT50 condition of photosensitisers and light doses. This finding shows that it
is necessary to optimize the treatment conditions as it may vary because of the different
pharmacokinetics of the drugs and also the cell lines used.125
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Figure 4.32 TPPS2a and AlPcS2a PCI of bleomycin in A431 cells. Cells were incubated
with TPPS2a (0.1 μg/ml) /AlPcS2a (1 μg/ml) for 18hrs. Bleomycin (up to 0.007 IU/ml)
was applied to cells 4 hrs before irradiation using a blue lamp for activating TPPS2a (5
min)and a 670 nm laser for AlPcS2a(10 min). MTT assay was carried out to measure the
cell viability 4 days after irradiation.
The most encouraging finding from these series experiments is the very low doses of
saporin used in the PCI treatments i.e. < 25 nM. It has been proven that PCI strategy
using TPPS2a and AlPcS2a could enhance the therapeutic effects of gelonin [Berg et al.,
1999;Selbo et al., 2000a]. With similar experimental settings, the results in this study
show that saporin is more effective than gelonin. Massive cell killing was achieved
using Amphinex PCI in combination with less than 50 nM of saporin after 3 min light
exposure (Table 4.1). Comparable results also have been reported in recent two studies
which saporin was photoactivated using TPPS2a in other cell lines [Weyergang et al.,
2006;Yip et al., 2007]. Increased drug and light doses may result in further reduction of
the cell viability. The results obtained in this and the previous section also warrant that
Amphinex can induce efficient photosensitisation and Amphinex PCI of saporin is
feasible for future tumour treatments in vivo and in the clinic.126
4.9 Summary
The results in this chapter have demonstrated the PCI action in vitro. The intracellular
distribution and the light-induced relocalisation of photosensitisers was observed using
fluorescence microscopy. From the results shown in section 4.4, the changes from
granular to diffuse distribution correspond to the process of photochemical reactions
which induced the rupture of endo/lysosomes. This significant difference also indicated
that PCI could achieve sufficient release of macromolecules by using a very low light
dose. Moreover, the intracellular distribution of Alexa488-labelled saporin was also
observed to become more diffuse following light exposure, consistent with lysosomal
rupture occurring during PCI
To investigate the efficacy of the cell uptake and the photobleaching of photosensitisers
after light treatment, cells were incubated with the photosensitisers and the fluorescence
intensity was measured by a spectrometer (Section 4.3). Further experiments to study
the detailed fluorescence changes within cells were carried out by imaging the
photodynamic modification inside cells (Section 4.5). The differences of the cellular
uptake and the photobleaching after irradiation between sensitisers are primarily caused
by their different physiochemical properties and the local concentration inside
endo/lysosomes. When cells were treated with relatively high concentrations of AlPcS2a,
the photochemical reactions leading to endo/lysosomal rupture induced an increase in
fluorescence intensity at the beginning of light exposure. This is most likely due to the
presence of photosensitiser dimerization at high concentrations and the dimerized
photosensitisers are weakly or non-fluorescent. Upon endo/lysosmal rupture these
dimers are converted to monomers which are fluorescent Sensitisers all underwent
photobleaching after longer light treatment.
Two anti-cancer drugs, saporin and bleomycin, exhibited enhanced cytotoxicity in
combination with TPPS2a, AlPcS2a and Amphinex based PCI (Section 4.8). Sub-lethal
PDT and toxins doses were generally the optimal condition to induce efficient PCI. It
may however be necessary to modify the treatment protocols to adapt to different
therapeutic drugs because of their different pharmacokinetic properties. Under optimal
treatment conditions, PCI can relocate bleomycin and saporin inside cells and thus
enhance cell death.127
In addition to photosensitisers, light source and the presence of molecular oxygen, the
three required elements for PDT treatment, the other participant in PCI is the
therapeutic macromolecule. As mentioned before, the size range of the internalized
drugs is very broad. For example: even though the molecular weight of bleomycin is
1400 but 30 kD for saporin, both chemotherapy drugs produced significant
enhancement of cytotoxicity after PCI procedure. The drug doses in this study were
calculated in different ways based on the information from the drug suppliers and the
conventional usage. Saporin doses were measured in molar concentration whereas
bleomycin was presented in IU/ml (IU – International Unit). The conversion between
different units is shown in Table 4.2.
Molecular
weight/Da
Doses used in this study Molar concentration
TPPS2a 775 0.1 μg/ml 130 nM
AlPcS2a 770 5 μg/ml 6.49 μM
Amphinex 777 0.1 μg/ml 129 nM
saporin 30K Up to 25 nM
bleomycin 1400 Up to 0.007 IU/ml Up to 3.36 μM
Table 4.2 Conversion of drug concentration.
It can be seen that saporin is effective using much lower doses than bleomycin. Studies
in this chapter have attempted to investigate the versatility of PCI by using three
photosensitising compounds in combination with two different anti-cancer drugs in two
cell lines. Promising results were obtained that PCI could induce significant
enhancement in combination with saporin and bleomycin in vitro. Furthermore, the
results also indicate that Amphinex has the properties deemed favourable for PDT and
PCI. In vivo studies to evaluate the efficacy of Amphinex PCI in combination with these
two toxins were carried out in normal rat liver/colon and subcutaneous rat tumour
models. Results will be presented in the following chapters.128
Chapter 5: Studies of Bioconjugates for PDT and PCI129
5.1 Investigation of a Tat Peptide-Photosensitiser Bioconjugate for
Photodynamic Therapy and Photochemical Internalisation
5.1.1 Introduction
Pharmaceutical agents should be internalised into cells and delivered to their target sites
to exert the therapeutic action. However, low bioavailability due either to poor cell
membrane penetration and/or the lack of water solubility is one of the key problems in
drug delivery. Porphyrins are well known photosensitising agents but their low water
solubility in many cases has limited their biomedical application. Meso-
tetraphenylporphine (TPP) is one example of non-water soluble photosensitisers, which
cannot be used without a suitable delivery system. There have been several approaches
to overcome this problem. For instance, the introduction of conventional pharmaceutical
carriers, such as liposomes [Postigo et al., 2004] or micelles [Roby et al., 2006],
improves the bioavailability by delivering the photosensitiser in a water-soluble
formulation. Another approach to improving bioavailability is the use of conjugating
drugs with cell penetrating peptides (CPP) which can enhance the water solubility and
cellular uptake of drugs. In this section, a new peptide-tetraphenylporphine conjugate is
described, using the cell penetrating ‘Tat’ peptide, derived from the human
immunodeficiency virus type I (HIV-1). These photophysical and photobiological
properties of this bioconjugate were investigated to see whether it is suitable as a
photosensitising compound for both photodynamic therapy and photochemical
internalisation.
In 1988, Green and Frankel independently reported the cell membrane translocation
ability of the trans-activating transcriptional activator (Tat), a protein from human
immunodeficiency virus type I (HIV-1) [Frankel and Pabo, 1988;Green and
Loewenstein, 1988]. Green chemically synthesized the 86-mer Tat protein and Frankel
used the purified Tat protein. Both Tat proteins were able to enter cultured cells and
induce the trans-activation of the viral promoter. The full-length protein was soon
characterized as a protein with multiple functional domains [Kuppuswamy et al.,
1989;Ruben et al., 1989] and the highly basic region which contains six arginine (Arg)130
and two lysine (Lys) in nine residues is assigned to the protein translocation activity
[Vives et al., 1997a].
Since the 1990s, other proteins or peptides also demonstrated the property of
translocation. One group is derived from natural proteins (penetratin (Antp), derived
from Drosophila Antennapedia [Joliot et al., 1991]; VP22, the transcription factor of
herpes simplex virus type 1 [Elliott and O'Hare, 1997]; pVEC, from murine vascular
endothelial cadherin [Elmquist et al., 2001]). Other groups include designed peptides
(transportan, a fusion peptide of neuropeptide galanin and mastoparan [Pooga et al.,
1998] or synthetic polyarginines [Futaki et al., 2001]. These proteins and peptides all
contain the highly positive charged protein transduction domains (PTDs) or cell
penetrating peptides (CPPs) that are responsible for protein transduction, i.e. the
translocation process across the cell membrane.
Several approaches to link pharmaceutical cargos to Tat peptides or other CPPs to
overcome the cell membrane barrier have been carried out over the past two decades.
Up to date, Tat peptides have been proven to facilitate the cell entry of various
molecules ranging from peptides [Gius et al., 1999] with hundreds of daltons molecular
weight to liposomes [Torchilin et al., 2001] with massive structure whose diameter up
to 200nm. The remarkable success of Tat peptides in drug delivery has drawn lots of
attention to researchers to study the mechanisms involved in the internalisation and
intracellular delivery. A reduction of cellular uptake was found when Tat peptides were
modified with single deletion or substitution of the core sequence ‘GRKKRRQRRR’ in
the basic domain resulted in the change of charges [Vives et al., 1997b;Wender et al.,
2000]. Diminished cellular uptake indicated the unique highly cationic nature of Tat
peptides certainly plays a key role in the cell uptake process. The direct electrostatic
interaction between the positively charged Tat peptides and the negatively charged
proteoglycans or glycosaminoglycans on the cell surface is required in the
internalisation [Console et al., 2003;Sandgren et al., 2002]. Despite earlier
misinterpretations of the uptake mechanism resulting from artificial uptake and nuclear
localisation caused during the cell fixation procedures endocytotic uptake is the
recognized mechanism for Tat peptides and most of other CPPs mediated drug delivery
[Richard et al., 2003].131
However, no specific import pathways could be concluded for the Tat-peptide-mediated
biological cargo deliveries. Both lipid raft-mediated caveolar endocytosis and the
clathrin-mediated endocytosis were identified as endocytotic routes of Tat-fusion
proteins [Fittipaldi et al., 2003;Vendeville et al., 2004]. Tat-protein conjugates was also
found entering cells via macropinocytosis, a rapid non-specific lipid raft cell uptake
pathway [Wadia et al., 2004]. Tat-Cre (cAMP response element) fusion protein
successfully entered cells and recombined DNA through macropinocytosis.
Additionally, in the same study, because of the observation that most of the Tat-Cre
proteins remain trapped in macropinosomes, another strategy was used to trigger the
endosomal escape of Tat fusion protein. Co-treament with dTat-HA2 which Tat peptide
conjugated to a fusogenic peptide, the N-terminus domain of the influenza virus
hemagglutinin protein HA2, was able to drop the pH in mature endosomes, release the
Tat fusion proteins into cytoplasm, and thereby achieve their nuclear localisation.
Therefore, the mechanism of Tat peptide mediated endocytic uptake may be dependent
on the attached cargo; this cargo-orientation manner was also suggested in the case of
other CPPs [Maiolo et al., 2005].
To date, more than 20 Tat-derived short peptides with various modifications at either
the N-terminal or the C-terminal ends have been used for delivering drugs into cells
[Brooks et al., 2005]. The advantages and versatility of the Tat peptide-mediated drug
delivery are not limited in vitro. The most well-known in vivo study was conducted by
Schwarze and his colleagues in 1999 using a Tat fusion protein (120 kD) in which β-
galactosidase (116 kD) was ligated to the protein transduction domain [Schwarze et al.,
1999]. After intraperitoneal injection in mice, Tat-β-Gal was found to distribute into
virtually every organ and even cross the blood brain barrier in 4 hours. Moreover, the
β-Gal enzyme activity was assayed by X-Gal staining and found to remain strong in
most of the tissue sections except kidney which is presumably due the clearance from
the blood stream. The promising results from this study opened the possibility of Tat
peptides as tools for in vivo drug delivery.
Porphyrin-type photosensitisers constitute the major class of photosensitising agents in
photodynamic therapy. Conjugation strategies that modify sensitisers by linking to
certain peptides or proteins with targeting function have been used to improve the
selectivity of photosensitiser delivery since 1994 [Chaloin et al., 2001;Hamblin and
Newman, 1994]. For example, penetratin coupled to 5-aminolevulinic acid was shown132
to be taken up by cells and could be successfully converted to photoporphyrin IX via the
haem biosynthetic pathway [Dixon et al., 2007]. CPPs-porphyrin conjugates also have
been synthesized as photoactive compounds. Sibrian-Vazquenz at al. synthesized
different porphyrin-peptide conjugates bearing PEG linkers to several targeting
sequences including the Tat peptide (48-60) to compare their cellular uptake,
subcellular localisation and the phototoxicity in vitro [Sibrian-Vazquez et al., 2006] .
Sehgal et al., from the same group, examined the cell uptake and phototoxicity of five
porphyrin-peptide conjugates using a prostate cancer cell line [Sehgal et al., 2008].
Among these bioconjugated photosensitisers, the Tat peptide-porphyrin conjugate
exerted favourable in vitro cellular uptake and phototoxicity, and also the
biodistribution in tumour bearing SCID mice.
In view of the recent literature reviewed above, enhancing the biological efficacy of
porphyrin sensitisers by conjugation with a Tat peptide appears to be a promising
approach. In the studies described below, a Tat peptide-tetraphenylporphine
bioconjugate (Tat-TPP) was carefully designed and its capability for photodynamic
therapy was investigated. The schematic structure is shown in Figure 5.1 with a
hydrophobic porphyrin macrocycle linked to a ‘Tat’ peptide, which is cationically
charged since the peptide contains several amino groups which will be protonated at
physiological pH. The full chemical structure is shown in Figure 5.2. With this
amphiphilic structure the bioconjugate should in principle localise well in membranes
with the hydrophobic porphyrin localised within the lipid membrane and the cationic
Tat sequence residing at the anionic membrane surface. Based on this reasoning it was
hypothesized that this bioconjugate would be effective for PCI.
porphyrin macrocycle
(uncharged and hydrophobic)
Tat peptide sequence
(cationic and hydrophilic)
TPP Tat
porphyrin macrocycle
(uncharged and hydrophobic)
Tat peptide sequence
(cationic and hydrophilic)
TPP Tat TPP Tat
Figure 5.1 Tat-tetraphenylporphine (Tat-TPP) bioconjugate133
Study aims:
It is hypothesized that a Tat-TPP conjugate could be suitable for photochemical
internalisation because of the amphiphilicity produced by the hydrophilic and cationic
Tat peptide sequence and the hydrophobic porphyrin. Experiments detailed below cover
the assessments of its photophysical properties (absorption/fluorescence spectra,
fluorescence lifetime and singlet oxygen production) and its photobiological properities
such as cellular uptake, subcellular localisation and phototoxicity, and finally the PCI
effect in combination with the cytotoxin saporin using HN5 cells.134
5.1.2 Materials and methods
Synthesis of Tat-TPP conjugates
The synthesis of the Tat-TPP conjugate was done by Dr Francesca Giuntini from the
Department of Pharmacy and Pharmacology, University of Bath. Details on the
synthesis and characterization are shown in Appendix I. The structure of Tat-TPP
conjugate is shown in Figure 5.2. The conjugate composes of three parts:
tetraphenylporphine, a linker to couple one of the TPP phenyl rings and the peptide, and
then the Tat peptide sequence. The role of the linker is to physically separate the
porphyrin from the Tat peptide and minimised the spatial interference between these
two components.
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Figure 5.2 The structure of Tat-tetraphenylporphine (Tat-TPP) bioconjugates. The
molecular weight is 3869.22.
Cell line and cultivation
The experiments in this section were carried out using HN5 cells. The cell culture
conditions have been described in the previous chapter.
Preparation of Tat-TPP conjugate solutions
The stock solution of the Tat-TPP conjugate was made by dissolving the powder in
water at the concentration of 100 μM.135
The aqueous dispersions of DMPC (dimyristoyl phosphatidylcholine) liposomes were
prepared according to the procedure described by Hope et al. [Hope et al., 1992]. A film
of lipid (total 20 μ moles) was prepared on the inside wall of a round bottom flask by
evaporation of CHCl3 solutions containing the required amount of DMPC to obtain the
molar percentage mixture. The obtained films were stored in a dessicator overnight
under partial evacuation and were then admixed with 1 ml of PBS buffer solution in
order to obtain lipid dispersions (12.5 mM). The solutions were vortex-mixed and then
freeze-thawed six times from liquid nitrogen to 313 K (40ºC). Dispersions were then
extruded (10 times) through a 100 nm polycarbonate membrane (Whatman Nucleopore,
UK). The extrusions were carried out at 307 K (34ºC), well above the transition
temperature of DMPC (297.2 K), using a 2.5 ml extruder (Lipex Biomembranes,
Vancouver, Canada).
Spectroscopic measurements
The absorption spectrum measurement was carried out on a Perkin-Elmer Lambda 25
UV/Vis spectrometer (Perkin-Elmer, UK) using a 1cm path length quartz cell. The
absorption spectrum was measured with samples prepared from the stock solution using
different solvents, e.g. water, methanol, or deuterated methanol (CH3OD) (Sigma-
Aldrich, UK). The fluorescence emission spectra of the Tat-TPP conjugate in aqueous
and liposomal solution were measured using a LS50B Perkin-Elmer spectrofluorimeter
(Perkin-Elmer, UK).
Fluorescence lifetime measurements
Fluorescence lifetimes were measured using the time-correlated single photon counting
method (TCSPC). A Tat-TPP conjugate solution in methanol at a concentration of 0.5
μM was placed in a 1 cm path length quartz cuvette. The light source was a 405 nm
pulsed laser diode (EPL-405, Edinburgh Instruments Ltd., UK) with a pulse duration of
90 picoseconds, and 5MHz repetition rate. The fluorescence was detected using a fast
multialkali photomultiplier module (model H5773-04, Hamamatsu Photonics K.K., UK)
via a longpass filter (OG510, Schott, UK) and a monochromator (model M300,
Bentham Instrument Ltd, UK).
TCSPC was carried out using a PC-mounted board (TimeHarp100, PicoQuant GmbH,
Germany) and lifetimes were derived using FluoFit software (PicoQuant GmbH,136
Germany). The Instrument Response Function (IRF) was obtained from a non-
fluorescent scattering Ludox
® solution (Sigmal-Aldrich, UK). Counts rates were
maintained at approximately 1% of the laser repetition rate to ensure single photon
counting statistics, and fluorescence decays were acquired with peak count of c. 2 x 10
4.
Optimum fitting with minimisation of the residuals was confirmed using a Chi-squared
value χ
2< 1.4.
Singlet oxygen measurements
The singlet oxygen phosphorescence at 1270 nm using time-resolved photon counting
from photo-excited solutions in 1 cm square quartz cuvettes. Deuterated solvents (e.g.
CH3OD) were employed here, which is the standard method since the decay lifetime is
much longer than water and thus easier to analyse.
For the detection in the near-IR, a specially designed thermoelectrically cooled
photomultiplier (model H10330-45, Hamamatsu Photonics Ltd, UK) was used which
has a quantum efficiency of 3% at 1270 nm and a rise time of 0.5 ns. The signal was
collected via a series of lenses from the cuvette in combination with a long-pass and a
band-pass filter centred at 1270 nm (Infrared Engineering Ltd, UK).
The solutions were excited using a 532 Nd:YAG laser (Lumanova GmbH, Germany)
with the beam axis aligned orthogonally to the collection optics. The laser was pulsed at
a repetition rate of 3 kHz and a pulse length of 3 ns, giving a mean power of 8mW, and
a fast photodiode (1 ns rise time, Becker-Hickl, Germany) was used to synchronize the
laser pulse with the photon counting detection system. A series of neutral density filters
was used to attenuate the laser power.
The photon counting equipment consisted of a PC-mounted multiscaler board (model
MSA-300, Becker-Hickl, Germany) and a pre-amplifier (Becker-Hickl, Germany)
which gave a resolution of 5 ns per channel. Time-resolved phosphorescence
measurements were accumulated by the multiscaler board for 100, 000 laser pulses,
over a 30 s integration time. No photobleaching of the signal was apparent. The traces
were analysed using the FluoFit software (PicoQunat GmbH, Germany) to extract the
singlet oxygen decay lifetime. To calculate the quantum yield the standard zero-time
intercept analysis was used where the intercept corresponds to the pre-exponential
factor governing the singlet oxygen decay.137
TPPS4 (tetrasulfonated tetraphenylporphine) was chosen as the reference whose singlet
oxygen quantum yield is known [Redmond and Gamlin, 1999;Tanielian et al., 1996].
Cellular uptake of Tat-TPP in HN5 cells
HN5 cells were plated onto 96-well plate at 2.5x10
4 cells/well one day before drug
application. For the time-dependent cell uptake experiment, cells were treated with 1μM
Tat-TPP for various time periods up to 8 hrs. For temperature-dependent experiments,
all protocols were the same except the incubations of sensitisers were performed at 4ºC
or 37 ºC for 1hour. For the dose-dependent uptake measurement, cells were incubated
with Tat-TPP with different concentrations from 0.1μM to 5μM for 16 hrs or 18 hrs.
Comparison studies were carried out followed the same protocols but cells were treated
with 1μg/ml (1.3μM) TPPS2a instead. At the end of uptake time points, cells were
washed with PBS and incubated in clear DMEM medium (no phenol red; no serum) for
fluorescence measurement using a LS50B Perkin-Elmer spectrofluorimeter (Perkin-
Elmer, UK).
Subcellular distribution, post-light redistribution and co-localisation studies using
confocal microscopy
HN5 cells overnight seeded onto glass bottom dishes FluoroDish
TM (WPI, UK) were
incubated with 2.5μM Tat-TPP for 18hrs. After thoroughly washed and incubated with
fresh full medium for further 4 hours, cells were incubated with clear DMEM for
microscopy study. The cellular distribution and redistribution after light irradiation (up
to 10 min) were observed by confocal microscopy. The light treatment was carried out
on stage by shining the light from the 543nm laser of the microscope. Fluorescence
images were taken during the irradiation process at several time points. The changes of
fluorescence intensity during irradiation was quantitatively estimated using the ImageJ
software (NIH, USA)
For co-localisation studies, after the 18hr-incubation with the Tat-TPP conjugate
(2.5μM), several times wash and another 4hr-incubation with fresh full medium, cells
were incubated 30min with 50nM LysoTracker Green for lysosomes labelling or
MitoTracker Green (Molecular Probes, UK) for mitochondria labelling. Clear medium
was later replaced for live-imaging using a laser-scanning confocal microscope
(FLUOVIEW FV1000, 60x magnification, NA 1.20, Olympus, Japan).138
Phototoxicity of Tat-TPP and its PCI effect in combination with saporin in HN5 cells
HN5 cells were seeded at 5000 cells/well in 96-well plates overnight. Cells were treated
with the Tat-TPP conjugate (0.05, 0.1 and 0.2 μM) or saporin ((10, 25 or 50 nM)) for
18hrs separately. Another three groups of cells were co-incubated with saporin (10, 25
or 50 nM) and 0.1μM Tat-TPP. Cells were then washed off trice with PBS and
incubated further 4 hours with fresh full medium. Irradiation was carried out up to 5
min using LumiSource
® (PCI Biotech, Norway). Cell viability was determined using the
MTT assay 2 days after the light exposure.139
5.1.3 Results
Spectroscopic analysis of Tat-TPP
Figure 5.3 shows the absorbance of 5 μM Tat-TPP conjugate in water. The peak
absorption of Soret absorption band was found at 418 nm. The weak series of Q bands
were measured at 518 nm, 556 nm, 588 nm and 642 nm (Figure 5.3, inset).
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Figure 5.3 Absorption spectrum of 5 μM Tat-TPP conjugate in water. Inset: the Q band
region from 450 nm to 700 nm.
Figure 5.4 Fluorescence spectrum of 2.5 μM Tat-TPP in aqueous and DMPC liposomal
solution. A: Emission spectra (λexcitation 420 nm); B: Excitation spectra (λemission 651 nm).
The spectrum was corrected for the variation of detector sensitivity with wavelength.
The fluorescence spectra of 2.5 μM Tat-TPP conjugate in aqueous and DMPC
liposomal solution are shown in Figure 5.4. Two peaks of fluorescence emission in
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aqueous solution were detected at 652 nm and 714 nm when excited at 420nm; the
maximum excitation was at 417 nm (λemission 651 nm). Red-shifted fluorescence spectra
were observed in the liposomal solution. The peaks of fluorescence emission are at 655
nm and 721 nm while the maximum excitation is at 420 nm.
Time-solved spectroscopic studies
In order to minimise dimerisation, methanol was chosen as the solvent for the
fluorescence lifetime measurement. For the determination of singlet oxygen quantum
yield, deuterated methanol (CH3OD) was used. To confirm that the methanolic solutions
at the concentrations studied were monomeric, absorption spectra were recorded as a
function of concentration. It was necessary to check for the presence of any aggregation
because aggregated porphyrins exhibit lower fluorescence lifetimes and lower singlet
oxygen quantum yields.
The absorption spectra of the Tat-TPP conjugate in methanol and deuterated methanol
are shown in Figure 5.5A. It should be noted that both solutions contained 0.5 % H2O
which is derived from the stock solution. Both solutions at the same concentration
displayed similar absorbance intensity and pattern. The peak absorption of the samples
at 414 nm against different concentrations is demonstrated in Figure 5.5B. The peak
absorbance performed as a function of the sample concentration is in agreement with
the Beer’s law. This also emphasizes the stability and disaggregation of the Tat-TPP
conjugate in deuterated methanol within this range of concentrations.
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Figure 5.5 Absorption spectrum of Tat-TPP and TPPS4 in methanol (MeOH) or
deuterated methanol (MeOD). A: 0.5 μM Tat-TPP conjugates in MeOH and MeOD.
Both solutions contained 0.5% H2O. B: The absorbance of the Tat-TPP conjugate in
MeOD at 414nm versus concentration.141
a. Fluorescence lifetime measurement of Tat-TPP conjugates
Figure 5.6 shows the fluorescence lifetime of Tat-TPP in methanol (0.5 μM). The
lifetime curve exhibits good mono-exponential decay fitting (χ
2<1.2) with the value for
the fluorescence lifetime measured as 8.7 ns. A slightly longer value was observed in
deuterated methanol (10.7 ns) as expected due to the isotope effect on the porphyrin.
Figure 5.6 Time-resolved intensity decay of 0.5 μM Tat-TPP conjugate in methanol
(with 0.5% H2O) and the instrument response function (top). Residuals for fitting
(bottom).
b. Singlet oxygen production measurement of Tat-TPP conjugates
It is widely considered that direct observation of singlet oxygen emission in the infra-
red (IR) region of the spectrum provides the most accurate determination of
1O2
quantum yields (ΦΔ).
The quantum yields of the Tat-TPP conjugate were estimated in comparison with the
known reference, TPPS4 (ΦΔ = 0.7 in CH3OD) [Redmond and Gamlin, 1999;Tanielian
et al., 1996]. The sample and the reference solution were with optically matched
weighted lifetimes (28 μs, data not shown) and similar absorbance (Figure 5.7B) at the
laser wavelength of 532 nm: 1.36 μM of Tat-TPP in CH3OD (with 2% H2O) and 1.97
μM of TPPS4 in CH3OD (with 1.3% H2O). Figure 5.7A depicts the time-resolved142
phosphorescence profile of the Tat-TPP conjugate. The initial fast spike represents
short-lived fluorescence followed by a mono-exponential singlet oxygen
phosphorescence decay over a hundred microseconds. The decay lifetime was measured
as 28 μs which is the expected value for deuterated methanol containing 2% water.
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Figure 5.7 A: Tme-resolved phosphorescence decay at 1270nm plotted on a logarithmic
scale of singlet oxygen sensitised by Tat-TPP in MeOD using a pulsed 532 nm laser,
together with a plot of the residual deviations from the fitted monoexponential decay. B:
The Q bands absorbance of Tat-TPP and TPPS4 in MeOD solution with similar
absorbance and optically matched lifetimes at 532nm.143
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Figure 5.8 Phosphorescence signal intensity at 1270nm versus laser power (mW) at
532nm.
Using various attenuation filters, the phosphorescence intensities (I) were found to be in
proportion to the laser power (P). The results are plotted in Figure 5.8. The individual
gradients (G) were then obtained by the slopes from the linear distribution, yielded
348.31 for Tat-TPP and 478.65 for TPPS4.
Equation (1) relates the parameters involved in the generation of singlet oxygen [Cantau
et al., 2007]:
 
A Φ P I

      10 1  (1)
where k is a constant incorporating the efficiency of light collection and detection
sensitivity, A is the absorbance of solutions at the laser wavelength, ΦΔ is the singlet
oxygen quantum yield, and P is the laser power. Therefore a plot of the intensity I
versus the laser power should be linear and the gradient G equates to:
 
A G
     10 1 Φ   (2)
Since near optically matched solutions have been employed, the absorbance factors are
virtually identical and only a very small corrections is required.144
The A532 values of both solutions have been measured (inset, Figure 5.7):
4
532
TPPS A =0.0076;
TPP Tat A

532 =0.00718. Therefore, taking ΦΔ for TPPS4 as 0.7, the quantum
yield of Tat-TPP was calculated from equation (3), resulting in the value of 0.54.
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Table 5.1 summarises the physical chemistry properties of the Tat-TPP conjugate.
 Photophysical properties
Soret band: 418 nm Absorption wavelength maxima
a
Q bands: 518, 556, 588, and 642 nm
Excitation: 417 nm Fluorescence wavelength maxima
a
Emission: 652 and 714 nm
Fluorescence lifetime
b 8.7 ns
Singlet oxygen quantum yields (ΦΔ)
b 0.54
Table 5.1 A summary of the photophysical properties of the Tat-TPP conjugate. a: in
H2O; b: in MeOD145
Subcellular distribution of Tat-TPP and its redistribution after illumination in HN5
cells
The intracellular distribution of the Tat-TPP conjugate was observed in HN5 cells by
confocal microscopy. A granular subcellular distribution was found and it became
diffuse following light exposure (Figure 5.9). The results of quantitative measurements
show that the fluorescence signals increased after 1 min irradiation and declined
afterwards (Figure 5.10). The fluorescence intensity dropped about one third of the
highest signals detected (i.e. 1 min light) after 10 min light exposure.
Figure 5.9 Cellular distribution of Tat-TPP in HN5 cells (A) and the redistribution after
10 min irradiation on stage by confocal microscopy (B). Light source: 543nm laser of
the confocal microscope. Cells were incubated with 2.5μM Tat-TPP for 18hrs.
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Figure 5.10 Photoinduced changes in integrated intracellular Tat-TPP fluorescence
intensities measured in HN5 cells at set times. Five cells were randomly chosen from
Figure 5.9 for fluorescence intensities analysis. AVE: the average intensity.146
Identification of the subcellular distribution of Tat-TPP using lysosome and
mitochondria probes in HN5 cells by confocal microscopy
The subcelllular localisation of Tat-TPP was investigated by co-labelling LysoTracker
Green or MitoTracker Green in HN5 cells using confocal microscopy. As shown in
Figure 5.11, most Tat-TPP was found co-localised with lysosomes and mitochondria but
some non-lysosome or –mitochondria co-localised Tat-TPP (red dots in the merge
images) were also observed.
Figure 5.11 Co-labelling Tat-TPP with LysoTracker Green or MitoTracker Green in
HN5 cells by confocal microscopy. Cells were incubated 2.5 μM Tat-TPP for 18hrs. 50
nM of LysoTracker Green or MitoTracker Green was applied to cells 30min before
imaging.147
Short-term time-dependent and temperature-dependent cellular uptake of Tat-TPP in
HN5 cells
HN5 cells were incubated with 1 μM Tat-TPP or 1.3 μM TPPS2a and their cellular
uptake were measured at up to 8 hours. As shown in Figure 5.12, the Tat-TPP conjugate
steadily accumulated within HN5 cells and produced measurable fluorescence signal.
Time-dependent cell uptake was found in both sensitisers. Higher fluorescence intensity
was measured in cells treated with Tat-TPP compared to TPPS2a even though the
concentration of Tat-TPP was slightly lower.
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Figure 5.12 Time-dependent cellular uptake of Tat-TPP (1 μM) and TPPS2a (1.3 μM) in
HN5 cells after 18 hr incubation.
To further study the uptake mechanism of Tat-TPP and the involvement of endocytosis,
experiments with drug incubation at low temperature were performed. Endocytosis can
be inhibited in a cold environment as the metabolism of cells stops or slows down.
The cell uptake of Tat-TPP showed a temperature-dependent manner. In Figure 5.13,
incubation at 4ºC resulted in an inhibition of cellular uptake where lower fluorescence
signal was detected compared to the incubation at 37ºC.148
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Figure 5.13 One hour cellular uptake of Tat-TPP (1 μM) and TPPS2a (1.3 μM) at 4ºC or
37 ºC in HN5 cells.
Long-term dose-dependent cellular uptake of Tat-TPP in HN5 cells
Long-term cellular uptake was observed with the drug concentrations ranged from 0.13
μM to 5 μM (Figure 5.14). After 18 hours incubation of 0.13 μM Tat-TPP in HN5 cells,
the fluorescence signal was higher than the cells treated with 0.13 μM TPPS2a by a
factor of five. Higher fluorescence intensity was detected when cells were incubated
with higher Tat-TPP doses. Rapid increase of fluorescence intensity was observed when
conjugates concentration is less than 1 μM, whereas the increase rate slowed down if
compared the conjugate concentrations at 5 μM and 1 μM.
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Figure 5.14 Dose-dependent cellular uptake of Tat- TPP and TPPS2a in HN5 cells. Cells
were incubated with Tat-TPP or TPPS2a (up to 5 μM) for up to 18hrs.149
Cytotoxicity of Tat-TPP PCI combing saporin in HN5 cells
The phototoxicity of the Tat-TPP conjugate was estimated in HN5 cells. The cell
viability results showed Tat-TPP produced little dark toxicity (Figure 5.15). The toxicity
induced by Tat-TPP was found in a light dose and drug dose dependent manner. Cell
viability reduced to less than 40 percent using the conjugate at the concentration of 0.1
μM after 3 min light treatment. The IC50 (the concentration of drug or light that kills
50% of cells) was achieved in combination of 0.1 μM Tat-TPP and 1-3 min irradiation.
The PCI effect of Tat-TPP was investigated in combination with saporin. With 25 nM
saporin and 0.1 μM Tat-TPP, PCI significantly enhanced the cell kill and reduced the
cell viability by a factor of 7.7 and 6.8 compared to saporin and Tat-TPP alone
respectively after 3 min light exposure.
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Figure 5.15 Tat-TPP PDT and PCI effect in combination with saporin in HN5 cells.
Cells were incubated with Tat-TPP (up to 0.2 μM) or incubated with 0.1 μM Tat-TPP
and saporin (up to 50 nM) for 18hrs. Irradiation was carried out up to 5 min using a blue
lamp. Cell viability was examined by the MTT assay 48 hrs after exposure to light.150
5.1.4 Discussion
It is more than 20 years ago since the protein translocation ability of the Tat activator of
HIV was first reported [Frankel and Pabo, 1988;Green and Loewenstein, 1988]. Since
then, several CPPs/PTDs have been recognised as proteins with membrane translocation
properties and described as promising tools to transport biologically active cargos and
induce efficient intracellular deliveries. Studies regarding the fundamental aspects such
as endocytosis mechanism, the interaction between Tat-peptides themselves and the
cargos, as well as the influence of the environment have been well documented, and
were summarised in the Introduction to this section.
According to the absorption and fluorescence spectra from spectroscopic studies (Figure
5.3), the Tat-TPP conjugate displayed typical photophysical properties of porphyrins, i.e.
an intense Soret band (λmax = 390-415 nm) and four weaker Q-bands in the 450-700 nm
region. The absorption spectra of Tat-TPP conjugates in methanol and deuterated
methanol (both contain 0.5% H2O) were also assessed (Figure 5.5) as solutions prepared
with these solvents were used for fluorescence lifetime and singlet oxygen quantum
yield measurements. The molar extinction coefficient of the Tat-TPP conjugate in
different solvents can therefore be calculated using the Beer’s Law: L c A     , where
A is the absorbance, ε is the molar extinction coefficient, c is molar concentration and L
is 1 when using 1cm width cuvettes. In this present study, the molar extinction
coefficient of the Tat-TPP conjugate was measured lower than TPP (4.05 x 10
5M
-1cm
-1
in toluene) [Du et al., 1998]. Among these three solvents, the value in water was found
to be the lowest (1.94 x 10
5 M
-1cm
-1) compared to other polar solvents (2.65 x 10
5 M
-
1cm
-1 in deuterated methanol and 2.92 x 10
5 M
-1cm
-1 in methanol). This may be
attributed to the dimerisation of the Tat-TPP conjugate when dissolved in water,
resulting in a lower molar extinction coefficient. The aggregation of compounds is also
evident as a second short lifetime was detected in the freshly-made solution (data not
shown).
The Tat-TPP conjugate displayed a significant fluorescence emission with two bands in
aqueous solution, but a red shift was observed in DMPC liposomal solution in both
excitation and emission spectra (Figure 5.4). The optical properties of photosensitisers
in relation to lipid membranes have been reported by many studies [Kessel and Rossi,151
1982;Ricchelli, 1995]. The finding here is therefore consistent with the binding of the
Tat-TPP conjugate to a liposomal lipid membrane which leads to the changes in
fluorescence spectra. This result would imply that the bioconjugate should also bind to
cellular/oraganelle membranes.
The fluorescence lifetime of Tat-TPP in methanol was measured 8.7 ns which is shorter
than the value for TPPS4 as 9.7 ns (data not shown). The fluorescence lifetime of TPPS4
measured in this study is similar to the result from another group [Castriciano et al.,
2009]. The isotope effect was also observed after the replacement of the solvent with
deuterated methanol where the substitution of hydrogen to deuterium led to a longer
fluorescence lifetime of 10.68 ns (data not shown). TPPS4 was used as a reference to
determine the singlet oxygen yields of the Tat-TPP conjugate. The value of ΦΔ for Tat-
TPP was found 0.54, very close to the value of 0.59 for m-THPC in oxygen-saturated
methanol [Bonnett et al., 1999] which is the most promising photosensitiser approved in
clinic. Nevertheless, it was lower to the value of 0.66 for Amphinex [Mojzisova et al.,
2009], a PCI sensitiser, although an indirect measurement was performed.
The subcellular distribution of the Tat-TPP conjugate was also observed similar to
TPPS2a in a granular pattern and was redistributed to become diffuse after light
exposure (Figure 5.9). Quantitative fluorescence measurements based on the imaging
results show that the fluorescence signals inside cells began with an increase while
irradiating and photobleaching was observed after longer light exposure (Figure 5.10).
Moreover, in the co-localisation studies co-labelling with lysosome and mitochondria
probes, the Tat-TPP conjugate appears to accumulate in lysosomes and mitochondria
(Figure 5.11). Most of the conjugates were found localised in lysosomes, possibly as a
consequence of endocytotic cellular uptake.
The cellular uptake of the Tat-TPP conjugate was then investigated by comparison with
TPPS2a which has structural similarity and also a common PCI photosensitiser. The
results shown in Figure 5.12 illustrate that Tat-TPP was taken up by cells efficiently
where the fluorescence signals were comparable to the signals produced from TPPS2a.
Incubations in 4ºC seemed to inhibit the uptake of both sensitisers which also suggests
the possible energy-dependent endocytotic mechanism of cellular uptake (Figure 5.13).
However, low fluorescence signals were measured due to the low drug doses which
might result in a misreading from the spectrometer, especially the incubation time is as152
short as only one hour. Further experiments to verify the influence of temperature in the
cellular uptake should be carried out using higher drug doses.
Since the molecular weight of the Tat-TPP conjugate is approx. 4000 Dalton,
endocytotic uptake would be expected for a molecule of this size. Collectively, the
experimental results presented here are in agreement with the data published by
Vicente’s group that Tat-porphyrin conjugates display a lysosomal intracellular
localisation [Sehgal et al., 2008;Sibrian-Vazquez et al., 2008]. Therefore, the results
support the conclusion that endocytotosis is the main uptake mechanism of Tat-
porphyrin conjugates.
To test whether the Tat-TPP conjugate has the potential for PDT, its phototoxicity and
was examined in vitro. As shown in Figure 5.15, Tat-TPP induced appreciable
phototoxicity under very low drug concentration. The remarkably enhanced cell killing
achieved combing saporin under sub-lethal PDT dose indicated that the Tat-TPP
conjugate is also a favourable PCI sensitiser.
The first attempt in using a Tat peptide in PDT was demonstrated by Sibrian-Vazquez et
al. using a PEG spacer to link a Tat peptide and porphyrins [Sibrian-Vazquez et al.,
2006]. The enhanced cellular uptake indicated that the Tat peptide-conjugation strategy
is able to increase the biological efficacy of porphyrins. The study in this section is the
first attempt to incorporate the use of a Tat peptide into photochemical internalisation
strategies.
The results demonstrate that the conjugation to a Tat peptide enables the
tetraphenylporphine to become bioavailable which results in three advantages of the
Tat-TPP conjugate: 1) The membrane permeability due to the increased solubility. 2)
Efficient cellular uptake contributed by the translocation ability of the Tat peptide. 3)
The specific subcellular localisation due to the amphiphilic structure (Figure 5.1 and
5.2). Other features such as low dark cytotoxicity, and intrinsic photosensitising
capability furthermore make the Tat-TPP conjugate a potent photoactive therapeutics
for photodynamic therapy. Last but not least, the marked enhancement of cell killing in
combination with saporin even implies that the Tat-TPP conjugate has a potential for
being a PCI photosensitiser. The hypothesis of the cellular uptake and endocytosis of
the Tat-TPP conjugate is shown in Figure 5.16. Due to the amphiphilic structure and the153
positive-charged Tat peptide end, the Tat-TPP conjugate enters cells via endocytotic
pathway or through direct plasma membrane penetration. According to the co-
localisation imaging results, the Tat-TPP conjugate remains in the membrane of
endocytotic vesicles (e.g. endo/lysosomes) or target other organelles such as
mitochondria. Photochemical internalisation could be initiated following the light
activation of Tat-TPP and therefore result in the rupture of the membranes and the
release of the endocytosed therapeutic macromolecules.
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Figure 5.16 Hypothesis of the cellular uptake of the Tat-TPP conjugate.
The results here demonstrate the feasibility for an enhanced bioavailability by linking
Tat peptides to other photosensitisers, particularly water soluble sensitisers with
restricted cell entry ability. Future studies to investigate the PCI effect of the Tat-TPP
conjugate will focus on either co-administrating or covalent biding to different
therapeutic agents. Studies using different cell lines and the in vivo application will be
carried out.
List favourable properties for PCI:
 Good photophysical properties and comparable singlet oxygen quantum yields
 Water soluble yet amphiphilic: lysosomal membrane localisation
 Efficient cellular uptake and low dark toxicity154
 PCI effect: synergistic cytotoxicity in combination with saporin
Based on many promising results as reviewed elsewhere [Brooks et al., 2005;Vives,
2003], it seems that these unique peptides can achieve unrestricted delivery
[Bogoyevitch et al., 2002;Schwarze et al., 2000]. However, this view has been
challenged by some other recent studies.
Koppelhus and his colleagues tested the translocation ability of a Tat peptide and
penetratin, and relatively poor or no cell uptake in five different cell lines were found
[Koppelhus et al., 2002]. Several studies also reported this cell-dependent phenomenon
of Tat peptides as distinct differences of cell uptake efficacy were found between ‘leaky
cells’ and ‘non-leaky cells’ [Kramer and Wunderli-Allenspach, 2003;Trehin et al.,
2004;Violini et al., 2002;Zhang et al., 2004]. Leaky cells like HeLa (cervical carcinoma)
demonstrated a greater cell uptake of Tat peptides, whereas tight junction forming
epithelial cells like MDCK (canine kidney) or CaCo-2 (human colonic carcinoma)
restricted their entry into cells. Not surprisingly, some studies have pointed out that Tat
peptide bioconjugates might behave differently in vitro and in vivo [Caron et al.,
2001;Niesner et al., 2002]. However, these seemingly negative results do not dispute the
biomedical potential of the Tat peptide-mediated drug delivery. In contrast, in order to
achieve successful therapeutic application of Tat peptide conjugates, future studies need
to carefully consider the differences in experimental settings.
A successful drug delivery should require both efficient uptake and specific targeting.
On one hand, the ubiquitous cell translocation ability of CPPs has resulted in numerous
impressive applications in the peptide-mediated drug delivery [Dietz and Bahr, 2004].
On the other hand, little cell specificity has therefore become a controversy feature for
most of the CPPs. Tat peptides are no exception. This might become the foremost
obstacle for their clinical utilities [Vives, 2005]. Nevertheless, the results shown in this
section have proved that it is unlikely a problem for the PDT or PCI applications.
Selectivity can be achieved by the site specificity of PDT and PCI that the therapeutic
effects only take place in the area exposed to light which therefore could alleviate the
‘drawbacks’ of the Tat peptide-mediated cellular deliveries, the ubiquity of their
translocation activity.155
5.2 Investigation an AlPcS2a-Saporin Conjugate for Photochemical
Internalisation
5.2.1 Introduction
As mentioned in Chapter 1, several studies have demonstrated that the synergistic effect
or at least additive effect can be induced using PDT in combination with chemotherapy.
In most of the cases, administration of photosensitisers and anti-cancer drugs are
separately, followed by irradiation. There is also a different approach in which
chemotherapeutic agents are conjugated with photosensitisers via a polymer carrier
[Peterson et al., 2003]. In fact, strategies of using photosensitiser-based bioconjugates
have been extensively studied where the concept is to increase the bioavailability,
solubility and targeted specificity [Sibani et al., 2008]. The study in the previous section
is indeed an example showing that the linkage to a cell penetration peptide, Tat, makes
tetraphenylporphine become water soluble and confers preferable properties for PDT
and PCI.
Conjugation of photosensitisers and proteins provides another platform of
photosensitiser-based bioconjugates in which specificity can be achieved when using
known ligands against cancer-specific receptor or antibodies. For instance, a complex
which comprises the anti-EGFR antibody (cetuximab) and a photosensitiser, BDP
Verteporfin was synthesized through PEGylation and termed PIC (photosensitiser
immunoconjugate) to combine immunotherapy and PDT. Compared to the use of
unconjugated sensitiser, PIC induced the synergistic effect on the inhibition of tumour
growth, indicating that targeted photosensitisers can improve the PDT treatment [del
Carmen et al., 2005].
Bioconjugation enables creation of a composite which couples several molecules of
interests together for multiple functions. It may be particularly beneficial to PCI, a drug
delivery system with the interplay of photosensitiser and delivered macromolecules.
Evidence has been shown by Nishiyama and co-workers as described previously in
Chapter 2 that a complex enclosing dendrimeric phthalocyanine (anionic) and DNA
packaged with cationic peptides can facilitate PCI-mediated gene delivery both in vitro
and in vivo [Nishiyama et al., 2005]. In this strategy, two components of PCI, the156
photosensitiser and the employed macromolecules, are assembled into one structure.
The fact that the complex can be administered at one time is especially an advantage for
PCI application in vivo or in clinic.
The design of the experiments in this section is derived from the same concept. It
seems to be a possible way to integrate a photosensitiser and its employed
macromolecule for PCI-directed drug delivery. In this chapter, a bioconjugate which
consists of AlPcS2a and saporin was synthesized. Two molecules were separately
modified and conjugated together through the linkers attached to the adjacent
disulfonate groups of AlPcS2a. Its bioavailability including cellular uptake and
intracellular distribution was investigated, and the ability to induce PCI effect was
examined in comparison with the photochemical enhancement led by conventional
AlPcS2a PCI of saporin using HN5 cells.157
5.2.2 Materials and methods
Synthesis of AlPcS2a-saporin conjugate
The synthesis of AlPcS2a-saporin conjugates was done by Dr Sinan Battah in our group
and the detailed synthesis process is shown in Appendix I. The schematic structure of
the conjugates is illustrated in Figure 5.17. AlPcS2a was conjugated via a linker with
two free sulfhydryl (-SH) group which can react with disulfide bridge-modified saporin.
The AlPcS2a-linker with two –SH free terminals, is expected to bind to two adjacent
protein molecules (Figure 5.17A) or one protein molecule (Figure 5.17B). The later
conjugate is more likely to be formed because the size of protein is much larger than the
photosensitiser. It is hypothesized that the hydrophobic side of phthalocyanine
macrocycle will be localised to the endo/lysosomal membrane and the hydrophilic
protein side will insert into the aqueous compartment.
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Figure 5.17 The schematic structure of AlPcS2a-saporin conjugates. A: One AlPcS2a
molecule links to two saporin protein molecules. B: One AlPcS2a links to one saporin
protein molecule.
Cell line and cultivation
The experiments in this section were carried out using HN5 cells. The cell culture
conditions have been described in the previous chapter.
Spectroscopic measurements
The absorption spectrum measurement was carried out on a Perkin-Elmer Lambda 25
UV/Vis spectrometer (Perkin-Elmer, UK) using a 1cm path length quartz cell. The
absorption spectrum was measured with samples prepared from the stock solution and
A B158
diluted in distilled water. AlPcS2a-saporin conjugate solution was prepared by 50x
dilution of the stock solution with distilled water. The absorption spectrum of the
conjugate was compared with 1 μg/ml AlPcS2a solution diluted in methanol. The
concentration of conjugate was then estimated using Beer’s law, assuming the
extinction coefficient of both compound are similar (the value for AlPcS2a is known)
Cellular uptake of AlPcS2a and AlPcS2a-saporin conjugate in HN5 cells
HN5 cells were plated onto 96-well plate at 2.5x10
4 cells/well one day before drug
application. In order to improve the solubility, AlPcS2a-saporin conjugate solution was
adjusted to be slightly alkaline by adding few drops of sterile NaOH. Cells were then
treated with up to 10μM alkaline conjugate or 10 μg/ml AlPcS2a for 18 hrs. At the end
point, cells were washed with PBS and incubated in clear DMEM medium (no phenol
red; no serum) for fluorescence measurement using a LS50B Perkin-Elmer
spectrofluorimeter (Perkin-Elmer, UK).
Subcellular distribution and localisation of AlPcS2a-saporin conjugate in HN5 cells
using confocal microscopy
HN5 cells overnight seeded onto glass bottom dishes FluoroDish
TM (WPI, UK) were
incubated with 10 μM AlPcS2a-saporin conjugate for 18hrs. After thoroughly washed
and incubated with fresh full medium for further 4 hours, cells were incubated with
clear DMEM for imaging using confocal microscopy (FLUOVIEW FV1000, 60x
magnification, NA 1.20, Olympus, Japan). For localisation studies, cells were incubated
with 50 nM LysoTracker Green (Molecular Probes, UK) for 30min, and imaged by
confocal microscopy.
PCI effect of AlPcS2a-saporin conjugate in comparison with AlPcS2a PCI of saporin in
HN5 cells
HN5 cells were seeded at 5000 cells/well in 96-well plates overnight. Cells were treated
with 100 nM AlPcS2a alone or AlPcS2a-saporin conjugate (20, 50 and 100 nM) for 18hrs
separately. Another two groups of cells were co-incubated with saporin (50 nM and 100
nM) and 100 nM AlPcS2a. Cells were then washed off trice with PBS and incubated
further 4 hours with fresh full medium. Irradiation was carried out up to 10 min using a
670nm laser (Hamamatsu Photonics, Japan) as described in Chapter 4 (Figure 4.2). Cell
viability was determined using the MTT assay 2 days after the light exposure.159
5.2.3 Results
Spectroscopic analysis of AlPcS2a-saporin conjugate
Figure 5.18 shows the absorbance spectra of 1 μg/ml AlPcS2a and the AlPcS2a-saporin
conjugates solutions diluted 50 times from stock solution in distilled water. The peak
absorption was found at 676 nm. The O.D. value for AlPcS2a at this wavelength was
measured 0.36 and it was 0.15 for the conjugate. As the extinction coefficient of
AlPcS2a is 2.56 x 10
5M
-1cm
-1 at 676 nm, the relative concentration of AlPcS2a of the
conjugate was then calculated as 0.6 μM. The dimerisation of photosensitisers due to
the aggregation in water was observed with the shoulder peaks beside the main peak at
676 nm.
The average ratio of AlPcS2a to saporin can be obtained from the measurement of the
relative saporin concentration. However, for these experiments, the supplier of saporin,
Sigma-Aldrich, was unable to provide reliable purity which made it difficult to measure
protein absorption at 280 nm. Since this is a preliminary study to conjugate
photosensitiser with protein toxin, the conjugate concentration was taken to be
equivalent of the calculated AlPcS2a concentration in the later experiments, assuming
the ratio of AlPcS2a and saporin is 1.
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Figure 5.18 Absorption spectra of 1 μg/ml AlPcS2a in water and the AlPcS2a-saporin
conjugate solutions in distilled water (dH2O).160
Cellular uptake of AlPcS2a and the AlPcS2a-saporin conjugate in HN5 cells
The cellular uptake AlPcS2a-saporin conjugate was determined and compared with
AlPcS2a by measuring the fluorescence intensity in cells following an 18 hour
incubation. HN5 cell monolayers were incubated with increasing concentrations of
compounds. Following washing, the fluorescence from the cells was measured using
fibre-optic spectrofluorimeter with the detection/excitation fibre placed above each well
in a 96 well plate.
A clear drug concentration dependent cellular uptake of the conjugate was observed in
HN5 (Figure 5.19). The fluorescence intensity linearly increased against drug
concentration and no saturation was found up to the drug concentration of 10 μM.
However, much lower fluorescence signals of the conjugate were detected in
comparison to AlPcS2a using similar concentrations, suggesting its cellular uptake is not
as efficient as AlPcS2a.
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Figure 5.19 Cellular uptake of AlPcS2a-saporin conjugate and AlPcS2a with increasing
drug concentrations (up to 10 μg/ml or μM) in HN5 cells after 18 hr incubation.
Subcellular distribution of AlPcS2a-saporin conjugate in HN5 cells
HN5 cells seeded onto FluoDish plates were incubated with 10 μM AlPcS2a-saporin
conjugate for 18hr and imaged using confocal microscopy. Figure 5.20 shows the
intracellular distribution of the conjugate in HN5 cells. A granular distribution was161
observed in which the granular particles were mainly found in the cytosol but some of
them were in or overlying the nuclei (the white arrow inset).
Figure 5.20 Cellular distribution of AlPcS2a-saporin conjugate in HN5 cells. Cells were
incubated with 10 μM AlPcS2a-saporin conjugate for 18 hours and imaged by confocal
microscopy. Inset arrow: nuclear localisation.
The subcellular localisation of the AlPcS2a-saporin conjugate was examined by
comparison with a lysosomal probe, LysoTracker Green (50 nM), which was applied to
cells 30min before imaging. As shown in Figure 5.21, most of the conjugate (red)
appeared to be localised at lysosomes (green), resulting in the yellow colour presented
in the merged image.
Figure 5.21 Co-localisation of AlPcS2a-saporin conjugate and LysoTracker Green in
HN5 cells by confocal microscopy. Red: AlPcS2a-saporin; green: LysoTracker Green;
yellow: merged image.162
PCI effect of AlPcS2a-saporin conjugate in comparison to AlPcS2a PCI of saporin in
HN5 cells
The PCI effect of AlPcS2a-saporin conjugate was investigated in comparison to AlPcS2a
PCI in combination with saporin using the same concentrations in HN5 cells. Cells were
either incubated with conjugate (20-100 nM), AlPcS2a (100 nM) or co-incubated with
AlPcS2a (100 nM) and saporin (50 and 100 nM) for 18 hrs. As shown in Figure 5.22, the
cell viability remained about 80% in the cells sensitised with 100nM AlPcS2a upon
increased light exposure. It was not unexpected that no phototoxicity could be observed
in this case since the dose of AlPcS2a used for in vitro PDT studies is usually more than
5 μg/ml (6.49μM) (see Section 4.7). In contrast, the PCI effect was observed in the cells
incubated with the conjugate with the concentration as low as 20 nM after 10 min light
exposure.
The PCI effect was much more clearly shown in the cases of using higher concentration
of conjugates (50 and 100 nM), in that a dramatic drop of cell viability was measured
after 10 min irradiation. It was also apparent that the conjugate itself exerted slight
toxicity in which half of the cells were killed without exposure to light (the intercept at
zero irradiation time). Nevertheless, after 10 min irradiation, the killing effects were
only found to be as good as the usual PCI strategy in which photosensitiser and toxin
were together added to cells.
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Figure 5.22 PCI effect of AlPcS2a-saporin conjugate in comparison with AlPcS2a PCI of
saporin in HN5 cells.163
5.2.4 Discussion
The study in this section focused on the feasibility of using a photosensitiser-protein
toxin bioconjugate for PCI technology. The absorption spectrum of conjugate was
found to be similar to unconjugated AlPcS2a with the typical peak absorption of
phthlocyanine around 670nm (Figure 5.18). The results indicate that the conjugate can
still be activated using the same light source. The relative concentration of AlPcS2a was
therefore obtained using Beer’s Law since the extinction coefficient of AlPcS2a is
known.
The cellular uptake of the conjugate was compared with AlPcS2a by measuring the
fluorescence intensity inside cells. When cells were incubated with similar
concentration of both compounds, the results show that the cellular uptake of the
conjugate was found to be much lower than AlPcS2a but displayed a concentration
dependent manner (Figure 5.19). The lower rate of uptake may be due to the larger size
of the bioconjugate. As shown in Figure 5.20, the conjugate displayed a granular
distribution in HN5 cells and it was found to be well localised with lysosomes (Figure
5.21). The distribution of the conjugate is consistent with the results of either AlPcS2a or
saporin observed in experiments in Chapter 4 (Figure 4.11 and 4.17).
Upon illumination, the AlPcS2a-saporin conjugate was found to be able to induce a PCI
effect in HN5 cells (Figure 5.22). The killing effects induced by the conjugate at the
concentration of 50 nM and 100 nM were as good as using 100 nM AlPcS2a PCI of
saporin with the same toxin doses after 10 min light exposure. These chosen
concentrations of saporin are slightly higher than the ones used for conventional PCI
studies in which cells were co-incubated with unconjugated AlPcS2a and saporin.
According to the results from Chapter 4, the sub-lethal dose of saporin is only about 25
nM for HN5 cells, whereas, the dose of AlPcS2a required for inducing PDT or PCI
effect is at least 5 μM (Table 4.1). Since one conjugate molecule composes one AlPcS2a
and two saporin in theory, when using the conjugate with nano-Molar concentrations,
the equivalent concentrations of photosensitiser may not be able to induce efficient
photochemical reactions and the consequent PCI effect. However, surprisingly,
although little phototoxicity was induced in the cells incubated with 100 nM AlPcS2a,
significant enhancement in cell kill was observed in combination with saporin (50 nM164
and 100 nM) under the light exposure up to 10 min. The results suggest that saporin
may still be released and induce significant cytotoxicity.
Prior to the study presented in this section, attempts also had been made to synthesize
different bioconjugates for PCI by conjugating saporin to porphyrin with various
functional groups and linkers. Most of the conjugates remained typical porpyrin
fluorescence spectrum but displayed inefficient cellular uptake probably due to the
hydrophilicity or other interferences derived from their chemical structures. Some of the
conjugates exhibited light dose and drug dose dependent phototoxicity; however,
unfortunately, none of them demonstrated a PCI effect in which synergistic cytotoxicity
should be involved.
These unsuccessful results show that there are still difficulties in making an ideal
conjugate which is not only bioavailable but also able to induce a PCI effect. Care
should be taken especially for the protein-involved conjugation that the structure of
protein moiety must be preserved during the synthesis to retain the protein function. The
results of this section also point out that the ratio of photosensitiser and protein toxin
should be concerned for the conjugate used for PCI.
In recent years, there has been significant development on the molecules with
nanostructures (liposomes, micelles or dendrimers) for their biomedical applications
such as the delivery of drugs, imaging agents, or gene transfection. For PCI, there is
always a hope to synthesise a complex which combines the targeting system (e.g.
antibodies), drugs (e.g. protein toxins), and photosensitisers together. The study using a
complex enveloped dendrimeric phthalocyanine and DNA to achieve efficient PCI-
mediated gene delivery is a good example. However, the complexity of the
nanostructures needs more delicate plans and further investigation. The study in this
section was the first attempt to use a photosensitiser-protein toxin bioconjugate,
AlPcS2a-saporin conjugate, designed for a PCI strategy. Although the preliminary
results show that this conjugate can be taken up by cells and induce PCI effects upon
irradiation in vitro, further studies on the chemical structure characterization, the
detailed cellular uptake mechanism and the optimisation of the treatment conditions for
PCI remain to be carried out.165
5.3 Summary
The aim of the studies described in this chapter was to investigate the PCI efficacy of
bioconjugates for drug delivery. It was hypothesised that the use of bioconjugates will
have several advantages: firstly for more efficient cellular delivery of the
photosensitiser in the case of peptide-photosensitiser bioconjugates; and secondly, the
co-delivery of the photosensitiser and toxin in the case of photosensitiser-toxin
conjugates. The fact that the complex can be administered at one time is especially an
advantage for PCI application in vivo or in clinic. Finally, in the longer term, such
bioconjugates could enable more efficient targeting with the inclusion of targeted
ligands.
In the first section of this chapter, a new porphyrin-peptide bioconjugate of a cell
penetrating peptide, Tat sequence (Tat) and tetraphenylporphine (TPP) was synthesised.
This Tat-TPP conjugate exhibited favourable optical properties for PDT and PCI (Table
5.1). In the in vitro studies, the conjugate displayed efficient cellular uptake and
lysosomal and partly mitochondria localisation due to the membrane-translocation
ability of Tat sequence and the amphiphilic structure derived from TPP (hydrophobic)
and Tat sequence (hydrophilic). As a photosensitiser, the conjugate showed efficient
light dose and drug dose dependent phototoxicity. In combination with saporin, the
conjugate was found to be able to induce a significant PCI effect with the enhanced
cytotoxicity after photosensitisation.
A photosensitiser-protein toxin bioconjugate, AlPcS2a-saporin, was synthesised and
designed for PCI application for the studies of the second section. After conjugation,
optical properties of the conjugate in terms of absorption and fluorescence spectra
remained similar to AlPcS2a. The cellular uptake was found to be dependent on the drug
concentration but the overall efficacy was not as efficient as AlPcS2a. Using confocal
microscopy, the granular distribution of the conjugate, the typical intracellular
distribution for PCI photosensitisers, was still observed. This conjugate also showed to
be able to induce PCI effect after illumination, resulting in the comparable increased
cell kill to the PCI effect using unconjugated AlPcS2a and saporin.
The studies in this chapter demonstrated the use of bioconjugation to synthesise photo-
products from available materials for PCI technology. The linking of a Tat peptide166
sequence significantly improves water solubility and the consequent bioavailability of
TPP to be an efficient photosensitiser for PDT and PCI. The AlPcS2a-saporin conjugate
has similar photophysical properties to the parent AlPcS2a and is also able to induce PCI
effect in combination with light. Further investigations are needed for the future
applications in vivo.167
Section C: In Vivo Studies – Evaluation ofAmphinex168
Chapter 6: Biodistribution ofAmphinex in Normal Rats169
6.1 Introduction
Investigating the biodistribution or localisation of drugs is always a necessary task for
any treatment. For drug treatments of cancer, the efficacies often rely on the drug
concentration in the cancerous sites and also the tumour selectivity - the ratio of drug
concentration in tumour to normal tissue. Amphinex displayed an efficient uptake by
cancer cells in vitro according to the results from Chapter 4. In this chapter, the
biodistribution of Amphinex in rats will be studied for further in vivo utilisation, e.g.
photodynamic therapy and eventually photochemical internalisation.
As mentioned before in Chapter 1, most of the photosensitisers form a biodistribution
preferential to tumours, although the mechanisms involved are not fully understood.
Unlike the 1
st generation photosensitisers, the 2
nd generation photosensitisers tend to be
pure compounds, which facilitate pharmacokinetic studies from the structure-
localisation point of view. To investigate the biodistribution of Amphinex, it is worth
looking at the distribution pattern of its fellow sensitisers as the biodistribution is
heavily influenced by their fundamental chemical properties. AlSnPc (sulfonated
aluminium phthalocyanines) and m-THPC (tetra(m-hydroxyphenyl) chlorin) are two
photosensitisers which are structurally similar to Amphinex. Both of them have well
documented PDT effects and in vivo pharmacokinetics, using different analytic methods
and models.
A comparative study of the biodistribution of di- and tetra-sulfonated aluminium
phthalocyanines (AlS2Pc and AlS4Pc) in rat colon has been carried out in our lab using
chemical extraction and fluorescence microscopy [Chatlani et al., 1991]. A good
correlation was found between both methods for both dyes that sensitisers were
eliminated with time, but the elimination of AlS2Pc was more rapid. Microscopic
distribution of the drug also gave more information about the drug localisation at the
cellular level. Peak fluorescence signals were measured 1h after i.v. injection in all
cases, except in the mucosa where the highest uptake of AlS4Pc was observed at 5hr
after administration. The microscopic biodistribution of AlS2Pc has also been
investigated in the canine prostate where the maximum drug concentration was
measured at 5-24hr after i.v. injection [Chang et al., 1997].170
Another study to compare the biodistribution of AlPcS2 in mice liver and muscle after
different administration routes (i.v., i.p., intramuscular (i.m.) and subcutaneous (s.c.))
was evaluated by chemical extraction and light-induced fluorescence spectroscopy
(LIFS) [Lee et al., 2001]. Despite the high level of drugs measured following i.v.
application, both analysis methods resulted in similar biodistribution patterns of the
drug in liver with the peak value at 1-4 hrs. The drug concentration appeared much
lower in muscle compared to liver by all measures. However, the i.v., i.m. and i.p.
deliveries produced higher drug uptake, particularly soon after injection when measured
using the LIFS method. This study indicates that different administration methods will
result in different biodistribution of drugs.
As for m-THPC which is a chlorin like Amphinex, Peng et al. investigated by chemical
extraction the uptake and localisation of m-THPC and m-THPP in tumour bearing mice
after i.p. injection [Peng et al., 1995]. The highest uptake of m-THPC was found 24-
48hrs after injection and the concentration in tumours were higher than most of the
normal tissues except liver, urinary tract and skin. Different intratumoural localisations
of drugs were observed by confocal microscopy where m-THPC was distributed in
vascular interstitium and neoplastic cells but m-THPP was localised in the stroma of
tumours.
m-THPC kinetics in normal rat liver and the implanted colon carcinoma in liver were
analysed by Rovers et al. using chemical extraction and LIFS methods to examine PDT
of liver metastases [Rovers et al., 1999]. Results from both methods showed that m-
THPC reached the peak concentration in normal liver at 4hrs after i.v. administration
and started to decrease in time. However, a different kinetic pattern was observed in
tumours; here the drug concentration remained high up to 48hrs after injection. The
tumour-to-liver ratio was measured at more than 5 using both methods which indicated
m-THPC is accumulated more in intrahepatic tumours. Another study using pegylated
m-THPC (m-THPC-PEG) was carried out to investigate the influence of drug
formulation [Rovers et al., 2000]. The results showed that pegylation of m-THPC
resulted in prolonged plasma half-life and higher uptake in tumours than in normal liver
at up to 75hrs. However, the concentration of m-THPC-PEG in liver tissue continued to
increase and it became higher than tumours when measured at 125 hrs after injection.171
Blant et al. demonstrated the comparison of the biodistribution of
14C-labelled m-THPC
in a hamster tumour model using three different methods- LIFS, fluorescence
microscopy and chemical extraction [Blant et al., 2002]. Results were consistent
between three methods, showing that the highest concentration of drug was found at 12-
24hrs post i.c. (intracardiac) injection in most of the tissues, including advanced
neoplasia.
Reports suggest that the pharmacokinetics of sensitisers is informative for determining
the timing of optical treatment during PDT. In most of the studies, most efficient PDT
outcomes were obtained while they were carried out at the timing chosen based on the
pharmacokinetic results i.e. when there was the sufficient photosensitiser concentration
in targeted tissues and lower drug concentration in the surrounding normal tissue, or the
highest ratio of drug concentration between tumour and normal tissue. Barr et al. have
discussed the correlation of the biodistribution photosensitiser with its biological effects
[Barr et al., 1991]. As stated before, the pharmacokinetics of sensitisers differs when
different administration modes, analysis methods or target models are employed.
The aim of this chapter is to investigate the biodistribution of Amphinex in Wistar rats
for further PDT and PCI treatment in normal liver and colon (the next chapters). Two
methods, quantitative fluorescence microscopy and chemical extraction, will be
compared and used for measuring the tissue uptake of Amphinex. To identify the tissue
localisation of Amphinex, H&E stained adjacent tissue sections will be used to compare
to the corresponding images collected with fluorescence microscopy.
The last experiment of this chapter describes the use of an optical pharmacokinetic (OP)
system to measure the absorption spectrum of Amphinex in rat liver. The technique has
been established in our laboratory [Austwick et al., 2009] and the acquired in vivo
optical properties of Amphinex can provide information on the optimum wavelength of
the light source suitable for activating Amphinex in vivo.172
6.2 Materials and Methods
Chemicals
Amphinex in Cremophor (10 mg/ml) was kindly donated by PCI Biotech (Norway).
Amphinex was diluted in phosphate-buffered saline (PBS) to a concentration of 2.5
mg/ml for intravenous injection. Solvable
TM, a standard tissue solubilizer and chemical
extraction agent containing dodecyldimethylamine oxide, secondary alcohol ethoxylate
and sodium hydroxide, was purchased from Perkin-Elmer (UK) [Kascakova et al.,
2008].
Animal models
All animal experiments were conducted under the authority of project and personal
licences granted by the Home Office and the UKCCCR Guidelines. Normal, female
Wistar rats (180-200g, Harlan, Oxon, UK) were used for both quantitative fluorescence
microscopy and chemical extraction studies. Female Hooded Lister rats (180-220g)
were additionally used for chemical extraction studies as future PDT treatments on the
subcutaneous tumour model are transplanted to Hooded Lister rats. Inhaled Halothane
or Isoflurane was used to maintain a state of general anaesthesia for drug administration.
Pharmacokinetic Studies Using Quantitative Fluorescence Microscopy
14 Wistar rats received 2.5mg/kg Amphinex intravenously via tail vein. Tissues of 4
organs (liver, colon, muscle (thigh) and skin (abdominal)) were obtained from seven
groups of animals (2 rats each) killed 1, 3, 6, 15, 24, 48, 96 hours after sensitisers
injection. In order to evaluate the skin photosensitivity, skin samples from another two
rats were taken 8 days after sensitiser administration. Two additional rats with no
sensitiser administration were used for control study. Fresh surgical specimens were cut
into suitable sizes, snap-cooled in isopentane for 10 sec. Excess liquid was removed
with a paper tissue and the tissues were placed into vials in a liquid nitrogen container.
Frozen tissues were stored in liquid nitrogen until sectioning. 10 μm sections were cut
from tissue blocks mounted with OCT Embedding Medium (Raymond A. Lamb, UK)
and picked up on poly-lysine coated slides. The cryosections were allowed to air dry for
at least 1 hour and then kept at -20°C in the dark until additional use.173
Sectioning was performed under minimal ambient light conditions to avoid
photobleaching of the photosensitiser. Five consecutive sections were prepared from
each sample for quantitative fluorescence microscopy. From each section, five images
were recorded in three different regions of the slice to avoid photobeaching.
The Amphinex fluorescence signal from frozen sections was detected using
fluorescence microscopy and the light source was a 532 nm laser (10mW). Fluorescence
was detected at 660 nm with a 50 nm bandpass filter. Images were taken using a Peltier-
cooled charge-coupled device (CCD) camera (Princeton Instruments, UK) and the
fluorescence intensity was analyzed using NIH Image J software. To determine the
exact histological localisation of Amphinex, one of the sections from each sample was
stained with haematoxilin and eosin (H&E) after recording the fluorescence images.
The H&E images were taken at an identical position. The subtraction procedure was
carried out for each measurement by subtracting the autofluorescence from the sections
of non-injected control animals.
Chemical extraction of Amphinex
8 Wistar rats and 6 Hooded Lister rats were given Amphinex 2.5mg/kg intravenously
via tail vein. Using two animals in each group, liver and colon tissues from Wistar rats
were collected at 3, 6 and 24hr after drug injection. Each time point has two animals
including the control group (no drug administered). Tissue samples were cut into small
pieces and frozen at -80 ºC.
Three fully defrosted samples (0.1g wet weight) from each animal (organ) were
immersed in 2ml Solvable in tubes and placed into a shaking water bath at 50 ºC for 2
hours until clear solution was observed. 0.15ml tissue solution from each tube was
diluted with 3ml Solvable and cooled to room temperature before measuring the
fluorescence. A standard curve of Amphinex in Solvable was established by making up
Amphinex solution of series concentrations with control tissue-containing Solvable.
Each sample solution was plated onto 4 wells of a dark 96-well plate. A standard curve
was obtained from the mean fluorescence intensity measured at 655 nm and the
corresponding concentrations of Amphinex in each sample could thereby be calculated.174
Optical pharmacokinetic (OP) measurement of the absorption spectrum of Amphinex in
liver
The spectroscopic technique used in these experiments enables measurement of the in
vivo absorption spectrum of the administered chromophore. All animals (except control
groups) were sensitised with 2.5 mg/kg Amphinex through the tail vein injection,
followed by the OP measurement carried out at laparotomy 6 hrs after drug
administration. The same dose was used in the fluorescence pharmacokinetic studies.
OP data were collected from liver using a pair of fibres (delivery and collection) inside
a catheter. The tip of catheter was pressed lightly against the liver surface. 10 separate
positions were chosen with 4 OP measurements being taken at each position. The
delivery fibre (400 μm in diameter) and the collection fibre (200 μm in diameter) are 1.8
mm apart. The light was delivered from a pulsed Xenon arc lamp (model LS
1130/FX1100, Perkin Elmer Optoelectronics, UK) and the signal scattered back was
analysed by a CCD spectrometer (model S2000, Ocean Optics Inc.,USA). The system
was calibrated before each experiment using a reference spectrum collected from white
Spectralon (Labsphere, USA), a spectrally flat diffuse-reflecting polymer.
The data analysis was carried out with help from Dr Austwick. The detailed optical
absorption data collection and further analysis methods can be found here [Austwick et
al., 2009].175
6.3 Results
6.3.1 Biodistribution of Amphinex in normal rats using quantitative fluorescence
microscopy
Pharmacokinetic studies using quantitative fluorescence microscopy showed highest
uptake of Amphinex in liver at 6hrs after drug administration (Figure 6.1). The
excretion of Amphinex from the liver slowed down after 24hrs, and a retention phase
was observed between 24 hrs and 48 hrs.
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Figure 6.1 Kinetics of Amphinex in Wistar rat liver (control rats subtracted) after i.v.
injection of 2.5 mg/kg Amphinex examined by fluorescence microscopy.
Figure 6.2 illustrates a comparison of the uptakes of the other 4 organs after measuring
their fluorescence quantities. These 4 organs displayed, overall, a much lower uptake of
Amphinex compared to the liver. Similar pharmacokinetic patterns were found as the
uptakes were highest at 24 hrs after administration in the mucosa of colon, skin and
muscle, and at 48 hrs in the muscle in colon. A clear decrease was observed in skin up
to 8 days after injection indicating minimum skin photosensitivity.176
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Figure 6.2 Comparative fluorescence kinetics examined by quantitative fluorescence
microscopy of Amphinex in skin, colon and muscle of Wistar rats (control rats
subtracted) after i.v. injection of 2.5 mg/kg Amphinex.177
6.3.2 Quantitative microscopic biodistribution of Amphinex
The fluorescence microscopy imaging results of the uptake of Amphinex 1hr after
administration in liver, colon and skin are shown in Figure 6.3A, B and C respectively.
The corresponding histology results (H&E stain) are shown in the right column of
Figure 6.3. The average fluorescence intensity was about 5000 counts/pixel in liver and
157 counts/pixel in the colon mucosa. It can be seen that Amphinex has spread
throughout the colon mucosa within 1hr after injection, and there is a distinct difference
in the uptake between the mucosa and muscle in the colon - the fluorescence signal was
only 37 counts/pixel in the muscle structure. A significant drug accumulation in
submucosa blood vessel wall was also observed with the fluorescence intensity around
1300 counts/pixel (Figure 6.3B, green arrow). Compared to the other tissues, the signals
from skin were very low; the drug level in the thigh muscle is even lower (images not
shown).
The highest uptake of Amphinex in liver and colon are shown in Figure 6.4. The
maximum drug accumulations in liver and colon were measured at 6 hrs and 24 hrs after
drug administration respectively. As these images were plotted on the same scale of
fluorescence intensity as the 1hr images, the larger number of areas presented in white
and yellow indicate the higher drug uptake in these two tissues. It should be noted that
the colon submucosa blood vessel wall still exhibits excellent drug uptake and the drug
level was slightly higher (1600 counts/pixel) compared to the 1hr data. The serosa layer
was on the edge of the section which usually folds up and results in multiple layers.
This could be the cause of the particularly high signals detected from the outer colon
wall.178
Figure 6.3 Fluorescence (left) and corresponding H&E stained (right) micrographs of
frozen sections of Wistar rat liver (A), colon wall (B) and skin (C) sampled 1h after i.v.
injection of 2.5mg/kg Amphinex. Individual colour scale bar refers to the relative
fluorescence intensity. Arrow: submucosa blood vessel; M: mucosa; SM: submucosa; S:
serosa.
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Figure 6.4 Fluorescence images of maximum uptake of Amphinex in Wistar rat liver
(A) and colon wall (B). Liver and colon was sampled at 6hr and 24hr after i.v. injection
of Amphinex 2.5mg/kg respectively. Green arrow: submucosa blood vessel.180
6.3.3 Quantification of Amphinex concentration in rat liver and colon using
chemical extraction
Pharmacokinetics of Amphinex in liver and colon of Wistar rats were also assessed by
chemical extraction. As shown in Figure 6.5, liver displayed a much higher Amphinex
uptake compared to colon. For the times studied, the highest concentration in both
tissues was detected at 6hrs after administration although the concentration in colon at
6hrs and 24hrs were similar. Good correlations were noted between the Amphinex
concentration measured by chemical extraction and the fluorescence intensity from
fluorescence microscopy. Using both techniques the levels observed in liver at 24 hrs
were significantly lower compared to 6 hrs as shown in Figure 6.1 and 6.5.
0
2
4
6
8
10
12
14
16
18
0 3 6 9 12 15 18 21 24
Time after administration (hour)
E
x
t
r
a
c
t
i
o
n
c
o
n
c
e
n
t
r
a
t
i
o
n
(
m
g
/
g
)
liver
colon
Figure 6.5 Concentration of Amphinex extracted from the liver and colon of Wistar rats
as a function of the time after i.v. injection of 2.5 mg/kg Amphinex.181
6.3.4 Optical pharmacokinetic measurement of Amphinex from rat liver
The mean tissue reflectance spectrum of Amphinex in liver measured by OP system is
illustrated in Figure 6.6. A low signal corresponds to weak diffuse reflectance as a result
of strong absorption by chromophores present in the tissue. The strong absorption of
haemoglobin can be seen in the region 520-600 nm. The absorption spectrum of
Amphinex in water has been measured with a strong peak lying close to 655 nm (Figure
4.5). The data obtained here also show a peak absorption in this region (red circle inset).
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Figure 6.6 Mean OP measurement of Amphinex signal from rat liver. Animals were
sensitised with 2.5mg/kg Amphinex (i.v.) for 6 hr. Red circle inset: peak absorption of
Amphinex in liver.182
After haemoglobin spectrum removal, linear interpolation was then carried out within
the region from 635 nm to 665 nm which represents the baseline at the peak (Figure 4.6).
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Figure 6.7 Linear interpolation of mean OP measurement of Amphinex signal from rat
liver. Animals were sensitised with 2.5mg/kg Amphinex (i.v.) for 6 hr.
After the above fitting processes, the peak absorption of Amphinex measured in liver is
identified and shown in Figure 6.8. The maximum absorbance was measured to be at
652 nm. The result here is close to the peak absorbance of Amphinex measured from
aqueous solution but with a slight redshift of 3 nm.
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Figure 6.8 Mean absorption peak position of Amphinex from rat liver. Animals were
sensitised with 2.5mg/kg Amphinex (i.v.) for 6 hr.183
6.4 Discussion
In this chapter, the biodistribution of Amphinex in rats was analysed using fluorescence
microscopy and chemical extraction methods. The drug kinetics in several chosen
tissues was examined and should offer useful information for further PDT or PCI
treatments.
Higher uptake of Amphinex in rat liver was measured compared to other organs using
both quantitative fluorescence measurement and chemical extraction methods.
According to the results from fluorescence microscopy, the drug concentration rises
quickly in the first 6 hrs after injection and a decline appears afterwards (Figure 6.1).
The same pattern was obtained using chemical extraction (Figure 6.5). The stable and
low drug concentration observed after 24hr indicate a good drug and light interval for
treatment in the liver.
In contrast to the liver, the peak values of the Amphinex level in other peripheral tissues
were found to be much lower (Figure 6.2). The highest was measured in the colon
mucosa followed by skin, colon muscle and muscle from thigh. The Amphinex
concentration in the colon wall was also examined by chemical extraction (Figure 6.5).
The fluorescence intensity was measured to be higher in colon mucosa than in colon
muscle, which suggests a higher drug uptake by the mucosa. However, this difference
could not be detected by chemical extraction, as the extraction data represents the drug
concentration within all colon structures.
Concerning the skin photosensitivity, the kinetics of Amphinex in rat skin were
examined and followed up to 8 days after drug application. The Amphinex level in rat
skin was observed to be low when using fluorescence microscopy with the highest
uptake measured during 3-24 hrs and a decline up to 8 days after injection. A high level
of photosensitisers distributed to skin will cause problems when patients are exposed to
ambient natural or artificial light. As prolonged cutaneous phototoxicity is still one of
the major side effects of PDT treatments in clinic [Mlkvy et al., 1998;Wagnieres et al.,
1998], the clear decrease of Amphinex in the longer term times which reduce the skin
sensitivity will certainly benefits the clinical utility of Amphinex. Further studies are
required to test the possible skin phototoxicity induced by Amphinex.184
It is an interesting finding that higher Amphinex uptake was measured in the smooth
muscle in colon wall, and the drug level was about a half that in the striated muscle
from the thigh. A similar result has been reported by Blant et al. -
14C-labelled m-THPC
exhibited significant higher drug concentration in smooth muscle (uterus) than in
striated muscle (skeletal) during the first 48hrs interval after injection [Blant et al.,
2002]. It was suggested that this difference could be an advantage from a clinical point
of view. When interstitial PDT for advanced SCC of unfavourable locations such as the
base of tongue or treatment of middle to lower oesophagus where smooth muscle is the
major component, the unwanted photodynamic damage to the muscle and the
consequent complications can be therefore reduced.
The main conclusion from these studies is that Amphinex accumulates in normal tissues
within a few hours of i.v. administration but then clears over a period of days. The
kinetics appear to be similar to those found for sulfonated aluminium phthalocyanines
in our laboratory also using Wistar rats, where liver uptake is also high but is cleared
over several days [Barr et al., 1991;Chang et al., 1997;Chatlani et al., 1991]. Further
studies using a tumour model are presented later in Chapter 8.
Quantitative fluorescence microscopy and chemical extraction were used to investigate
the biodistribution of photosensitisers in this study. In fact, based on the optical
properties of photosensitisers, there is another approach also often to be used to quantify
the drug concentration in tissues with time: fibre-based light-induced fluorescence
spectroscopy (LIFS). The LIFS technique quantifies the photosensitiser levels in tissues
by measuring the corresponding fluorescence spectra. The in vivo system particularly
provides a rapid, real-time and non-destructive measurement of drug concentration in
tissue. However, the tissue optical properties would certainly affect the light penetration.
Panjehpou has reported that the signal detected from muscle could be 5 times higher
than from liver when given the same concentration of phthalocyanine to two tissues
[Panjehpour et al., 1993]. This is due to the absorption of the excitation light by
haemoglobins in the more vascularised liver. Also, it was found that different
composition of epithelial layers could lead to changes in the shape and intensity of the
predicted spectra [Pavlova et al., 2008]. Therefore, in order to avoid misinterpretation, it
is important to understand the changes in the optical properties of photosensitisers when
they are in different biological environments.185
It is well known that UV light can only pass through 200μm at oral mucosa due to the
strong absorption from haemoglobins. In this regard, the light penetration depth would
limit the application of LIFS. Chemical extraction does not suffer from this problem as
it measures the fluorescence intensity from the digested tissue solution. In spite of its
intensive and time-consuming nature, chemical extraction has the advantage that it
gives quantitative analysis in terms of mass of drug per mass of tissue. Also, the
requirement of a large amount of tissue gives chemical extraction a better accuracy and
makes it a gold standard method for pharmacokinetic studies. An obvious disadvantage
turns out to be the loss of detailed information from the separate substructures of tissues.
For some tissues like colon with complex composition, it is impossible to virtually
dissect the colon wall into mucosa and submucosa layers. Another problem is that,
ideally, photosensitising compounds will all become monomers after chemical
extraction. As a result, the extraction data might not reflect the actual amount of the
photosensitisers with photosensitising ability when sensitisers have the tendency to
aggregate and exhibit negligible fluorescence. However, some studies have shown that
e.g. AlS2Pc can remonomerise during PDT [Kunz et al., 2007]. Therefore, LIFS, which
can be carried out during treatment, might be more suitable in this circumstance.
Fluorescence microscopy can yield drug biodistribution at the cellular level. It also
requires series sample preparation procedures but the pharmacokinetic details regarding
the drug localisation and the levels of accumulation could be observed at the same time.
Moreover, the fluorescence intensity detected by fluorescence microscopy should be
from the monomerised photosensitisers which are able to induce photochemical
interaction upon irradiation. In this case, the pharmacokinetics obtained from
fluorescence microscopy might be more correlated with the efficacy of further
photodynamic treatments. However, several things also need to be taken into account.
Firstly, the measured fluorescence intensity is a relative value which does not represent
the absolute drug concentration. Secondly, the sample size of fluorescence microscopy
is small compared to chemical extraction. The thickness of a frozen section is usually
about 8-10μm and one fluorescence image covers an area of less than 0.02 mm
2 of
tissues when using a 60x objective. Also, a good section is required as non-flat sections
would result in inaccurate fluorescence measurements.
There is no one analytic method that is superior to the others. Each has its own
advantages and limitations. Hence, it is necessary to use more than one method to186
compare and determine the drug pharmacokinetics in vivo. In this chapter, good
correlations between the kinetics pattern of Amphinex in rat liver and colon using
quantitative fluorescence microscopy and chemical extraction were obtained.
Fluorescence images provided the detailed drug localisation at the cellular level.
Chemical extraction results yielded the actual drug concentrations in tissue.
The separate experiment of optical pharmacokinetic measurement of Amphinex in liver
gives therapeutically relevant information about the tissue absorption spectrum of
Amphinex. The OP system is a non-invasive method to quantify drug concentrations
using white light spectroscopic measurement [Mourant et al., 1999] and has been
recently applied to measure topical m-THPC (liposomal mTHPC-gel) in the skin of
albino hairless mice [Johansson et al., 2007] and AlS2Pc in various organs in rats
through i.v. injection [Austwick et al., 2009]. The figures from present study show that
the peak absorbance of Amphinex in liver is at 652 nm which is similar to the value
measured from aqueous solution (649 nm, Figure 4.5). The variation between the two is
tiny and, in fact, its peak absorbance from liver is closer to the available light source
used for m-THPC, a 652 nm laser. The results warrant the use of the 652 nm laser for
activating Amphinex in vivo. In the subsequent PDT and PCI studies presented here a
652 nm laser has been used.
Further PDT and PCI treatments using Amphinex in normal rat tissues and tumours will
be shown in the following chapters.187
Chapter 7:Amphinex PDT and PCI in Normal Rat
Liver and Colon188
7.1 Introduction
Photochemical internalisation (PCI) is a novel technology which enhances the
therapeutic effects of macromolecules by releasing them from vesicular compartments
after sub-lethal PDT treatment. The results in Chapter 4 have proven that Amphinex
PCI is able to improve the therapeutic effect of saporin and bleomycin resulting in the
enhancement of cell killing in vitro. In this chapter, the in vivo efficacy of Amphinex
PCI of saporin and bleomycin would be investigated on normal rat liver and colon.
As mentioned before, PCI has been shown to be effective for in vitro release of drugs
and genes [Berg et al., 1999;Hogset et al., 2004]. While PCI action at the cellular level
has been well studied, it is not always possible to directly translate the mechanisms into
animal models. The involvement of some elements such as the vascular system would
certainly make the in vivo situations different from the ones in vitro. In the past few
years, PCI using AlPcS2a has exploited its utilisation in releasing gelonin or bleomycin
in vivo, particularly using animal tumour models in nude mice [Berg et al.,
2005a;Dietze et al., 2005;Norum et al., 2009b;Norum et al., 2009a;Selbo et al., 2001b].
Previous study has shown that AlS2Pc PCI could induce the intracellular relocalisation
of gelonin and therefore enhance its cytotoxic effect on normal liver [Woodhams et al.,
2009]. The study looked at the importance of treatment parameters (the sensitiser dose
and the administration timing for gelonin), demonstrating a qualitative and quantitative
analysis to compare the PDT and PCI effect. The volume of necrosis in liver was
increased by a factor of 2.5 when using a very low dose of gelonin intravenously 1hr
before light delivery compared to the corresponding PDT treatment. The relocalisation
of gelonin was also observed by staining gelonin before and after illumination using
immuhistochemistry.
The present study adopted the same experimental design as the previous study but
involved more aspects such as the influences of different anti-cancer agents and the
target organs employed in the PCI treatment.
First of all, bleomycin and saporin were chosen to be used in the PCI strategy.
Bleomycin has been used clinically in combination with a number of other drugs for189
treating several types of cancers [Sikic et al., 1985]. Saporin and gelonin are both type I
ribosome-inactivating proteins but saporin exhibits higher toxicity than gelonin [Stirpe
and Battelli, 2006]. As a consequence, immunotoxins and bioconjugates of saporin have
been developed for cancer treatments [Stirpe and Battelli, 2006]. The promising in vitro
results in Chapter 4 also indicated the feasibility of using Amphinex PCI combining
saporin and bleomycin in vivo.
Secondly, liver and colon are the organs of interests in this study. Previous studies at the
National Medical Laser Centre have used normal liver to investigate HpD and AlSPc
PDT effects [Bown et al., 1986;Woodhams et al., 2004;Woodhams et al., 2009] and the
colon model for m-THPC, AlSPc, porfimer sodium, 5-ALA and WST09 PDT
treatments and mechanism studies [Barr et al., 1990;Chatlani et al., 1991;Curnow et al.,
1999;Messmann et al., 1995;Tsutsui et al., 2002;Woodhams et al., 2006]. It is suggested
that the relative homogeneity of liver, its sufficiently large size, easy accessibility and
the well-characterised photochemical responses make it a good model for investigating
the biological effect of PDT treatments [Bown et al., 1986]. Colon, unlike liver, is a
hollow and relatively pale organ. The colon wall is thin but anatomically more
complicated than liver with layers of different tissues. The treatment responses from
those substructures of the colon wall might be different. Hence, the differences of these
two tissues in terms of their optical properties which affect the light delivery, the
photosensitiser levels that liver displays a much higher uptake of Amphinex (results
from previous chapter), as well as the amount of bleomycin or saporin would certainly
provide valuable information for investigating PCI treatment in vivo.
The scheme of Amphinex PDT or PCI treatment using normal rat liver and colon
models is shown in Figure 7.1.190
Figure 7.1 Scheme of Amphinex PDT and PCI treatments in combination with saporin
and bleomycin on normal rat liver and colon models.
To optimize the treatment conditions for PCI, experiments began with looking at the
PDT effect with the interplay between different amounts of Amphinex and a range for
the excitation light dose. Thereafter, the PCI effect with the application of saporin and
bleomycin were investigated. Experiments of PCI using AlPcS2a in combination with
saporin were also carried out to compare with the previous study.
This chapter is a cross-comparison study to compare PDT alone and PCI of saporin and
bleomycin in normal rat liver and colon using the photosensitiser Amphinex. Under the
optimal PDT treatment conditions with fixed Amphinex dose and sensitisation time,
studies would focus on how varying the dose of anti-cancer agents and drug application
time would influence the PCI treatment efficacy on the liver and colon.
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7.2 Materials and Methods
Chemicals
Amphinex in Cremophor (10 mg/ml) was kindly donated by PCI Biotech (Norway).
AlPcS2a was purchased as a powder from Frontier Scientific (USA). Amphinex was
diluted in phosphate-buffered saline (PBS) to a concentration of 0.25 mg/ml for
intravenous (i.v.) injection. AlPcS2a was dissolved in 0.1M NaOH, and then diluted in
PBS at pH 7.4 to a concentration of 5 mg/ml for i.v. injection. Saporin was purchased
from Sigma-Aldrich (USA). Stock solution of saporin (1mg/ml) was prepared by
dissolving the drug power in sterile water. Aliquotes of saporin stock solution were kept
at -20ºC until use. The saporin solution for injection (0.5 mg/ml) was prepared by
diluting the stock solution with PBS. Bleomycin (Kyowa Hakko, Mayne) was provided
as a powder (15 IU per vial according to the U.S. standard equivalent to 15,000 IU
according to the European Pharmacopeia. 5.1), and was dissolved in 0.9% NaCl which
is ready for injection.
Animal models
All animal experiments were conducted under the authority of project and personal
licences granted by the Home Office and the UKCCCR Guidelines. Normal, female
Wistar rats (180-200g, Harlan, Oxon, UK) were used for all PDT and PCI treatment
experiments. Inhaled Halothane or Isoflurane was used to maintain a state of general
anaesthesia for drug administration. Analgesia was administered subcutaneously 30
minutes before surgery.
Light source
The light source used for Amphinex PDT and PCI treatments was a diode laser emitting
at 652nm (Diomed Ltd, UK). An attenuator (FVA-UV fibreoptic variable attenuator,
World Precision Instruments Ltd, UK) was used when the laser power needed to be
50mW. For AlPcS2a PDT and PCI treatments, the light source was a diode laser
emitting at 670nm (Hamamatsu Photonics K.K., UK). Lasers were calibrated and the
power at the tip of the fibre was measured using a wavelength-independent pyroelectric
power meter (TPM-300, Gentec Inc, Canada) before each treatment.192
Amphinex PDT effects on normal rat liver
For PDT experiments, Amphinex was administered via a tail vein at various drug doses
(0.1, 0.25, 0.5, 1 and 2.5mg/kg) 24 hrs before light delivery. At laparotomy, a cleaved
tip 400 μm laser fibre was placed gently touching the surface of the liver. The laser
power was 100mW for providing the light doses of 15J and 25J or 50mW for 5J and 10J.
Animals were killed by cervical dislocation 3 days after surgery and the livers were
removed immediately. At post mortem, the dimensions of the necrotic lesion were
measured on the surface of the treated lobe using an electronic slicing caliper. The depth
of necrosis was measured after cutting through its centre along the long axis. The
necrotic surface area was then calculated using the formula πLW/4, where L =the
maximum length of the lesion, and W = the width of the lesion, perpendicular to the line
of L. The volume of necrosis was estimated using the formula πLWD/6 instead, where
D is the depth measured from the centre on the surface. The tissues were then fixed in
4% formalin for 24 hrs. The samples were wax-embedded and sectioned at 4μm
thickness onto poly-lysine coated slides after being placed in a tissue processing
machine for further fixation. Sample slides were stained using the conventional
Haematoxylin and Eosin (H&E) stains for histological examination.
H&E stained sections were examined using the Hamamatsu Nanozoomer Digital
Pathology (NDP) scanner (Hamamatsu Photonics K.K., UK) where high-resolution
digital images of the whole section were recorded. This microscopy imaging system
uses a time delay integration (TDI) camera instead of the traditional CCD camera to
scan images in lines, resulting in high-speed and high resolution (approx. 1 min 40s for
1.9 billions pixels at 20x magnification) scanning. The highest resolution obtainable is
0.23 μm per pixel. Thus one can view both the whole section and/or examine selected
sites at high resolution within the section.
Treatments with drug (2.5 mg/kg) or light (10J and 25J) alone were also carried out as
control studies. The rat given 2.5 mg/kg Amphinex was monitored up to 4 days until
sacrificed. Animals receiving light treatment only without sensitisers were examined for
possible necrotic lesions in the liver 3 days after a 25J light dose delivery (animal
number = 1) or 10J light delivery (animal number = 2).193
Figure 7.2 is a photograph of the light treatment on liver.
Figure 7.2 The light treatment on the rat liver.
Amphinex PCI in combination with saporin or bleomycin in rat liver and colon
All animals were sensitised with Amphinex through the tail vein injection at a dose of
0.25 mg/kg 24hrs prior to light irradiation. Two strategies were carried out to
investigate the optimum effect achieved by Amphinex PCI in combination with saporin
or bleomycin in liver or colon: varying the dose of toxins or varying the administration
time of toxins.
For PCI of saporin, 250 μg/kg saporin was either administered intravenously 2 hrs, 1 hr
or 30 min before light treatment or injected to rats at a range of doses of saporin (50,
100 or 250 μg/kg) 1hr prior to light delivery. For PCI of bleomycin, rats were given 30
IU/kg bleomycin 2 hrs, 1 hr or 30 min before light treatment or received bleomycin (15,
30 and 60 IU/kg) 1hr prior to light treatment.
For the treatments in colon, at laparotomy, the tip of the laser fibre was inserted at the
antimesenteric side of the colon, 25-30mm from the pole of the caecum and placed just
touching the surface of the mucosa on the opposite side to the entry point. The rest of
the abdominal viscera were shielded from forward light scattering by covering pieces of
opaque paper soaked in PBS. The light dose of 10J was used with the laser power of
50mW for 200 seconds. Animals were killed 3 days after treatment. The treated section
of colon was removed and opened along the long axis, exposing the mucosal surface,194
which was then gently flattened out for macroscopic inspection. The lesions were often
yellow with irregular shapes. Macroscopic measurements were made by recording the
maximum length (L) of the lesions. Sections were fixed in 4% formalin and then run
through the same procedures as the liver samples for histological analysis.
The setting for the treatment in colon can be seen in Figure 7.3.
Figure 7.3 The light treatment on the rat colon.
Treatments in liver were carried out followed the same protocols described before. The
light dose of 10J (50mW, 200sec) was chosen throughout all Amphinex PCI
experiments. Control groups include animals receiving toxins alone, light only,
sensitisers only, and sensitisers with toxins but no light as well as toxins with light
treatment. Animals were killed 3 days after treatment and followed by macroscopic
measurements, sample fixation and histological analysis whose details have been
mentioned previously.
AlPcS2a PDT and PCI in combination with saporin on normal rat liver
Using AlS2Pc as a PDT/PCI sensitiser has been investigated in our lab previously
[Woodhams et al., 2009]. In this thesis study, commercially purchased pure AlPcS2a
was used instead to compare the treatment efficacy with Amphinex. Animals were
sensitised by tail vein injection of AlPcS2a (0.1 mg/kg) 24 hrs prior to light delivery.
According to the results from previous studies, the optimum AlPcS2a PCI condition on195
normal rat liver model was found when gelonin was given 1 hour prior to light
treatment. Therefore, the dose of saporin at 0, 50 or 250 μg/kg was given 1 hour before
in combination with various light doses (5J, 10J and 25J). Experiments in which
animals received saporin 1 hour after 25J illumination were also carried out. All animals
were killed 3 days after surgery. Macroscopic measurements, sample fixation and
histological examination were conducted followed the same protocols as described
before.
Statistical analysis
All data were presented as mean ± SD. Significant differences between PDT and PCI
treatments were assessed by one tailed Student’s t-test analysis. P ≤ 0.05 was considered
statistically significant.196
7.3 Results
7.3.1 Amphinex PDT effects on rat liver
PDT effects on normal rat liver in combination with 1mg/kg AlS2Pc and 25J light
irradiation have been previously investigated in our laboratory [Woodhams et al., 2009].
The present study expanded the picture, examining the PDT effects induced by
Amphinex using various light and drug doses. Sub-lethal doses induced appropriate size
necrotic lesions in liver suitable for PCI applications.
Animals in control groups were all observed to be healthy throughout the study without
weight loss. No necrosis was found in liver when rats were treated with Amphinex or
light only (Figure 7.4). Amphinex, with the dose up to 2.5 mg/kg, produced no toxicity
in rat liver in the absence of light.
In figure 7.4, the necrotic lesions induced after PDT treatments were all of ellipsoid
shapes and the size was measured 3 days after surgery. The size of necrosis induced
after Amphinex PDT treatment increased when higher drug or energy doses were
applied. The maximum lesion size was found under the 2.5 mg/kg Amphinex and 25 J
light treatment condition which was 43.5 mm
2 with full thickness necrosis. A drug dose
dependent manner was well displayed in the group with 15J light treatment. The size of
lesions was more than 4 times larger on average using 1 mg/kg Amphinex compared to
0.1 mg/kg Amphinex.
The volume of necrosis induced after Amphinex PDT is displayed in Figure 7.5. Some
measurements in volume are underestimated as full thickness necrosis was caused due
to high drug dose or light dose. Three groups with rats having full thickness necrosis
(0.5 or 1 mg/kg Amphinex with 15J light irradiation and 2.5 mg/kg Amphinex with 25J
light) were marked with stars in Figure 7.5.
The optimum PDT treatment conditions for further PCI application was chosen
combining a dose of 0.25 mg/kg Amphinex and 10J light which caused a suitable size
of necrosis (no full thickness necrosis involved) and reduced the possible thermal
effects of light delivery. An example of the corresponding H&E stained histology
results of Amphinex PDT in rat liver is shown in Figure 7.12A.197
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Figure 7.4 Mean surface area of necrosis induced by Amphinex PDT in normal rat liver.
The necrotic lesions induced after PDT were measured 3 days after surgery. Stars mark
the animal number of non-control PDT groups which is only one. At least 2 animals
were investigated for other PDT treatment groups.198
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Figure 7.5 Mean volume of necrosis induced by Amphinex PDT in normal rat liver.
Stars mark the groups with the involvement of full thickness necrosis in liver induced
after light treatments.199
7.3.2 Amphinex PCI in rat liver
Direct comparison studies of AlS2Pc PDT alone and PCI in combination with a
ribosome inactivating protein toxin, gelonin, using normal rat liver have been
investigated in our lab previously [Woodhams et al., 2009]. This present study followed
the same methods but using Amphinex as the sensitiser. The PCI effects combining
saporin, another member of type I RIP, and bleomycin, a chemotherapeutic in clinic,
was investigated in the same rat liver model.
In order to clarify the PCI effects applied to PDT, various saporin and bleomycin doses
were used in the optimum PDT condition in this model (i.e. Amphinex: 0.25 mg/kg;
light dose:10J; drug light interval: 24 hrs; saporin or bleomycin given 1hr prior to light
treatment). The mean surface area of necrotic damage in liver was increased but not
significantly when animals received 50-100 μg/kg saporin or 15-60 IU/kg bleomycin 1
hour before light delivery if compared to PDT alone (Figure 7.6). The mean surface
area of necrosis increased significantly by a factor of 2.4 when a dose of 250 μg/kg
saporin was injected to animals (t-test, p<0.01). The corresponding H&E stained
histology results of the maximum liver damage induced after PCI treatment are shown
in Figure 7.12.
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Figure 7.6 Mean surface area of necrotic lesions in liver at three days after light
treatment in animals treated with 0.25 mg/kg Amphinex (i.v.) 24 hrs before light against
various doses of saporin and bleomycin given 1 hour before light treatment. (*: p<0.01)200
Figure 7.7 shows the mean surface area of necrosis induced 3 days after light treatment
against different administration intervals of 250 μg/kg saporin or 30 IU/kg bleomycin
prior to the light irradiation. The maximum enhancement was found when saporin was
injected 1 hour before light delivery where the necrotic area increased by a factor of 2.4
compared to the PDT alone treatment (p<0.01). The mean surface area of necrosis was
about doubled compared with the lesions in PDT treated animals when saporin was
injected 30min prior to the light treatment (p=0.02). The maximum PCI damage
combining with bleomycin was found when the drug was injected 15-30min before light
so that the mean necrotic area increased significantly by a factor 1.8. The results of the
animals treated with bleomycin just before light irradiation (T=0) showed an increase in
the necrosis size on average but not significant with a wide variation. Examples of H&E
stained histological analysis of liver sections after PCI treatments combining saporin
and bleomycin are shown in Figure 7.12B and C.
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Figure 7.7 Mean surface area of necrotic lesions in liver at three days after light
treatment in animals given 0.25 mg/kg Amphinex (i.v.) 24 hrs before light against the
administration time of saporin (250 μg/kg) or bleomycin (30 IU/kg) prior to light
treatment (hour). A minimum of 3 animals was involved in each experiment group. (*
1:
p<0.05; *
2: p<0.01; *
3: p=0.02; *
4: p<0.01; *
5: p=0.03)
No macroscopic necrosis in liver was observed in any control animal. Rats which
received saporin or bleomycin (either sensitised with Amphinex or treated with light)
had about 15 g weight loss but were all in healthy condition.201
7.3.3 Amphinex PCI in rat colon
PCI effects combining saporin or bleomycin on different organs were estimated using
the rat colon model. The necrosis induced by PCI treatments in combination with
saporin (250 μg/kg, i.v. 1 hour before light delivery) was increased but not significantly
compared to the PDT treatments alone (Figure 7.8).
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Figure 7.8 Extents of necrotic lesions in colon at three days after light treatment in
animals given 0.25 mg/kg Amphinex (i.v.) 24 hrs before light against two doses of
saporin given 1 hour before light treatment. Four animals were involved in each
experiment group.
Following the same protocols, the effects of Amphinex PCI in combination with
bleomycin (15 IU/kg) was also investigated using the rat colon model. As shown in
Figure 7.9, PCI of bleomycin induced enhanced necrotic damage in colon significantly
in all animals either receiving bleomycin before or after light treatments. The mean
longest length of the necrosis was found when bleomycin was given 15 min before the
light treatment. The diameter of the lesion was increased by more than a factor of 2
compared to PDT treatment alone (p<0.01). The second longest length of the necrotic
lesions was observed when applying bleomycin to rats 1hr before light.202
Giving double dose of bleomycin (30 IU/kg) 30 min before light induced larger necrotic
damage to colon but with a wide variation. The minimum increase of necrosis using 15
IU/kg was observed when bleomycin was administered 30 minutes before light.
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Figure 7.9 Mean surface area of necrotic lesions in colon at three days after light
treatment in animals given 0.25mg/kg Amphinex (i.v.) 24 hrs before light against
bleomycin administration time prior to light treatment (minutes). A minimum of 3
animals was involved in each experiment group. (*p=0.02~0.04; **p<0.01)
An example of the corresponding H&E stained histology results of Amphinex PDT in
rat colon is shown in Figure 7.14.203
7.3.4 AlPcS2a PCI in combination with saporin in rat liver
Similar experiments were carried out to investigate the AlPcS2a PCI effects combining
different saporin doses and light doses on normal rat liver.
In the previous study, animals receiving 50 μg/kg gelonin prior to AlS2Pc PDT (1
mg/kg, 24hrs drug light interval) had significantly increased necrotic lesions after 3
days compared to treatments in the absence of gelonin [Woodhams et al., 2009]. In the
present studies, enhancement of PDT in combination with saporin (50 μg/kg and 250
μg/kg) did not appear after 10J and 25J light treatments (Figure 8.10). Increased mean
surface area of necrotic lesions in liver was only observed from the animals treated with
5J light irradiation in combination with 250 μg/kg saporin. When 25J light was
delivered 1 hour before saporin injection, the size of necrosis was similar to the light
after saporin strategy. Two out of three and one out of four rats receiving 50 μg/kg and
250 μg/kg respectively 1hr before irradiation were observed full thickness necrosis in
the livers after 25J light treatment.
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Figure 7.10 Mean surface area of necrosis induced by AlPcS2a PDT and PCI of saporin
in rat liver. Stars mark the groups with the involvement of full thickness necrosis in
liver induced after light treatments. L.B.: light before; 250 μg/kg saporin was given after
light.204
7.3.5 Macroscopic examination and histology
No macroscopic and histological changes could be detected in any control animals
which received toxins or photosensitisers separately with no exposure to light. Sections
from the animals receiving light treatments alone without any drug administration also
showed normal tissue architecture.
Figure 7.11 Photographs of examples of the macroscopic damage in normal rat liver (A)
and colon (B and C) after PDT or PCI treatments.
The macroscopic damage induced after PDT and PCI treatments was observed to be
similar despite the size differences in the necrotic lesions. Figure 7.11A is an example
of the typical appearance of treated liver. The necrotic lesion was observed of oval
shape and clearly distinguishable from the normal area. An example of the necrosis seen
on colon was shown in Figure 7.11B and C. A sharply defined ulcer in colon was
observed at post mortem (arrow, Figure 7.11B) and the necrotic lesion in yellow colour
could be seen after the colon was opened up (Figure 7.11C). No obstruction or
perforation was observed after either treatment but diarrhoea sometime could be seen in
the harshest treatments in which higher drug and light doses were involved. Detailed
histological studies are shown below.205
Figure 7.12 H&E stained histology sections of rat liver 3 days after Amphinex PDT (A)
and PCI treatments in combination with 250 μg/kg saporin given 1 hour before light (B)
or with 30 IU/kg bleomycin given 30 minutes before light (C).
Liver sections from animals receiving Amphinex PDT or PCI treatments in combination
with saporin or bleomycin are shown in Figure 7.12. There was a well-defined zone of
necrosis with inflammatory cells and early signs of healing with many fibroblasts in the
region adjacent to untreated liver in each experimental group. The central area of the
zone of necrosis induced by PCI treatments in combination with saporin and bleomycin
are similar.
Histological results indicated the possible participation of the vasicular system in PDT
or PCI treatments according to the surroundings of blood vessels by well-formed
fibroblasts. Images with higher magnification are shown in Figure 7.13.206
Figure 7.13 H&E stained histology sections of rat liver after PCI treatments at higher
magnification. A: Amphinex PCI of 250 μg/kg saporin; B: Amphinex PCI of 30 IU/kg
bleomycin.
Figure 7.14 H&E stained histology sections of rat colon 3 days after Amphinex PDT
treatments.
The histological changes induced by Amphinex PDT in normal rat colon are shown in
Figure 7.14. A comparison of the colon wall in the light treated and untreated area with
higher magnification are shown in Figure 7.15. The absence of the mucosal structure in
the treated area indicated severe damage caused by the treatment. The submucosal layer
was also affected and replaced by necrotic cells.207
Figure 7.15 H&E stained histology sections of rat colon at higher magnification. A:
treated area; B: untreated area. Both figures are in the same magnification.208
7.4 Discussion
The present study has demonstrated the comparisons between PDT and PCI treatment
using a new chlorin-based sensitiser, Amphinex, on the rat normal liver and colon.
Meso-tetra(3-hydroxyphenyl)chlorin (m-THPC) is a clinically approved photosensitiser
in the European Union for treating head and neck cancers. Chlorin e6 (Ce6) is in the
stage of completing its first clinical trial in Russia. In comparison with its chlorin-based
analogues, Amphinex exhibits a similar quantum yield for singlet oxygen production
and induces comparable lipid peroxidation in homogenous isotropic conditions
[Mojzisova et al., 2009]. It is assumed that Amphinex is not only capable of inducing
efficient photochemical reactions but also suitable for PCI treatment due to the
amphiphilic property resulting in its membrane affinity.
The in vivo Amphinex PDT effect was investigated using the liver model in this chapter.
Liver is a convenient organ which facilitates the quantitative measurement in three
dimensions [Woodhams et al., 2009]. The size of the necrotic lesions induced after light
treatment increased using higher drug or energy doses. In the previous study, the mean
volume of necrosis induced by AlS2Pc PDT (1mg/kg, 24 hours drug light interval and
25J light) was measured as 41 ± 8 mm
3 three days after light delivery. Similar results
were obtained using Amphinex PDT in the present study. As shown in Figure 8.5, the
mean volume of necrotic lesions was measured as 50mm
3 after Amphinex PDT using
the same drug and light dose in spite of the half laser power (50mW) used for the
current study. Because full thickness necrosis was found in some of the Amphinex PDT
treatments using higher light or drug doses (Figure 7.5), a reduced combination of light
and photosensitiser dose (0.25 mg/kg Amphinex and 10J light) was chosen for further
PCI treatments which is different from the previous study.
PCI of saporin enhanced the PDT damage to liver. The maximum enhancement was
found when saporin was given 1 hour before light delivery. This is consistent with the
results of the previous study using gelonin [Woodhams et al., 2009]. The mean size of
necrosis was increased by a factor of 2.4 in surface area and was 2.8 in volume (data not
shown) in combination with saporin (250 μg/kg) compared to the PDT treatment.
However, the enhancement was moderate in the treatments in colon.209
Liver is known as one of the main organs for the uptake of type I RIP [Battelli et al.,
1990]. It was found in mice that Type I RIPs were cleared rapidly with a blood half-life
4-8min and 0.4-23% of toxin was detected in liver 30min after i.v. injection [Barbieri et
al., 1990]. The kinetics of gelonin in mice liver was reported with the highest
concentration at 10 min, a decrease observed onwards and a retention between 1 and 2
hours after administration [Colaco et al., 2004]. It is not surprising that saporin
markedly enhance the PDT effect in liver but not in colon. As type I RIPs are mainly
concentrated in kidney, liver and spleen [Battelli, 2004], the saporin concentration in
colon might be too low to induce an efficient PCI effect.
In contrast to saporin, PCI of bleomycin induced a significant increase of necrosis in
both liver and colon (Figure 7.7 and 7.9). The maximum effects were found when
bleomycin was given 30min before irradiation, a drug light interval shorter than saporin
(Table 7.1). The enhancements in liver is by a factor of 1.8 in the surface area and is
more than a factor of 2 in diameter in colon using half of the drug dose (15 IU/kg).
Moreover, significant enhancements of the necrotic lesions in colon were observed in
all PCI of bleomycin treatments regardless of the bleomycin administration timing. The
results indicate a greater PCI effect using bleomycin in colon than in liver. The
biodistribution of bleomycin may explain this as
67Gallium-labelled bleomycin was
found accumulated on average 1.2-1.9 times more in mice colon than in liver during the
first 4 hours after i.v. injection [Tabeie et al., 2003].
Drug\ Treatment site liver Colon
Saporin 1h No significant enhancement
Bleomycin 15-30min 15min
Table 7.1 Optimal administration time of saporin and bleomycin for Amphinex PCI
treatments in rat liver and colon. Animals were injected with 0.25 mg/kg Amphinex 24
hrs before irradiation. Toxins were administered before light.
In Figure 7.6, no significant enhancement of necrosis was induced in liver when a range
of doses of bleomycin was given 1 hour before illumination. Whereas, marked
enhancement of necrosis can be seen when bleomycin was injected within 30 min
(Figure 7.7). It is suggested that the administration time of bleomycin may play a more
important role than the given dose in PCI treatment.210
Although the results from the previous study show that AlS2Pc PCI of gelonin is
superior to PDT [Woodhams et al., 2009], the present study using pure AlPcS2a
displayed a different picture. No significant enhancement in the necrosis size was
observed in the liver treated with AlPcS2a PCI using saporin (50 and 250 μg/kg). The
reason for the different results compared with the previous study is not fully understood.
However, the direct comparison is not appropriate as AlS2Pc is a mixture not a pure
compound. Although the AlPcS2a dose used in this study was 10 times lower than the
AlS2Pc in the previous study, full thickness necrosis was measured in the PCI treatment
using 25 J. This much more efficient therapeutic efficacy of the pure AlPcS2a PDT may
therefore hinder the PCI effect in combination with saporin although the enhancement
of PCI effect can not be seen using lower PDT dose. Multiple mechanisms may be
involved in the AlPcS2a PDT and PCI treatments and require further investigation.
The toxicity of anti-cancer drugs is another thing that needs to be noted. Animals with
PCI treatments were measured to have an average of 15g weight loss which was to be
assumed a result from treatment. However, the same physiological changes were also
observed in the control animals receiving only toxins (250 μg/kg saporin or 30 IU/kg
bleomycin), suggesting the possibility of drug toxicity. The LD50 of saporin in mice is
4-8 mg/kg and is 358 IU/kg in the case of bleomycin (bleomycin sulphate) in rats by i.p.
injection (from the safety data sheet of the manufacturers). The current study is a
pioneering investigation using Amphinex PCI in combination with these two anti-
cancer agents. The drug doses were chosen less than one tenth of the sub-lethal doses in
order to obtain a rough idea of their therapeutic efficacy of this PCI strategy in vivo.
Although animals behaved normally in terms of the activity, appearance and food and
water uptake, the toxicity of drugs themselves should be taken into account regardless
of the applied dose as unexpected side-effects may affect the treatment results as well as
the animal welfare.
PDT is a treatment with the combination of photosensitisers and light. PCI is a modality
based on PDT but with the additional application of other drugs. The study in this
chapter focused on the influence of several parameters of PCI treatment and aimed to
optimise the treatment conditions. PDT using Amphinex was shown to be favourable
for PDT and PCI. The consistent results from both in vitro and in vivo experiments
indicate the benefits of the Amphinex PCI approach which enhanced its PDT treatment
and displayed synergistic effects in combination with cytotoxic drugs.211
Further studies to investigate the PDT/PCI effects on a syngeneic rat fibrosarcoma
tumour model will be shown in the next chapter. Mechanistic studies of in vivo
Amphinex PDT and PCI in terms of the redistribution of Amphinex and saporin after
illumination and the possible involvement of apoptosis after treatments will be
addressed in Chapter 9.212
Chapter 8:Amphinex PDT and PCI in a Transplanted
Syngeneic Rat Fibrosarcoma Tumour Model213
8.1 Introduction
The previous chapter has established that Amphinex PCI can enhance the biological
effect of saporin and bleomycin using normal rat liver and colon models. However, as
tumours often present altered biological and biochemical properties compared to normal
tissues, the therapeutic effect of Amphinex PCI on tumours remains to be investigated.
The detailed PCI applications in vivo for cancer treatment have been discussed in
Chapter 2. In this chapter, the effects of Amphinex PDT and PCI would be examined
using a syngeneic rat fibrosarcoma tumour model.
This tumour model is a fibrosarcoma cell line, MC28, which is syngeneic for the
Hooded Lister rat. As a result, the advantages such as the same genetic background hold
by the inbred animal and derived cell line and the occurrence of metastasis would make
this model closer to the natural circumstances of human neoplastic diseases [Khanna
and Hunter, 2005;Talmadge et al., 2007]. This tumour model has already been
established in our lab to investigate the PDT effects of m-THPC and WST09 [Tsutsui et
al., 2002;Woodhams et al., 2006].
In the present study, experimental protocols in terms of the drug dose, light dose and
drug light interval were planned based on the experiences in the treatments on normal
tissues from the previous chapter. All the drugs including Amphinex, saporin and
bleomycin were systemically administered by intravenous (i.v.) injection. This is
different from other in vivo PCI studies in which either direct injection of drugs to
tumour (i.t.) or i.p. application was used mostly. Although, theoretically, i.t. injection of
anti-cancer agents should lead to higher local drug concentration in the target tumour
and lower systemic toxicity, the undesirable increased drug concentration in the
surrounding normal tissues observed in some experimental and clinical studies should
be taken into account [Brincker, 1993]. Moreover, the invasive nature of i.t. injection
and the question of whether drug could distribute homogeneously within the target
tumour after direct injection also needs to be addressed. In this regard, intravenous
injection is still a preferable administration method, especially for new drug
investigation. Intravenously injecting drugs to rats was performed in the previous
chapters and would also be used in this section.214
In the previous chapter, Amphinex PCI was shown to be able to enhance the therapeutic
efficacy of saporin and bleomycin treating normal rat liver and colon while the
treatment effects were observed under the influences of the administration timing of
these two anti-cancer drugs. The maximum necrotic lesions in liver were achieved when
saporin and bleomycin were given 1hr and 30min before light delivery respectively
(Table 7.1). Therefore, the same administration timings of these two drugs were adopted
for the experiments in this chapter.
The kinetics of Amphinex in normal Wistar rats has been studied in Chapter 6. The
Amphinex level in liver displayed a rapid decrease after the peak uptake at 6 hrs after
injection and a retention phase between 24hrs and 48 hrs with a much lower drug level
(Figure 6.1). On the other hand, the drug level in colon mucosa reached the highest
amount at 24hrs post i.v. (Figure 6.2). Although the kinetics results provide the
information of the biodistribution of Amphinex in rats, the data for its tumour uptake is
unavailable. Therefore, prior to PDT and PCI treatments, experiments to quantify the
Amphinex level in tumour at the time of light delivery (24 hrs post injection) were
carried out using chemical extraction and quantitative fluorescence microscopy. The
photosensitiser levels in other normal tissues including liver, colon, skin and muscle at
the same time point were also estimated and compared with the uptake in tumours.
These experiments were to assess the biodistribution of Amphinex in tumour-bearing
rats and the drug level in tumour in comparison with other organs at the time of
illumination. The information of the cellular localisation of Amphinex in tumours could
also be obtained from the fluorescence imaging results.
As mentioned before, PCI using AlPcS2a has demonstrated its potential for treating
cancers significant tumour growth inhibition was reported in several pre-clinical studies.
It was also hoped that PCI might have further clinical utilisation as an adjunct to surgery
and radiotherapy [Norum et al., 2009c]. This chapter continued the previous research to
investigate Amphinex PDT and PCI in combination with two potent anti-cancer drugs,
saporin and bleomycin, on tumour eradication. This is also the first attempt to compare
PDT and PCI by quantifying the extent of necrosis induced in tumours. Biodistribution
of Amphinex at the time of light delivery were analysed by chemical extraction and
quantitative fluorescence microscopy. The cellular localisation in tumours and other
tissues was identified using fluorescence microscopy.215
8.2 Materials and Methods
Chemicals
Amphinex in Cremophor (10 mg/ml) was kindly donated by PCI Biotech (Norway).
Amphinex was diluted in phosphate-buffered saline (PBS) to a concentration of 0.25
mg/ml for intravenous (i.v.) injection. Saporin was purchased from Sigma-Aldrich
(USA). Stock solution of saporin (1mg/ml) was prepared by dissolving the drug powder
in sterile water. Aliquotes of saporin stock solution were kept at -20ºC until use. The
saporin solution for injection (0.5 mg/ml) was prepared by diluting the stock solution
with PBS. Bleomycin (Kyowa Hakko, Mayne) was provided as powder (15 IU per vial
according to the U.S. standard equivalent to 15,000 IU according to the European
Pharmacopeia. 5.1), and was then dissolved in 0.9% NaCl which is ready for injection.
Solvable
TM, a solubilizer containing dodecyldimethylamine oxide, secondary alcohol
ethoxylate and sodium hydroxide, was purchased from Perkin-Elmer (UK).
Animals and tumour models
Experiments were performed using a well-established subcutaneous transplanted
syngeneic rat fibrosarcoma tumour model [Amirkhosravi and Francis, 1993;Tsutsui et
al., 2002;Woodhams et al., 2006]. Female Hooded Lister rats (180-220g) were used
through out. All animal experiments were conducted under the authority of project and
personal licences granted by the Home Office and the UKCCCR Guidelines. Inhaled
Halothane or Isoflurane was used to maintain a state of general anaesthesia for drug
administration. For PDT and PCI experiments, animals were given analgesia
subcutaneously 30 minutes before surgery.
MC28 cells, a methylcholanthrene-induced fibrosacoma cell line [Murphy et al., 1986],
were cultured cultured in Dulbecco’s Modified Eagle’s medium containing 10% FCS
(Invitrogen, UK), 2mM Glutamine (GIBCO BRL, UK) and 500μg/ml Gentamicin
(GIBCO BRL, UK). All cells were incubated at 37 °C in a humidified atmosphere
containing 5% CO2. When exponential cell growth was reached, cells were washed
twice with Ca
++ and Mg
++ free PBS and detached from the culture flask by incubating
with 1x trypsin solution (Sigma, UK) at 37ºC for 30 second. Trypsinization process was
neutralised by adding serum containing medium and cell solution was then centrifuged
at 1500 rpm for 3min.Cells were re-suspended and re-centrifuged using Ca
++ and Mg
++216
free PBS. For the subcutaneous tumours, 2.5x10
6 cells in 0.1ml PBS were inoculated
subcutaneously into the lower flanks of each rat. Approximately after 10-12 days,
tumours would reach about 10mm in diameter, which is a suitable size for PDT and PCI
treatment. No evidence of spontaneous necrosis in tumours was observed from our
previous experience when the tumour size is smaller than this.
In vivo localisation and quantification of Amphinex in rat tumours
Amphinex (2.5 mg/kg) was injected to rats (animal number = 3) intravenously via tail
vein. After 24 hrs, animals were killed and tissues from tumour, liver, colon, muscle
(thigh and under tumour) and skin (abdominal) were removed. Fresh surgical specimens
were cut into suitable sizes. Half of the samples were directly frozen into liquid nitrogen
and stored at -80 ºC for chemical extraction study. Half of the samples prepared for
fluorescence microscopy were snapped into cooled isopentane for 10 sec, wiped out
extra liquid with paper tissue, and placed into vials in a liquid nitrogen container.
Frozen tissues were stored at -80 ºC until sectioning.
The protocol for fluorescence microscopy was almost the same as what has been stated
in Chapter 6. The laser activation and detection system was changed to a 405 nm laser
(3 mW) and the fluorescence was detected at 660 nm using a 35 nm bandpass filter.
Sections were also stained with H&E. The procedure for chemical extraction was also
described previously. The mean fluorescence intensity from tissue solution in Solvable
was measured at 655nm and the corresponding concentrations of Amphinex in each
sample could thereby be calculated. Emission spectra of Amphinex in different tissue
Solvable solutions measured with the excitation wavelength at 420 nm and with a cut-
off filter at 515nm using a LS50B Perkin-Elmer Spectrofluorimeter (Perkin-Elmer, UK).
Light source
The light source used for Amphinex PDT and PCI treatments was a diode laser emitting
at 652 nm (Diomed Ltd, UK). An attenuator (FVA-UV fibreoptic variable attenuator,
World Precision Instruments Ltd, UK) was used to reduce the laser power to 50mW.
Lasers were calibrated and the power at the tip of the fibre was measured using a
wavelength-independent pyroelectric power meter (TPM-300, Gentec Inc, Canada)
before each treatment.217
PDT and PCI treatments on tumours
For PDT experiments, 0.25 mg/kg Amphinex was administered via tail vein 24 hrs
before light delivery. The area of subcutaneous tumour was shaved and exposed by a
small incision in the overlying skin. The capsule of the tumour was pierced with a 21G
needle and a cleaved tip 400 μm laser fibre was placed by inserting perpendicularly just
into the top of the tumour. The laser power was 50 mW for providing the light doses of
10J. Photographs of the light treatment on tumours are shown in Figure 8.1.
Figure 8.1 Photographs of the procedures of PDT and PCI treatments on the rat tumour.
A: The subcutaneous transplanted tumour model growing on the lower flank 10-12 days
after tumour cell injection. B: Skin incision and tumour exposure. C: Light delivery. D:
Tumour at 24hr after light treatment.
For PCI treatment, animals were also sensitised with 0.25 mg/kg Amphinex via tail vein
for 24 hrs before illumination. Saporin (250 μg/kg) and bleomycin (30 IU/kg) was
injected to animals 1hr and 30min before light respectively.218
Animals from each treatment group were killed by cervical dislocation at 24 hrs (six
rats of each group) after surgery. The tumours were removed and fixed immediately in
4% formalin for 24 hrs. The tumours were sliced at 2mm intervals in the plane
containing the line of fibre. Samples were wax-embedded and sectioned at 4 μm
thickness onto poly-lysine coated slides after being placed in a tissue processing
machine for further fixation. Sample slides were stained with H&E for histological
examination.
The detail of PDT and PCI treatment schedule is shown below in Figure 8.2.
Figure 8.2 The scheme of PDT and PCI treatments on rat tumours.
H&E stained sections were examined using the Hamamatsu Nanozoomer Digital
Pathology (NDP) scanner (Hamamatsu Photonics Ltd, UK) where digital images of the
whole section were recorded. The PDT or PCI treatment response was examined by
pathologically measuring the mean maximum area of necrosis (the plane extended from
the line of fibre and perpendicular to the tumour surface) using the NDP server software.
Statistical analysis
All data were presented as mean ± SD. Significant differences between PDT and PCI
treatments were assessed by one tailed Student’s t-test analysis. P ≤ 0.05 was considered
statistically significant.
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8.3 Results
8.3.1 Quantification and in vivo localisation of Amphinex in tumour-bearing rats
The biodistribution of Amphinex in tumour-bearing rats at 24hrs after i.v. injection was
analysed by chemical extraction (Figure 8.3) and quantitative fluorescence microscopy
(Figure 8.5). As shown in Figure 8.3, Amphinex displayed the highest concentration in
liver and then tumour, colon, and skin at the time of light delivery. The concentration in
muscle was the lowest and either from the thigh or the muscle under tumour was similar.
The drug concentrations in the liver and colon of Hooded Lister rats 24hr after injection
are consistent with the result of Wistar rats which is shown in Chapter 6 (Figure 6.5).
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Figure 8.3 The concentration of Amphinex extracted from liver, colon, tumour, skin
and muscle (thigh and under tumour) in Hooded Lister rats bearing tumours 24hrs after
i.v. injection of 2.5 mg/kg Amphinex. Bars (SD) are based on three individual animals.
The fluorescence emission spectra of Amphinex in Solvable solution containing
different tissues were shown in Figure 8.4. No shift was observed in different tissue
solutions and all spectra display typical emission spectrum of Amphinex with the peak
emission at 655 nm.220
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Figure 8.4 Representative fluorescence emission spectra (excitation wavelength 420nm)
of Amphinex in different tissue solvable solutions. A cut-off filter at 515nm was used to
remove the scatter light of shorter wavelength.
Half of the samples, originated from the same animals were used for fluorescence
microscopic analysis. Similar results were obtained compared to chemical extraction
where liver exhibited the highest Amphinex level among all tissues and tumour
displayed higher drug uptake than colon mucosa (Figure 8.5). The fluorescence signal
in the colon mucosa was measured significantly higher than the underlying muscle
(p<0.01) by more than a factor of 2. The drug level in the muscle under tumour was
estimated similar to the muscle in the colon wall but was slightly higher than in the
muscle from thigh.221
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Figure 8.5 Fluorescence photometry of Amphinex in liver, colon, tumour, skin and
muscle (thigh and under tumour) of Hooded Lister rats bearing tumours 24hrs after i.v.
injection of 2.5 mg/kg Amphinex. Bars (SD) are based on three individual animals.
The comparison of the biodistribution of Amphinex examined between two different
methods is showed in Figure 8.6. The value presents the normalised drug level to
tumour. The drug uptake in colon by fluorescence microscopy is the average of the
fluorescence intensity from colon mucosa and muscle. In general, the tissue-to-tumour
ratios were measured in a good correlation between these two methods. The drug level
measured in tumour was approximately 3-4 times lower than in liver and 2 times higher
than in colon by two methods.222
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Figure 8.6 Comparison of the relative Amphinex concentration in different tissues
determined by chemical extraction and fluorescence microscopy. Hooded Lister rats
were sensitised with 2.5 mg/kg Amphinex for 24 hrs after i.v. injection. Bars (SD) are
based on three individual animals.
The spatial distribution of Amphinex in tumour was analyzed by imaging the
fluorescence signals of the frozen sections. A representative set of fluorescence images
of tumour sections can be seen in Figure 8.7. Amphinex was homogeneously distributed
in tumour 24 hrs after i.v. injection.
The fluorescence images of Amphinex in tumour with higher magnification are shown
in Figure 8.8. Amphinex was accumulated inside tumour cells but not localised in the
nuclei which are the shadow areas in the images (white arrows).
The endothelial localisation of Amphinex can be seen in Figure 8.9. The blood vessel in
tumour is shown in the rectangles and the one in muscle is pointed out by the white
arrows. The rectangle area is magnified in Figure 8.9a and b. These imaging results
indicate that Amphinex accumulated in the endothelium at 24 hrs after i.v.
administration. As shown in Figure 8.9C and D, Amphinex was found accumulated in
the extracellular matrix of muscle tissues rather than the muscular cells.223
Figure 8.7 Fluorescence (right) and corresponding H&E stained (left) micrographs of
frozen sections of fibrosarcoma tumour in Hooded Lister sampled 24h after i.v.
injection of 2.5mg/kg Amphinex. The inset colour scale bar refers to the relative
fluorescence intensity applied to all fluorescence images.
Figure 8.8 Fluorescence micrographs of the intracellular distribution of Amphinex in
tumour with higher magnifications. Images were taken from frozen sections of the
tumour tissue sampled 24h after i.v. injection of 2.5mg/kg Amphinex. The arrows
indicate the cell nuclei.224
Figure 8.9 Distribution of Amphinex in tumour, muscle and vascular endothelium.
Amphinex fluorescence micrographs (A, C and a) were from frozen sections of
fibrosarcoma tumour sampled 24h after i.v. injection of 2.5mg/kg Amphinex. The
corresponding H&E staining of the same sections are shown in B, D and b. The blood
vessel in tumour is pointed out in the inset rectangle in (A) whose higher magnification
image is in (a). The white arrow indicates the blood vessel in muscle.225
Figure 8.10 illustrates the Amphinex localisation in rat liver 24hr after injection.
Amphinex is evenly localised in liver cells with much higher fluorescence intensity
compared to other tissues. The drug uptake in the endothelial cells (pointed by white
arrows) of the blood vessel is lower than in the liver cells.
Figure 8.10 Fluorescence (right) and corresponding H&E stained (left) micrographs of
frozen sections of liver in Hooded Lister sampled 24h after i.v. injection of 2.5mg/kg
Amphinex. The inset colour scale bar refers to the relative fluorescence intensity
applied to both fluorescence images. Arrows point out the identical blood vessels in the
paired images.226
According to the imaging results in Chapter 6, Amphinex is spread throughout colon
mucosa 24hr after drug administration in Wistar rats (Figure 6.4). The distribution of
Amphinex in colon in this tumour-bearing rat also shows the same pattern at this time
point (Figure 8.11). A great drug uptake can be seen in the blood vessel in the
submucosa (arrows). The distinct difference in the drug level between the colon muscle
and mucosa was found.
Figure 8.11 Fluorescence (right) and corresponding H&E stained (left) micrographs of
frozen sections of colon in Hooded Lister sampled 24h after i.v. injection of 2.5mg/kg
Amphinex. The inset colour scale bar refers to the relative fluorescence intensity
applied to both fluorescence images. The arrows indicate a large blood vessel.227
8.3.2 Amphinex PDT and PCI effects on a transplanted rat fibrosarcoma tumour
model
Animals were sensitised with 0.25 mg/kg Amphinex for 24hrs before light delivery. For
PCI treatment, the dose and administration timing of saporin and bleomycin was chosen
based on the results of the treatments on liver, i.e 250 μg/kg saporin and 30 IU/kg
bleomycin given 1hr and 30min prior to illumination respectively. The responses of
treatments were evaluated by measuring the necrotic lesions at 24hrs after light
treatment.
Tumour damage was found after Amphinex PDT and PCI treatments. As shown in
Figure 8.12, the mean maximum necrotic area extended from the line of fibre induced
after PDT treatments is about 7.6 mm
2. PCI in combination with either saporin or
bleomycin significantly increased the necrotic area by a factor of 2 compared to PDT
alone.
0
6
12
18
PDT PCI-SAP PCI-BLM
Treatments
N
e
c
r
o
s
i
s
a
r
e
a
(
m
m
2
)
*
1 *
2
Figure 8.12 Mean maximum area of necrosis induced 24hrs after PDT/PCI treatments.
There were six animals for each group. Saporin (250 μg/kg) and bleomycin (30 IU/kg)
were given 1hr and 30min prior to illumination respectively. (*1: p<0.001; *2: p=0.002)
All animals were in healthy conditions after light treatments without any weight loss.228
8.3.3 Macroscopic examination and histology
Figure 8.13A demonstrates the tumour growing on the lower flank of rats. Unlike the
PDT damage on liver and colon, it is not easy to differentiate between the necrotic
tumour and viable tumour. Tumour tissues, together with the attached muscles, were
removed (Figure 8.13B) and fixed in 4% formalin for 24hrs (Figure 8.13C). The
fixation time was kept constant to 24hr to minimise the variation of shrinkage between
samples. The section cut through the plane extended from the line of fibre is displayed
in Figure 8.13D). It is still difficult to recognise the difference between damaged lesions
and viable tumours in this stage.
Figure 8.13 Photographs of representative MC28 subcutaneous tumours treated with
0.25μg/kg Amphinex PDT with a drug light interval of 24hrs. A: A tumour on the lower
flank 24hr after PDT treatment. B: A freshly removed tumour. C: A tumour after the
24hr-fixation in 4% formalin. D: A 2mm thick section cut through the plane extend
from the line of fibre and perpendicular to the tumour surface.229
Histological examination was carried out on the H&E stained paraffin tumour sections.
The non-treated MC28 fibrosarcoma was presented a monotonous hypercellular look
after H&E stain (Figure 8.14A). Cells are closely packed with a high degree of nuclear
pleomorphism and variation in cell shape and size. These are typical characteristics of
poorly differentiated tumours. There is usually a fibrous capsule layer surrounding the
tumour (Figure 8.14B, arrow). However, sometimes tumours could be highly malignant
when tumour cells have infiltrated muscle tissues without the tumour capsule
surrounded in the transitional zone on the border between tumour and muscle tissue
(Figure 8.14C).
Figure 8.14 The MC28 fibrosarcoma tumour model. A: Tumour cells. B: The
transitional zone between tumour (T) and muscle (M) without tumour infiltration. The
fibrous tumour capsule was surrounding the tumour (arrow pointed). C: The transitional
zone between tumour (T) and muscle (M) with tumour infiltration.230
24hrs after PDT treatment, necrosis was observed from the top to the centre of tumour
and viable tumour cells were found in the tumour periphery (Figure 8.15A). As shown
in Figure 8.15B, the zone of necrosis is irregular. The areas in the green and yellow
rectangles are highlighted in C and D. Figure 8.15C displays the region of the green
rectangle at higher magnification. This is the transition zone between necrotic and
viable tumour area. Half of the cells were damaged and fragmented nucleus was formed
in some cells. Some dilated blood vessels could be found in this region. Figure 8.15D is
a highlight of the yellow rectangle. Few viable tumour cells can be seen in the central
necrotic area where necrotic cells with absence of nuclei were dominating. Moreover,
the appearance of red blood cells scattered in this area indicated the blood vessels have
become leaky due to the damage from treatments.
Figure 8.15 H&E stained histology section of transplanted rat sarcoma tumour one day
after Amphinex PDT treatment. A: The whole tumour section. N: necrosis; V: viable
tumour cells. B: The transition zone between necrosis and viable tumour area. The areas
in the green and yellow rectangles are magnified in C and D. C: The region adjacent to
necrotic area. D: The region in the necrosis centre.231
Examples of the histological sections of tumours after PCI treatments combining
saporin or bleomycin are shown in Figure 8.16 and 8.17. The areas of necrosis were
found to be notably larger than the ones induced by PDT. The depths of necrosis
between PDT and PCI treatments are similar since all treatments induced considerable
depth of necrosis (close to the muscle layer). However, much wider necrotic lesions
were observed in the tumour after either PCI treatment.
Severe extravasation with blood cells leaking out from blood vessels into the
surrounding tissue was observed after both PCI treatments (Figure 8.16B and 17B).
Like PDT treatment, transition zones with tumour cells containing fragmented nuclei
could be found in between necrotic region and viable tumour area after PCI treatments
(Figure 8.16C and 17C). Dilated blood vessels were also abounded in these areas.
Compared to PDT, PCI treatments were shown to induce greater transition areas,
resulting smaller area of viable tumour cells in the periphery.
Moreover, perivascular survival of tumour cells was more obvious in the tumours after
PCI treatments, particularly in the transition region (Figure 8.16C and 17C).
Nevertheless, as mentioned before, most of the viable cell here were apoptotic with
fragmented nuclei.
Figure 8.16 H&E stained histology section of transplanted rat sarcoma tumour one day
after Amphinex PCI of saporin. A: The whole tumour section. N: necrosis; V: viable
tumour cells. B: The region in the necrosis centre. C: The transition zone between
necrosis and viable tumour area.232
Figure 8.17 H&E stained histology section of transplanted rat sarcoma tumour one day
after Amphinex PCI of bleomycin. A: The whole tumour section. N: necrosis; V: viable
tumour cells. B: The region in the necrosis centre. C: The transition zone between
necrosis and viable tumour area.233
8.4 Discussion
This is the first study to investigate the Amphinex PDT and PCI effect using a
syngeneic rat fibrosarcoma tumour model. Quantification of the Amphinex uptake in
different tissues including tumour was carried out in tumour-bearing rats at the time of
light delivery. Samples from the same animal (three animals in total) were divided into
two groups for chemical extraction and quantitative fluorescence microscopy separately.
According to the results of chemical extraction, the drug level in the liver and colon of
Hooded Lister rats at 24hr after drug application was measured consistent with the data
obtained from Wistar rats shown in Chapter 6 (Figure 8.3 and 6.5). This indicates that
the uptake of Amphinex between this two species is similar.
The biodistribution of Amphinex in different tissues by chemical extraction was found
in agreement with the results estimated by fluorescence microscopy (Figure 8.5)
although the tissue-to-tumour ratios were slightly higher using fluorescence microscopy,
particularly in liver.
According to the results of chemical extraction (Figure 8.3), Amphinex displayed a
comparable tumour uptake compared to other water soluble porphyrin sensitisers e.g.
TPPS4 and m-THPP. The tumour accumulation of these two sensitisers has been
investigated in a nude mice tumour model [Peng, 1987;Peng et al., 1995]. Much higher
tumour-to-skin and tumour-to-muscle ratios of Amphinex uptake were obtained than the
values for TPPS4 and m-THPP. The results show that Amphinex has an efficient tumour
uptake and the concentration in other normal tissue such as skin and muscle is much
lower than other water soluble sensitisers, TPPS4 and m-THPP.
The information of the drug distribution at the cellular level was also obtained from the
fluorescence images. In Figure 8.7, Amphinex was observed homogenously distributed
in the tumour cells apart from the absence of nuclear localisation. The same
phenomenon has been reported in AlPcS2a using HT1080 xenograft tumour models 48hr
after i.p. injection [Dietze et al., 2005;Norum et al., 2009a]. Norum et al. additionally
pointed out that the fluorescence intensity of AlPcS2a was measured higher in the centre
of tumour and declined towards the tumour border but with intense fluorescence signals
in the transitional zone between tumour and muscle [Norum et al., 2009a]. These234
findings were not shown in our results; constant uptake of Amphinex was detected
throughout the whole tumour. This discrepancy may be due to the differences in the
biological nature between different tumours. The HT1080 tumour model is rather
aggressive with the absence of tumour capsule compared to our MC28 tumour models
as tumour capsule often remains and no spontaneous necrosis is observed with the size
less than 1cm in diameter. It was also suggested by the authors that neovascularisation
is particularly active in periphery of HT1080 tumour model which may explain the
higher uptake of AlPcS2a in some areas in this region.
Amphinex was also observed localised in blood vessel walls in different tissues. The
fluorescence intensity in endothelial cells was measured lower than in liver cells (Figure
8.10), similar to or slightly lower than the signals from tumour cells (Figure 8.9A and C)
and higher than the signals from colon mucosa and colon muscle layer (Figure 8.11).
The drug localisation in the endothelium of blood vessels gives the implication of the
possible photochemical damages to the vascular system after light treatment.
Amphinex PCI showed a significant enhancement in inducing necrosis in tumour. The
mean maximum extent of necrotic lesions after PCI in combination with either saporin
or bleomycin appeared to be significantly increased by a factor of 2 compared to PDT
treatment (Figure 8.11). Measurements were based on the histological examination. It
should be noted that some tumours were excluded when haemorrhage or cavities were
observed (data not shown). As tumour cells grow aggressively, the above features can
occur naturally, especially when the tumour size is too big. In this case, spontaneous
necrosis may also occur in the centre of large tumours due to hypoxia. Other situations
such as multiple tumours grown together are not suitable for measurements either.
Hence, it is important to carry out experiments on the tumours with appropriate size to
avoid misinterpreting the treatment responses.
Figure 8.18A and B show a tumour slice before and after fixation. The tumour flesh was
often found amorphous before fixation (Figure 8.18A). Together with Figure 8.13, it is
difficult to differentiate the damaged area by the appearance without further
processesing. A direct macroscopic examination was not feasible in practice.235
Figure 8.18 An example of tumour sections preparation. A and B: tumour slice before
and after fixation. C: the corresponding H&E stained section. This is a tumour treated
with PCI of bleomycin.
In the previous studies in our lab, the necrotic lesions induced after treatment were
identified macroscopically after a staining procedure with Evans Blue dye [Tsutsui et al.,
2002;Woodhams et al., 2006]. Evans Blue is a di-azo compound which binds firmly
with the plasma albumin after injection intravenously. The viable tissues are stained
with the dye but the necrotic areas remain unstained due to the lack of blood circulation.
However, the margin might be ambiguous as the staining mainly relies on the blood
supply which is not an absolute difference between necrotic and viable tissues.
Moreover, Evans Blue dye may interfere the results of the following H&E stain and
hinder other possible histological stains. Taking this into account, it was decided to
carry out the measurement by histological examination based on the H&E stained
tumour sections.
An early attempt to measure the depth of necrosis induced after PDT and PCI treatment
was reported by Dietze and his colleagues in which the PDT effect resulted in 3-4mm
deep necrotic lesions compared with the depth of 6-7 mm in the PCI group [Dietze et al.,
2005]. However, as shown in the histological examination results in our tumour model
(Figure 8.15-17), the necrosis areas often had irregular and asymmetric shapes which
make it difficult to define the depth or width of the necrotic lesion. Therefore, instead of
measuring the extent of necrotic lesion in one dimension, the measurement of the
necrotic area, in the plane extended from the line of fibre and perpendicular to the
tumour surface, was performed to evaluate and compare the treatment response between
PDT and PCI quantitatively in this study.236
The histological results show that necrotic lesions were induced after PDT and PCI
treatments and the regions were observed from the tumour surface to deeper locations.
The central areas of necrosis were observed to be similar with either treatment, i.e. most
cells were necrotic and some cells were apoptotic.
Extravasation of blood can be seen in the centre of the necrosis zone and is particularly
exaggerated in the tumour after PCI treatments (Figure 8.15D, 16B and 17B). The
photodynamic effect on the vasculature in the PDT treatment of solid tumours has been
recognized since early 1980s [Star et al., 1984]. The vascular damage acts as an
additional therapeutic effect to the direct cytotoxicity of PDT. It causes blood flow
stasis and the consequent reduced perfusion, resulting in the ischaemic death of tumour
cells [Fingar, 1996]. The accumulation of Amphinex in the blood vessel wall was
observed by fluorescence microscopy. The presence of the large number of blood cells
in the centre of necrosis area (Figure 8.15D, 16B and 17B) again emphasises the
vascular damage after Amphinex PDT and PCI treatments.
Dilated blood vessels were found in the transition area (Figure 8.15C, 16C and 17C).
This appearance was caused by the inflammation reactions induced after PDT and PCI
treatments. The occurrence of perivascular survival of tumour cells in this area is more
noticeable in the tumours receiving PCI treatments. These results are consistent with the
results of PDT and PCI treatment in normal rat liver in the previous chapter, as well as
the results using AlS2Pc PCI of gelonin in normal rat liver in the previous study
[Woodhams et al., 2009]. Viable liver cells were observed surrounding blood vessels in
the area near the border of necrotic regions (Figure 7.13).
The central necrosis is induced by PDT treatment and the outer area, the transition zone
is thought to be due to PCI effects. Although oxygen should be favourable for PDT,
photochemical reactions may be inefficient in this area as the light fluence rate is
already low here. Tumour cells localised in perivascular areas (oxygenated region) often
have higher survival rates after treatments compared to the cells in the remote area. Due
to the benefits of a higher oxygen and nutrient supply from the microcirculation,
perivascular tumour cells have potential protection against the harmful damage from
treatment.237
Although the lack of control studies on animals that are only given anti-cancer agents
can not estimate the influence of the cytotoxicity from saporin and bleomycin alone in
our study, evidence has been showed in other studies that toxins alone had no
contribution to tumour growth retardation [Berg et al., 2005a;Dietze et al., 2005;Norum
et al., 2009a;Selbo et al., 2001b]. The enlarged necrosis lesion induced by PCI of
saporin and bleomycin compared with PDT in this study has demonstrated the benefit of
this combined modality. Further studies to assess the mechanism of the therapeutic
effect of PDT and PCI will be presented in Chapter 9.
The model used in this study is a syngeneic rat fibrosarcoma which is different from the
xenograft models in immunodeficiency mice used in other in vivo PCI studies. As
mentioned before, a syngeneic tumour model could naturally metastasize with less
immune response expected and this is therefore of benefit for new drug investigation in
cancer [Khanna and Hunter, 2005;Talmadge et al., 2007].
Amphinex PCI in combination with saporin and bleomycin has demonstrated a
significant enhancement in inducing tumour destruction. PCI has recently started its
first clinical trial using Amphinex PCI of bleomycin in head and neck cancers in the
University College London Hospital. The results in this chapter show that Amphinex
has the potential for further clinical utilization by enhancing the delivery of co-
administered anti-cancer drugs.238
Chapter 9: Mechanistic Studies of In Vivo
Amphinex PDT and PCI239
9.1 Introduction
The concept of PCI is based on photo-induced membrane rupture followed by cytosolic
release of anti-cancer agents entrapped in the vesicles of endocytotic systems. The
results from the previous chapters have shown that Amphinex PCI is a novel technology
to enhance the cytotoxicity of saporin and bleomycin in vitro and in vivo. The
mechanisms of the killing effects from PDT has been studied extensively as described
in Chapter 1, whereas there are rare studies to investigate the mechanisms behind the
enhanced cytotoxicity using PCI in combination with anti-cancer drugs. For this reason,
the aims of this chapter are to examine the cell death induced by PCI and to monitor the
photosensitisation and the consequent redistribution of macromolecules in vivo.
Firstly, as discussed before in Chapter 1, PDT is known to be able to induce apoptosis
or necrosis or a combination of both pathways. It is generally considered that cells
undergo apoptosis when treated with lower doses while cells can die through necrosis
when receiving higher doses [Oleinick and Evans, 1998]. Many studies have
documented the cell death triggered by PDT using different cell lines and
photosensitisers; however, the cell death in response to PCI is not understood.
According to the results shown in Chapter 7 and 8, necrosis was observed in the liver
and tumour treated with Amphinex PDT and PCI of saporin or bleomycin. However,
there is an observation of fragmented nuclei in some cells remaining in the central
necrotic area, as well as the cells in the adjacent regions of tumours treated with
Amphinex PDT and PCI. Because PCI is a drug delivery technology based on the use of
a sub-lethal PDT dose, it is possible that apoptosis is also involved in Amphinex PDT
and PCI.
To investigate the involvement of apoptosis in Amphinex PDT and PCI, a terminal
deoxynucleotidyl transferse (TdT)-mediated dUTP nick-end labelling (TUNEL) assay
was performed. TUNEL assay is used to detect apoptotic cells by measuring the nuclear
DNA fragmentation, one of the biochemical hallmarks of apoptosis. The principle of
this method is to target the break 3’-OH DNA end with fluorescein labelled dUTP in the
presence of the recombinant enzyme TdT. Cells are often further stained with
propidium iodide in their whole DNA and can therefore be visualised by fluorescence
microscopy or quantified by flow cytometry.240
In this section, TUNEL assay was used to stain the paraffin-embedded sections of liver
and tumour treated with Amphinex PDT and PCI of saporin or bleomycin. The results
were analysed using confocal microscopy with parallel H&E stained micrographs.
The following two sections of this chapter describe mechanistic studies of PCI action in
tissue. The first describes the use of the TUNEL assay as detailed above, and the second
section describes using confocal microscopy to image the distribution of Amphinex
using the rat liver model. Confocal microscopy has been shown to be able to provide
microscopic imaging of tissues in vivo or in human at high resolution [Goetz et al.,
2008b;Rajadhyaksha et al., 1995]. For skin samples, melanin can be a natural contrast
agent but for other tissues like liver, an additional administration of fluorescent agents
such as fluorescein sodium or FITC-labelled dextran is necessary. Because the required
benchtop device still limits its in vivo utilisation, a recent development of a miniaturised
confocal scanner integrated into a flexible endoscope, named confocal laser
endomicroscope (CLE), has made it possible to be used for clinic practice in
gastroenterology [Hurlstone et al., 2008]. Combined with minilaparoscopy, CLE also
can be used for imaging some interstitial organs like liver [Goetz et al., 2008a].
Since photosensitisers are fluorescent, in vivo imaging of the uptake of photosensitisers
in tissue has been applied clinically (Table 1.1) for diagnosis purpose which is known as
photodynamic diagnosis (PDD). Apart from this aspect, since confocal microscopy
provides high-resolution subsurface imaging, it may be able to detect the distribution of
photosensitisers on the cellular scale. In this regard, the experiment in this section was
designed to show the feasibility of using such confocal microscopy to image the
distribution and redistribution of Amphinex after illumination using intact freshly
excised liver samples ex vivo.
The last section of this chapter examines the redistribution of saporin after light
exposure using rat liver model. Amphinex PCI-induced redistribution of saporin in cells
was demonstrated in chapter 4 of this thesis. Other examples of in vitro AlPcS2a PCI-
mediated endo-lysosomal release of macromolecules also have been shown elsewhere
[Selbo et al., 2000a;Selbo et al., 2009]. In a previous study from our laboratory, using
immunohistochemistry, in vivo redistribution of gelonin was observed after AlPcS2a PCI
in rat liver model [Woodhams et al., 2009]. In the present study, changes of the241
distribution of saporin in liver after Amphinex PCI was investigated based on the same
method but using a commercial available antibody against saporin.242
9.2 Materials and Methods
Chemicals
Amphinex, in Cremophor (10 mg/ml) was kindly donated by PCI Biotech (Norway).
Saporin was purchased from Sigma-Aldrich (USA). Bleomycin (Kyowa Hakko, Mayne)
was provided as a powder (15 IU per vial according to the U.S. standard equivalent to
15,000 IU according to the European Pharmacopeia. 5.1). Detailed formulation and
drug preparation for in vivo experiments has been mentioned in the previous chapters.
Animals and tumour models
All animal experiments were conducted under the authority of project and personal
licences granted by the Home Office and the UKCCCR Guidelines. Inhaled Halothane
or Isoflurane was used to maintain a state of general anaesthesia for drug administration.
For PDT and PCI experiments, animals were given analgesia subcutaneously 30
minutes before surgery.
Female Hooded Lister rats (180-220g) were subcutaneously transplanted with MC28
cells in the lower flank to establish the transplanted syngeneic rat fibrosarcoma tumour
model. The protocols for cell cultivation and the tumour model have been stated in the
previous chapter. The experiments of Amphinex and saporin redistribution in liver were
carried out using female Wistar rats (180-200g, Harlan, Oxon, UK).
Light source
The light source used for Amphinex PDT and PCI treatments was a diode laser emitting
at 652nm (Diomed Ltd, UK). An attenuator (FVA-UV fibreoptic variable attenuator,
World Precision Instruments Ltd, UK) was used to reduce the laser power to 50mW.
Lasers were calibrated and the power at the tip of the fibre was measured using a
wavelength-independent pyroelectric power meter (TPM-300, Gentec Inc, Canada)
before each treatment.
Detection of apoptosis in liver and tumour after PDT and PCI treatments
TUNEL assay (DeadEnd
TM Fluorometric TUNEL System, Promega, UK) was used for
the detection of fragmented DNA in apoptotic cells. The assay was carried out using
paraffin liver and tumour sections. PDT and PCI treatments on liver and tumour have243
been described in the previous chapters. Liver sections after PDT and PCI of saporin
(250μg/kg, i.v. 1hr before light) or bleomycin (30 IU/kg, i.v. 30 min before light) were
obtained from the samples of the experiments in Chapter 8. Tumour sections were
collected from the tumours sampled 4 hrs after light treatments. Paraffin sections of
liver and tumour were stained with the commercial apoptosis detection kit according to
the manufacturer’s instructions. Propidium iodide (PI) solution (Sigma-Aldrich, UK) in
PBS (1 μg/ml) was used to stain nuclei. Sections were examined using confocal
microscopy (FLUOVIEW FV1000, 60x magnification, NA 1.20, Olympus, Japan). The
apoptotic bodies will be stained with fluorescein (green) and also PI (red), resulting in a
yellow colour when the two images are merged.
Adjacent sections were stained with H&E and scanned using the Hamamatsu
Nanozoomer Digital Pathology (NDP) scanner (Hamamatsu Photonics, UK).
Ex vivo observation of the redistribution of Amphinex after light in fresh rat liver
Animals were sensitised with Amphinex (i.v. 2.5 mg/kg) 24hrs before irradiation. A 652
nm laser was used for irradiation with the power of 50 mW for providing the light dose
of 5J. One control animal, animals without light and with light treatments (N=2 each)
were killed by cervical dislocation. Livers were removed and kept in vials with PBS on
ice and immediately studied using confocal microscopy (FLUOVIEW FV1000, 60x
magnification, NA 1.20, Olympus, Japan). In the light-treated liver, the area of
irradiation was marked in the margin of tissue and thus can the position be identified.
With a few drops of PBS, liver samples (approx. 1 cm
2) were ‘face-down’ placed on the
centre of FluoroDish (WPI, UK), in full contact with the glass coverslip bottom of the
dish and imaged using a 543 nm laser (Figure 9.1). All confocal microscopic studies
were carried out using fresh liver samples taken within 1hr of the animal sacrifice.
Figure 9.1 Micrographs of light treatment on liver (A), FluoroDish (B) and the imaging
setup for confocal microscopy (C).
60x
liver
objective
treatment
zone
FluoroDish
Glass bottom
treatment zone
A B
C244
Immunnohistochemistry of saporin distribution in liver before and after light treatment
5 Wistar rats were sensitised with 0.25 mg/kg Amphinex for a 24hr drug light interval.
One rat was used for control study, 2 rats were injected with 250μg/kg saporin 1hr
before light and 2 rats were given 250μg/kg saporin but with no light treatment. Light
treatments were carried out following the same protocol as mentioned before using a
50mW laser power for providing the light dose of 10J. 30 min after irradiation, all rats
were killed and the livers were dissected. The livers from all rats were fixed in formalin,
dehydrated and mounted in paraffin. The sectioning procedure of paraffin-embedded
samples has been described in previous chapters.
Sections were then de-waxed (immersed in xylene solution three times), rehydrated
(through graded ethanol washes- 100%, 95%, 85%, 70% and 50%) and rinsed in
running water. For antigen retrieval, sections were placed in boiling citrate buffer
(10mM, pH 6) in a pressure-cooker, cooked under full pressure for 2 min and cooled
with running water. Sections were then incubated with 3% H2O2 in Methanol for 15min
before the application of primary antibodies to quench the endogenous peroxidise.
Saporin was detected by incubating with polyclonal goat anti-saporin (1:350 dilution,
Advanced Targeting System, USA), the primary antibody, for 1hr at room temperature.
Sections were then rinsed thoroughly with Tris Buffer Saline Tween-20 (TBST) and
blocked with rabbit serum (Sigma-Aldrich, UK) for 20min to prevent non-specific
binding. After rinsing with TBST three times, sections were incubated with secondary
antibodies which are conjugated with horse radish peroxidise (rabbit anti-goat
antibodies HRP conjugated, 1:1500 dilution, abcam, UK). After 40min incubation,
antibodies were washed off with TBST and subtract solution containing
diaminobenzidine (DAB) was added a few drops to sections. The colour development
procedure (2-5min) was stopped by immersing sections in water. Counterstaining with
haematoxylin was carried out followed by dehydration in graded ethanol solutions and
section mounting.
Sections without primary or secondary antibodies were also prepared for control tests.
All sections were scanned using the Hamamatsu Nanozoomer Digital Pathology (NDP)
scanner (Hamamatsu Photonics Ltd, UK).245
9.3 Results
9.3.1 Detection of apoptosis induced by Amphinex PDT and PCI in rat liver and
tumour
PDT- or PCI-induced apoptosis was examined in rat MC28 sarcoma 4hrs after light
treatment by TUNEL assay using confocal microscopy. Figure 9.2 shows the results of
control untreated tumours in which TUNEL stained nuclei (merged in yellow colour)
were nearly absent.
Figure 9.2 TUNEL staining of MC28 sarcomas without treatment. Tumour sections
were obtained from control animals and stained with TUNEL assay and analysed using
confocal microscopy. The green fluorescence maps the nuclei of apoptotic cells,
opposed to the red fluorescence from propidium iodide which stains normal nuclei,
resulting in yellow colour.
In contrast, TUNEL positive tumour cells were detected in the tumours treated with
Amphinex PDT or PCI. Figure 9.3 shows the tumour after Amphinex PDT treatment.
Figure 9.4 and Figure 9.5 are examples of PCI treatments in combination with saporin
and bleomycin. Figure 9.3A, 4A and 5A are the whole H&E stained tumour section.
Other subfigures are the confocal images and their corresponding H&E stained
micrographs from nearby areas which are presented together.
As shown in Figure 9.3, Amphinex PDT induced apoptosis in MC28 sarcoma.
Apoptotic tumour cells (Figure 9.3b, nucleus stained yellow) were particularly observed
in the transition area between necrosis region (N) and viable tumour cells (V). In the246
case of this tumour, many tumour cells infiltrated into muscle layers which are far away
from the tumour surface where irradiation began, were also detected to be apoptotic (c),
suggesting the tumour cells in this area were under the influence of PDT treatment as
well. Muscle cells (c) and fibrous tumour capsule (d), on the other hand, were not
observed to be apoptotic after PDT treatment. The information of the cells in the
necrotic region is unfortunately not available. Necrotic tissues usually can not attach
slides firmly and therefore these tissues are easily washed off during the staining
procedure.
Figure 9.3 Histopathological analysis and TUNEL staining of MC28 sarcomas treated
with Amphinex PDT. Hooded Lister rats bearing tumour were sensitised with 2.5 mg/kg
Amphinex for 24 hrs. Tumour sections were obtained 4 hrs after light treatment (10J
light dose using a 652nm laser). (A)-(D) are H&E stained and (b)-(d) are TUNEL
stained fluorescence micrographs taken from nearby regions. A: the whole image of
treated tumour with a scale on the bottom; B and b: the areas with viable tumour cells
(V) adjacent to necrotic region (N); C and c: the transition zone between tumour and
muscle (M); D and d: Tumour capsule. bv: blood vessels.
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The TUNEL assay results of the tumour treated with Amphinex PCI of saporin is shown
in Figure 9.4, presented together with the H&E stained sections from nearby regions. As
shown in Figure 9.4C, the number of viable cells in the necrotic area (N) is low and
some of the cells remaining were apoptotic with the whole nuclei stained TUNEL
positive (c2). An increase of apoptotic cells was observed in the area (V) adjacent to the
necrotic region (c1); however, the number of the apoptotic cells (presented in yellow)
was not as many as the case from the same area treated with PDT alone (Figure 9.3b).
Viable tumour cells located near muscle were rarely observed apoptotic (Figure 9.4d).
Muscle cells and fibrous tumour capsule (Figure 9.4e and b) were not observed to be
apoptotic after PCI of saporin treatment, either.
After the PCI of bleomycin, tumour cells in the necrotic area (Figure 9.5B and b)
displayed similar pattern to the ones after treated with PCI of saporin: some cells were
apoptotic with the whole nuclei stained TUNEL positive. Muscle cells (e) and fibrous
tumour capsule (d) here were not apoptotic as well. However, less TUNEL positive
cells were shown in the area adjacent to necrotic region (5c) compared to the ones
treated with PDT or PCI of saporin.248
Figure 9.4 Histopathological analysis and TUNEL staining of MC28 sarcomas treated
with Amphinex PCI of saporin (SAP). Hooded Lister rats bearing tumour were
sensitised with 2.5 mg/kg Amphinex for 24 hrs and saporin (250 μg/kg) was injected to
rats (i.v.) 1h before irradiation. Tumour sections were obtained 4 hrs after light
treatment (10J light dose using a 652nm laser). (A)-(E) are H&E stained and (b)-(e) are
TUNEL stained fluorescence micrographs taken from nearby regions. A and a: the
whole image of treated tumour with a scale on the bottom; B: tumour capsule; C: the
transition zone between necrotic (N) and viable tumour (V) regions; c1: the area with
viable tumour cells adjacent to necrotic region; c2: necrotic area; D and d: the area with
viable tumour cells (M); E and e: the transition zone between tumour and muscle.
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Figure 9.5 Histopathological analysis and TUNEL staining of MC28 sarcomas treated
with Amphinex PCI of bleomycin (BLM). Hooded Lister rats bearing tumour were
sensitised with 2.5 mg/kg Amphinex for 24 hrs and bleomycin (30 IU/kg) was injected
to rats (i.v.) 30 min before irradiation. Tumour sections were obtained 4 hrs after light
treatment (10J light dose using a 652nm laser). (A)-(E) are H&E stained and (b)-(e) are
TUNEL stained fluorescence micrographs taken from nearby regions. A: the whole
image of treated tumour with a scale on the bottom; B and b: necrotic area (N); C and c:
the areas with viable tumour cells adjacent to necrotic region; D and d: Tumour capsule;
E and e: the transition zone between tumour and muscle (M). bv: blood vessel.
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TUNEL assay was also used to detect apoptosis in the rat liver treated with Amphinex
PDT and PCI of saporin or bleomycin. Liver sections were obtained from the same liver
tissues used for the studies in Chapter 7 which were collected 3 days after light
treatment. The sections were from the samples with maximum necrosis whose treatment
conditions are- PCI of saporin: 250 μg/kg saporin given 1 hr before light and PCI of
bleomycin: 30 IU/kg bleomycin given 30 min before light. Each experiment contains 3
individual liver samples. The results were consistent and one of them was chosen to be
presented here.
Figure 9.6 shows the results of untreated liver and the liver treated with PDT or PCI
with the confocal images of TUNEL stained liver sections and the H&E stained
micrographs from nearby regions. Images were chosen from the necrotic zone.
No apoptotic nuclei were detected in the control untreated liver (Figure 9.6A). On the
other hand, apoptotic liver cells were found in the sample treated with PDT or PCI
(nuclei in yellow, Figure 9.6B, D and F). However, there is an interesting finding that
not all cells in the necrotic zone of treated liver presented the same results after TUNEL
assay. It was observed that some cells were TUNEL positive but some were negative.
The differences are consistent with the H&E stained sections that some cells were
necrotic with the absence of nuclei (Figure 9.6c, e and g) and some cells have apoptotic
nuclei (pointed with arrows, Figure 9.6b, d and f). These cells were randomly
distributed and their locations were not related to the distance to the laser fibre.251
Figure 9.6 Histopathological analysis and TUNEL staining of rat liver treated with
Amphinex PDT or PCI of saporin (SAP) or bleomycin (BLM). Wistar rats were
sensitised with 2.5 mg/kg Amphinex for 24 hrs. Liver sections were obtained 3 days
after light treatment (10J light dose using a 652nm laser). For PCI treatment, saporin
(250 μg/kg) and bleomycin (30 IU/kg) was injected to rats (i.v.) 1 hr and 30 min before
irradiation respectively. All micrographs (except control groups) are the areas in the
central necrotic region. (a)-(g) are H&E stained and (A)-(G) are TUNEL stained
fluorescence images taken from nearby region. A: untreated liver. B and C: PDT treated
liver. D and E: PCI of SAP treated liver. F and G: PCI of BLM treated liver.252
9.3.2 Ex vivo observation of the distribution of Amphinex and redistribution after
illumination in rat liver using confocal microscopy
The studies of this section are to observe the distribution of Amphinex and its
redistribution after light using intact liver samples by confocal microscopy ex vivo. The
detailed protocols are described in Materials and Methods. After removal of the liver
samples (approx. 1 cm
2) from untreated or light-treated animals sensitised with 2.5
mg/kg Amphinex for 24 hrs, samples were kept on ice and imaged using confocal
microscopy immediately (within 1hr). The sample from the control animal was also
prepared with the same procedure.
Before carrying out these exeriments the distribution of Amphinex in liver was
investigated using frozen liver sections. Sections were obtained from liver samples with
or without light treatment and were attached to large coverslips instead of conventional
slides whose thickness is not ideal for imaging using the available inverted confocal
microscope. Therefore CCD camera imaging was used but it was found that the lower
resolution from the relatively thick frozen sections prevented reliable detection of
intracellular distribution. Moreover fine details are not well preserved using frozen
section preparation. Consequently, the next series of experiments as described here were
carried out using fresh unfrozen liver samples under confocal imaging.
The results demonstrated that most images were of excellent quality in which nuclei and
individual hepatocytes can be easily identified without using contrast agents.
Nevertheless, images from the control animal exhibited negligible fluorescence signal
(data not shown).
As shown in Figure 9.7A and B, a clear granular distribution of Amphinex in untreated
liver was observed, whereas Amphinex appeared to be diffuse in light-treated livers
(Figure 9.7C and D). Under higher magnifications, it is clearer that the granular
distribution of Amphinex in liver is well distributed in the cytosol (Figure 9.8A and B).
Although the detection depth is unknown, the detectable distance was about 50 μm
which covers more than 2 layers of cells.253
Figure 9.7 Ex vivo confocal images of Amphinex in fresh Wistar rat liver without or
with illumination. Animals were sensitised with 2.5 mg/kg Amphinex for 24 hrs. A and
B: liver samples without light treatment. C and D: liver samples after light treatment
using a 652 nm laser with a dose of 10J (laser power: 50mW; irradiation time: 200 sec).
Liver samples were placed on the FluoroDish (WPI, UK) and imagined using a 543 nm
laser.
Figure 9.8 Ex vivo confocal images of Amphinex in fresh Wistar rat liver under higher
magnifications without light. Animals were sensitised with 2.5 mg/kg Amphinex for 24
hrs. Liver samples were placed on the FluoroDish (WPI, UK) and imaged using a 543
nm laser. A: zoom in 2x. B: zoom in 4x. Scale bars: 20 μm.254
9.3.3 Immunohistochemistry of saporin distribution in liver before and after
Amphinex PCI
To observe the distribution of saporin and the redistribution after illumination in liver,
saporin was stained by immunohistochemistry and the images were scanned using NDP
microscopy. The results are shown in Figure 9.9; saporin was observed to be mainly
localised in the kupffer cells (resident macrophages of the liver, the inset white arrows
in Figure 9.9A) throughout the whole liver section. The granular pattern in the cytosol
suggests that the intracellular localisation of saporin is in the endocytotic vesicles. In the
liver 30min after light exposure, less kupffer cells with granularly distributed saporin
were observed and the relocalisation of saporin can be seen in some cells that their
cytosols were stained with diffused brown colour (the inset red star in Figure 9.9B).
Some debris from lysed cells can be found in the sinusoid space (the inset black arrow
in Figure 9.9B). Most of the hepatocytes appeared to be damaged with some large
vesicles in the cytosol (the inset white arrow in Figure 9.9B).
Figure 9.9 Photochemical-induced redistribution of saporin in Wistar rat liver by
immunohistochemical staining. Animals were sensitised with 0.25 mg/kg Amphinex for
24 hrs. Saporin (250 μg/kg) was injected (i.v.) to rats 1hr before light treatment. A:
Untreated liver. B: Liver examined 30 min after treated with 10J light using a 652 nm
laser. Liver samples then fixed and stained with antibodies against saporin with details
described in the Materials and Methods section.
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9.4 Discussion
The results of the histological examination in this section show that necrosis can be
detected 4hr after Amphinex PDT or PCI in combination with saporin or bleomycin in
the MC28 rat sarcoma tumour model (Figure 9.3A-5A). This is consistent with the
results shown in Chapter 8 in which tumours were sampled 24hr after light treatment
(Figure 8.15-17). The experiment here further proved that apoptosis can be induced by
Amphinex PDT and PCI. It should be noted that the sampling time point of the study
here was earlier than the study in the previous section. The reason for this is that early
PDT-induced apoptosis (within 24hr) was reported by many groups using different
photosensitisers and tumour models [Fantini et al., 2008;Frank et al., 2003;Jalili et al.,
2004]. Because this is the first study to examine apoptosis induced by PCI, a separate
experiment where tumour-treated with Amphinex PDT or PCI was collected 4 hr after
light exposure for TUNEL assay analysis.
Although apoptosis was detected in either Amphinex PDT or PCI of saporin and
bleomycin, the distribution of apoptotic cells was observed to be different. In all cases,
tumour cells in the necrotic area mainly die necrotically but with some apoptotic cells
scattered (Figure 9.4c2, and 5b). However, the cells in the area adjacent to necrosis
appeared to be different between these three treatments after TUNEL assay. The
number of apoptotic cells in this region after PDT (Figure 9.3b) was higher than the one
after PCI of saporin treatment (Figure 9.4c1). Few apoptotic cells can be seen in the
tumour treated with PCI in combination with bleomycin (Figure 9.5c). Moreover, in the
case of Amphinex PDT-treated tumour, the tumour cells in the area near muscle layer or
already infiltrated into muscle were found to be apoptotic as well which was not
observed in the tumours treated with Amphinex PCI in combination of saporin or
bleomycin.
There is another interesting finding shown in Figure 9.3b that the endothelial cells of the
blood vessels remain non-apoptotic while most of the surrounding tumours were stained
TUNEL positive. There might be a selectivity of the photochemical effects on the
tumour cells and the vasculature or a different mechanism for the endothelial cells in
response to Amphinex PDT which needs further investigations.256
The results of the Amphinex PDT and PCI treated livers show no differences after
TUNEL assay analysis (Figure 9.6). Within the same liver, some cells in the treated area
were stained TUNEL positive but some appeared to be negative. This was observed in
all liver samples treated with either Amphinex PDT or PCI. A possible explanation is
the time point of sample collection. The liver samples were the ones used for the studies
in Chapter 7 for investigating the treatment efficacy which were sampled 3 days after
illumination. It is possible that the same final outcomes maybe be obtained although
cells actually die through different pathways.
As described in Chapter 1, PDT can induce necrotic and/or apoptotic cell death, which
is likely to be dependent on the treatment dose (drugs and light). For PCI, the principal
therapeutic effect may come from the employed anti-cancer drugs. The primary toxicity
of saporin is due to the inhibition of protein synthesis, but it was also reported that
apoptosis was observed from the cells treated with many ribosome-inactivating proteins,
as well as antibody-conjugated saporin [Bolognesi et al., 2000;Narayanan et al., 2005].
Likewise, bleomycin mainly causes DNA breakage but cells were also found to die by
apoptosis when using high drug concentrations [Tounekti et al., 2001]. In this regard,
apoptosis is a reasonable assumption of the treatment response of Amphinex PDT/PCI.
The histological and the TUNEL assay results together indicate both necrosis and
apoptosis can be induced in Amphinex PDT- and PCI- treated rat liver and tumour.
However, TUNEL assay is a method to detect fragmented DNA, a common outcome of
all the apoptosis pathways, so that it is not specific; the results based on the microscopic
examination are not quantitative. As apoptosis is a dynamic process, further studies
choosing different end points are important to monitor the changes during this
biological process. Also, because several pathways are involved in apoptosis and the
enzymatic steps employed are different (see Figure 1.4), examining the participation of
different enzymes will be useful to determine the exact mechanisms undertaken in
response to Amphinex PDT and PCI treatments.
The later two sections were aimed to observe in vivo PCI actions using ex vivo
experiments: to observe the distribution of photosensitisers and the relocalisation of
both photosensitisers and the employed anti-cancer drugs in tissues. Because
photosensitisers are fluorescent, confocal microscopy was used to image Amphinex in
liver (the organ with the highest drug uptake) at high resolution. For detecting the257
redistribution of employed macromolecules, saporin was chosen as the target because
proteins can be approached easily by immunostaining method in use of their antibodies.
Confocal laser laparoscopy and near-infrared reflectance confocal microscopy have
been used for diagnosis purpose using normal and abnormal liver samples ex vivo and in
vivo [Campo-Ruiz et al., 2005;Goetz et al., 2008b]. The results in section 9.2
demonstrate for the first time the use of confocal microscopic imaging technique to
visualise the distribution and the redistribution of photosensitiser in intact tissue ex vivo.
Through the intact surface of liver, confocal microscopy imaging of freshly excised
livers allowed a clear observation of the liver architecture with the presentation of
parenchyma and vascular structure. Detailed cellular information such as individual
hepatocytes and their nuclei were also visualised without the use of contrast agents
(Figure 9.7A and B). The granular distribution of Amphinex was depicted, indicating
that using confocal microscopy to observe the intracellular distribution of
photosensitiser in tissues is feasible (Figure 9.7AB and Figure 9.8). Moreover, the
distinct difference in the distribution of Amphinex before and after illumination also
implies that a further use of confocal laser endomicroscopy may be a feasible technique
for in vivo observation of photosensitisers. This is particularly beneficial to PCI
mechanism studies where the redistribution of photosensitisers can therefore be
monitored real time in vivo.
Using immunohistochemistry (IHC), the present study continued the previous work
[Woodhams et al., 2009] and demonstrated the relocalisation of saporin in liver after
Amphinex PCI treatment (Figure 9.9). Attempts have been made to detect the changes
of saporin distribution in MC28 tumours after illumination using the same method but
the results were not convincing (data not shown). It may be because the staining
protocols have to be adjusted when applied to different tissues. The successful detection
of the distribution of saporin in kidney (data not shown) gives another implication that
the uptake of saporin in tumour may be never high enough for IHC staining since
kidney and liver are known as the two organs with higher type I RIPs accumulation
[Battelli, 2004]. It is also possible that the time point chosen for examination (4 hrs after
irradiation, in this case) was not appropriate. Since the relocalisation of saporin in rat
liver was observed using the liver sampled 30min after exposure to light, experiments
choosing earlier sampling time points should be considered for future studies.258
Together with the presented studies, other experiments also have been attempted for the
aims of this chapter but with less success. In the experiment using the
immunofluorescence (IF) staining method (using fluorescence labelled second
antibodies) to detect saporin in liver, it was found that the resolution was insufficient to
draw conclusions. In general, owing to the specific detection wavelength used, IF
staining should give better specificity than IHC method. However, optimal staining
protocols and the imaging setup were difficult to establish using either frozen or
paraffin embedded liver sections. Therefore, satisfactory results were not obtained.
To summarise, the studies of this chapter have attempted to approach the in vivo
mechanism of PCI. Using TUNEL assay, the results show that apoptosis can be induced
by Amphinex PDT and PCI where cells with fragmented DNA were observed in treated
liver and tumour samples. The distribution and relocalisation of Amphinex and saporin
in liver before and after PCI were demonstrated using confocal microscopy and
immunohistochemistry respectively. Further studies are required to understand the in
vivo PCI mechanisms in details which will provide relevant information for clinical
applications.259
Section D: Discussion260
General Discussion
Photochemical internalisation is attracting interest as a novel technology for improving
macromolecular drug delivery to cells. It is a technique based on photodynamic therapy
but in combination with membrane-associated photochemical reactions that enable site-
specific light-induced drug delivery. Amphinex, a disulfonated chlorin (TPCS2a), is a
new photosensitiser designed for PCI. Investigations of the PCI effects using Amphinex
in combination with saporin or bleomycin, two anti-cancer agents, were carried out in
vitro and in vivo in this thesis. Using bioconjugates for their uses for PDT and PCI was
studied in a separate chapter. Below is the general discussion of the studies in this thesis.
PCI with Amphinex vs TPPS2a and AlPcS2a in vitro and in vivo
Because TPPS2a and AlPcS2a are the most common photosensitisers for PCI, in vitro
studies of Amphinex were compared to the results using these two sensitisers. It was
found that Amphinex displayed the same efficient and concentration-dependent cellular
uptake as TPPS2a. In combination with saporin or bleomycin, enhanced cytotoxicity was
found after PCI using these three photosensitisers in either A431 or HN5 cells although
the synergistic killing effect was not obvious using bleomycin. For instance, Amphinex
PCI of saporin induced the greatest cell kill by a factor of 29 compared to saporin alone
in HN5 cells, whereas the cell viability only reduced by a factor of 3 compared to
bleomycin alone.
For in vivo studies, the treatment efficacy of Amphinex PCI was investigated by
measuring the extent of necrotic lesions induced in normal rat liver/colon and
transplantable sarcoma tumour models. Although PCI treatments on normal tissues were
designed to look at the influence of different treatment parameters (e.g. the dose of
saporin/bleomycin and their administration time points) and the comparison of
treatment responses between these two anti-cancer drugs in two tissues, the results also
point out another important fact that Amphinex PCI in combination with bleomycin
induced significantly larger necrotic lesions compared to PDT alone in both liver and
colon. Using certain concentrations of bleomycin, the increased size of lesions was
comparable to PCI of saporin. The results of treatments on tumours are consistent with
the ones on normal tissues that Amphinex PCI of bleomycin can induce analogous
enhancement in tumour destruction to the treatment using saporin.261
Altogether, Amphinex PCI in combination with bleomycin seems to induce more
pronounced cytotoxicity in vivo than in vitro. Similar findings were reported by Berg et
al. (personal communication). The well-known selective toxicity of bleomycin towards
different cells, different tumours and organs may explain this, since bleomycin causes
DNA damage through multiple mechanisms and the consequent cellular response and
repair pathways vary between cells as well [Chen and Stubbe, 2005].
Treatment responses of Amphinex PDT and PCI in vivo: normal vs tumour tissues
The pharmacokinetics of Amphinex in Wistar rats and the drug accumulation between
normal and tumour tissues of Hooded Lister rats at the time of light delivery was
studied in Chapter 6 and 8. The selectivity of Amphinex in terms of the response to its
treatments in normal and tumour tissues can also be examined by comparing the depth
of necrosis induced after treatments, although two tissues were derived from different
animals. Figure D.1 shows a comparison of the depth of necrosis induced in rat liver
and transplanted MC28 tumours between PDT and PCI treatment. The measurement
was based on the H&E stained tissue sections and the data presented here was collected
from the same sections used for other measurements described in the chapters.
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Figure D.1 Mean depth of necrosis induced after Amphinex PDT and PCI treatments in
normal rat liver and transplanted MC28 tumours. PDT treatment: 0.25 mg/kg Amphinex,
652nm laser 10J (50mW x 200s), 24hrs drug light interval. Saporin (250 μg/kg) was
administered (i.v.) 1h before light; bleomycin (30 IU/kg) was administed (i.v.) 30min
before light. (*1: p < 0.01; *2: p = 0.02)262
The depth of necrosis in tissues induced after treatment is an indicator of treatment
efficacy and deeper necrosis would certainly benefit the treatment of large tumours. As
shown in Figure D.1, tumour tissues are more susceptible to Amphinex PDT and PCI
treatments in which deeper necrosis on average was measured compared to the value for
liver. This might be due the different optical properties between tissues since more light
will be absorbed by liver rather than tumour and results in shorter light penetration
depth in treatments in liver. The variation of the necrosis depth in tumour was found to
be larger than in liver which was due to the difficulty in the measurement as the necrotic
lesions were often observed to be irregular as described in Chapter 8.
In comparison between PDT and PCI treatments, significant enhancements in the depth
of necrotic lesions were only observed in PCI of saporin in liver and PCI of bleomycin
in tumour. This may be due to the amount of anti-cancer agents in these two tissues that
saporin accumulates more in liver than tumour and bleomycin displays the opposite
biodistribution. It should also be noted that the treatment on liver was optimised after
varying several treatment parameters whereas the protocols for tumour treatments were
adopted from the above. In other words, it is possible that the mean depth of necrosis in
tumour after Amphinex PDT or PCI can be larger than the present results under optimal
treatment conditions. Nevertheless, the enhancement by PCI would reduce the required
PDT dose to achieve the same therapeutic effect which is indeed the original concept of
PCI treatment.
Clinically, the important selectivity is the difference of the drug uptake and/or the
treatment responses between tumour and the tissue of origin of the tumour. Using
models such as hamster cheek pouch tumour model can provide a more suitable
platform for a direct comparison.
Amphinex vs m-THPC PDT
m-THPC is a clinical approved photosensitiser which is one of the most powerful
sensitisers used for PDT. The similarities in the optical characteristics (e.g. strong
absorption at 649 nm) of Amphinex and m-THPC, as well as their singlet oxygen
quantum yields [Mojzisova et al., 2009], indicate the potential of Amphinex being an
effective photosensitising agent. Studies of PDT using m-THPC in normal rat colon and
MC28 tumours have been published from our laboratory [Tsutsui et al., 2002]. The laser
powers used in the previous study were 20 mW and 100mW for treatment in colon and263
were 5 mW and 100mW in the cases of tumour treatments which are different from
present study (50 mW), but information still can be obtained from the value in between.
Other treatment parameters such as the light dose (10 J), the light source (a 652 nm laser)
and the drug-light-interval (24 hr) were the same, and the dose of photosensitiser were
also similar (0.3 mg/kg for m-THPC and 0.25 mg/kg for Amphinex). The results in the
previous study showed that the mean diameter of necrosis in colon induced by m-THPC
PDT was less than 4 mm which is similar to the results in present study (Figure 8.9).
However, PDT using m-THPC can induce necrosis in tumour about 4-6 mm in depth
which was deeper than the treatment response of Amphinex PDT (Figure D.1). In this
regard, m-THPC PDT is more effective in inducing damage to tumour.
Mechanistic studies and treatment monitoring
According to the results of histological examination and TUNEL assay on liver and
tumour samples, both necrosis and apoptosis can be induced by Amphinex PDT and
PCI. The distribution of Amphinex and the relocalisation of Amphinex and saporin
were imaged by ex vivo confocal microscopy and immunohistochemistry.
The results together point out the importance of timing for mechanistic studies since the
light-induced drug delivery process and consequent treatment responses are dynamic.
Different photosensitisers, drugs and target tissues employed may lead to distinct results.
The gathered information from different time points will be useful for the understanding
of treatments and beneficial to treatment optimisation.
Light delivery
The light delivery system in the in vivo experiments in this thesis was using a laser with
a bare tip fibre. Light treatments were carried out by perpendicularly placing the fibre
against the surface of liver/colon or inserting the fibre just into the top of tumours. By
using a point source of light on the tissue, measurement of the macroscopic dimensions
of the zone of necrosis produced is a convenient way of comparing the effect of
different treatment parameters, a technique we have used successfully for many years in
a range of organs. One advantage of this technique is that all the light from the fibre is
delivered directly into the tissue, like the system used for interstitial PDT treatment in
clinic, whereas using external illumination results in reflection losses. The difference in
the light delivery may be the reason for the diverse histological results between the
tumours treated with Amphinex PDT in this study and the tumours treated with AlPcS2a264
PDT from another group [Norum et al., 2009a]. In their study, a rim of viable tumour
cells was observed to be on the top of the subcutaneous tumour 5 days after treatment.
Although the samples in our study were collected 24 hrs after light delivery, a more
light-dependent distribution of necrosis was found to be from the top to the centre of
tumours.265
Conclusions and Future Work
This thesis is a study of photochemical internalisation and aimed to investigate the PCI
effects induced by a new photosensitiser, Amphinex, in combination with two anti-
cancer agents, saporin and bleomycin, both in vitro and in vivo.
Prior to the introduction to cells, the photophysical properties of Amphinex were
examined and the results show that Amphinex has favourable photophysical properties
as an efficient photosensitiser including the strong absorption in red region and
photostable (less photobleaching). In combination with saporin, Amphinex PCI
displayed a synergistic inhibition of cell growth with two cell lines, and an increased
cytotoxicity was also measured in combination with bleomycin.
In the in vivo studies, pharmacokinetic studies using quantitative fluorescence
microscopy showed highest-uptake of Amphinex in liver at 6hrs after drug
administration. The amounts in other organs were lower and a clear decrease was
observed in skin up to 8 days after injection. In addition, considerable drug
concentration ratios of tumour to normal tissues (e.g. skin and muscle) were measured
at 24hr after administration, which indicate the selectivity of Amphinex in normal and
tumour tissues. Significant enhancement in inducing the necrosis was observed by
Amphinex PCI compared to PDT treatment on normal rat liver/colon and transplanted
sarcoma models.
In Chapter 9, experiments focused on looking at several in vivo Amphinex PCI
mechanisms. The PCI effect, the redistribution of Amphinex and saporin after
illumination was observed in liver. In addition, similar treatment responses (i.e. necrosis
and apoptosis) were found between Amphinex PDT and PCI.
Bioconjugation was also applied to PCI strategy in this thesis in which a bioconjugate
Tat-TPP (a cell penetrating peptide, Tat peptide conjugated with tetraphenylporphine)
and an AlPcS2a-saporin conjugate were synthesized. In the former study, unlike non-
water soluble TPP, the Tat-TPP conjugate became bioavailable and amphiphilic. The
results show that the Tat-TPP conjugate exhibited a high cellular accumulation and
lysosomal localisation, resulting in synergistic cell kill effects in combination with266
saporin in HN5 cells upon irradiation. In the later study, the AlPcS2a-saporin conjugate
was designed to combine the photosensitiser and the delivered macromolecule. The
conjugate demonstrate a comparable PCI effect, inducing a similar cytotoxicity to the
results using unconjugated AlPcS2a and saporin in HN5 cells after exposure to light.
The overall results in this thesis have established that Amphinex is an efficient
photosensitiser for PCI. The consistency between in vitro and in vivo experiments
indicates that Amphinex has the potential for clinical utilization by enhancing the
delivery of co-administered anti-caner drugs.
The first clinical trial of Amphinex PCI of bleomycin is currently being undertaken for
head and neck cancers in University College London Hospital. The preliminary results
from the first few patients are encouraging. A short description is given in Appendix II.
Like PDT, the key advantage of PCI is the site specificity due to the light-dependent
activation of photosensitisers which are co-administered with the macromolecule. The
photochemical effect therefore only takes place in areas under light exposure. With this
localized treatment effect and the use of sub-lethal PDT dose, PCI should result in lower
side-effects.
Future work is firstly aimed to optimise the treatment parameters (i.e. the lowest drug
and light dose enables the maximum therapeutic efficacy) under the safety guidelines
obtained from the current trial. Different illumination regimes (i.e. light fractionation
and low fluence rate) may provide options for enhancing the therapeutic effect of
Amphinex PCI since these strategies are beneficial to PDT with ALA and m-THPC
[Curnow et al., 1999;de Haas et al., 2008;Robinson et al., 1998;Tsutsui et al., 2002].
Studies on the skin phototoxicity of Amphinex PCI are also essential. Although the
pharmacokinetics results in this thesis showed a clear decrease of Amphinex level in rat
skin up to 8 days after administration, skin photosensitivity may be minimal but needs
further solid investigation. Other experiments such as using confocal endomicroscopy to
monitor PCI in real time in vivo and further investigations of the cell death in response
to treatment can be of benefit to the understanding of Amphinex PCI.267
The combination with targeted drugs such as immunotoxins is another future study of
interest which could enhance treatment selectivity. A recently published study
demonstrated the use of a fusion toxin for PCI which was composed of gelonin and a
recombinant single-chain antibody against a marker protein associated with a large
number of cancer cells [Selbo et al., 2009]. This construct was able to inhibit tumour
growth significantly. The results indicated the potential using targeted anti-cancer drugs
for PCI application in vivo in which improved therapeutic efficacy can be achieved by
increasing the specificity of drug uptake to target tissues.268
Appendix I
The synthesis of conjugates of Tat-TPP and AlPcS2a-saporin
 Tat-TPP Conjugate
General Remarks
This work was carried out at the department of Pharmacy and Pharmacology, University
of Bath. Chemical reagents were purchased from Sigma-Aldrich, Fluka, Acros,
Lancaster and Novabiochem. All other solvents were purchased from Fisher Scientific
and used as received. Peptide grade dimethylformamide was purchased from Rathburn
Chemicals Ltd. Preparative RP-HPLC was performed on a Dionex HPLC system
consisting of an Ultimate 3000 WPS autosampler, a P680 preparative pump (HPG), a
UVD 170U multiwavelength detector, and a Foxy Jr fraction collector. The
purifications were performed on a Phenomenex Gemini 5 μm C-18 (250 x 30 mm)
column with a flow rate of 22.5 mL/min. Mobile phase A was 0.1% TFA in water,
mobile phase B was 0.1% TFA in acetonitrile. High resolution mass spectrometry was
performed using a Bruker MicroTOF autospec ESI mass spectrometer.
Synthesis
Porphyrin 1[Sibrian-Vazquez et al., 2007] was prepared from 2 by acylation with
maleimidopropionic acid (F. Giuntini and I. M. Eggleston, unpublished). The peptide
sequence GRKKRRGRRRGYKC was assembled on an Activo P11 automated peptide
synthesizer (Activotec, Cambridge, UK) on a 0.32 mmol scale on Rink Amide MBHA
resin (Novabiochem), according to Fmoc-SPPS strategy. The resin was loaded using a
5-fold excess of Fmoc-protected aminoacid, using HOBt/DIC as the activating agents (5
cycles). The chain-elongation couplings were performed using a 3-fold excess of the
protected amino acid, using PyBOP as the activating agent (double coupling).
Deprotections were accomplished by washing the resin with 20% piperidine in DMF (3
x 3 min). Cleavage from the resin and deprotection was performed by treatment with
TFA/water/TIS/EDT (94/2.5/2.5/1 volume ratio) during 3 hours. The peptide was
purified by semi-preparative RP-HPLC (mobile phase A: 0.1% aq TFA, mobile phase B:
0.1% TFA in MeCN). Conjugate 3 was obtained as follows: 5 mg of peptide were
dissolved in DMSO (200 L), and the resulting solution was added to a solution of 2 (6
mg) in DMSO (200 L), containing pyridine (3 L). The mixture was shielded from
light, and was allowed to stand overnight at room temperature. The mixture was then269
partitioned between ethyl acetate and deionised 0.1% aq TFA. The aqueous layer was
evaporated to a small volume, and applied to a Discovery DSC-18 solid phase
extraction cartridge (Supelco). The desired compound was eluted with (5% MeCN-
0.1% aq TFA) mobile phase: and lyophilised to give 9 mg of 3, which was characterised
by high resolution mass spectrometry.
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Abbreviations:
DIC: diisopropyl carbodiimide
DMF: dimethylformamide
DMSO: dimethylsulfoxide
EDT: ethanedithiol
HOBt: 1-hydroxybenzotriazole
PyBOP: benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
PyBrOP: Bromo-tris-pyrrolidino phosphoniumhexafluorophosphate
SPE: solid phase extraction
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 AlPcS2a-saporin Conjugate
Materials and Methods
The materials utilized in the conjugation methods were purchased from Sigma-Aldrich
(Sigma-Aldrich, UK) otherwise stated: N-succinimidyl 3-(2-pyridyldithio) propionate
(SPDP) reagent, dimethylsulfoxide (DMSO), Phosphate buffered saline with EDTA
(PBS-EDTA): 100 mM sodium phosphate, 150 mM NaCl, 1 mM EDTA, 0.02%,
sodium azide, pH 7.5. Dithiothreitol (DTT), Desalting column (Zeba™ Desalt Spin
Columns). Dialysis tubing (Tubing Specta/Por Biotech dialysis membrane,
Fisherscientific) 500 molecular weight cut off (MWCO). Sephadex G-50 Fine GE
Healthcare. This work was carried out at School of Biological Science, University of
Essex.
Synthesis of AlPcS2a-SPDP linker (1-4)
AlPcS2a 1 (50mg, 63.6 µM) was dissolved in thionyl chloride (5 ml); the mixture was
refluxed for 8 h. The excess of thionyl chloride was evaporated under vacuum and the
residue was washed with dichloromethane (DCM) several times, and then evaporated to
obtain pure dichlorosulfonyl phthalocyanine 2. β-Alanine hydrazine (32 mg, 159 µM)
was dissolved in dimethylformamide (DMF, 5 ml) under Argon. AlPcS2a dichloride,
Compound 2 was dissolved in 5 ml of DMF and added to the above solution. The
mixture was heated to 50ºC and stirred for 12 h. The excess of solvent was evaporated
under high vacuum to dryness, and the residue was dissolved in DCM and washed with
water. The organic layer was dried with MgCl2 and then the solvent was evaporated.
The residue was purified on silica gel using 20% methanol and DCM, the layer of
Phthalocyanin-alanin 3 with Rf 0.2 was collected. Compound 3 was dissolved in DCM
10 ml under Argon and 1 ml of trifluoroacetic acid (TFA) was added to remove BOC
group. The mixture was stirred for 2h, and then solvents were evaporated in vacuum.
Compound 5
SPDP Reagent (20 mM solution) was prepared in DMSO (2 mg reagent in 320 μl of
DMSO). SPDP solution (25 μl of the 20 mM) was added to 2-5 mg of AlPcS2a dissolved
in 1.0 ml of PBS-EDTA. The reaction mixture was incubated overnight at room
temperature. SPDP-AlPcS2a-ß-alanine was dialyzed in 2L of ultrapure water using
dialysis membrane 500 MWCO to remove byproducts and excess non-reacted SPDP
reagent. DTT (23 mg) was dissolved in 1 ml PBS-EDTA. DTT solution and was added271
0.5 ml per 1 ml of SPDP-AlPcS2a (results in 50 mM DTT) to reduce the disulfide bridge
and prepare sulfhydryl terminal group for conjugating with saporin. The solution was
kept stirring overnight, then dialyzed again using 500 MWCO dialysis membranes for
one day.
Compound 6
The above procedure for solution A was repeated using saporin instead of AlPcS2a
without reducing the disulfide bridge of SPDP linker. The reaction mixture was kept
stirring gently overnight at 4ºC. The solution of saporin was eluted on desalting column,
which was previously equilibrated with PBS-EDTA, to remove the DTT. Solution A
(AlPcS2a-SPDP) with free sulfhydryl terminal was stirred with solution B (saporin-
SPDP) in (20mM PBS-EDTA at pH 7.5) over for 18 h at 4C. The reaction mixture was
dialyzed in 2L of pure water for 6h at 4C. The AlPcS2a-saporin was purified on
Sephadex and eluted with PBS. The first band, which contains AlPcS2a-saporin was
collected.
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Appendix II PCI “First in man”
Based at least partly on the results described in this thesis, the first trial of PCI in man
has recently started in University College London Hospital. The first patient was a 56
year old man with a chondroblasticosteosarcoma of the jaw which had failed to respond
satisfactorily to surgery, radiotherapy and chemotherapy. No further conventional
treatments were possible for him. The tumour had destroyed much of the right side of
the face and a metal plate had been inserted to close the hole between the mouth and the
skin, caused by the cancer. The prominent nodule at the front of the cancer, marked
with an arrow in Figure 1 (shown on day 0, the day Amphinex was given) was chosen
as the “target” lesion for PCI as it was the easiest area to document the extent of the
PDT effect. Four days later, bleomycin was given, followed 3 hours after this by light
delivery to the entire tumour surface. Darkening of the target lesion was seen almost as
soon as light delivery was completed. Changes to the less vascular parts of the tumour
back as far as the ear were less obvious at this stage (Figure 2). By 7 days (Figure 3),
changes were apparent over the whole tumour area and by day 14 (Figure 4) the target
lesion was black and completely necrotic with considerable loss of volume. Some other
parts of the tumour had also sloughed. The metal plate, previously hidden by tumour,
had become partly visible (arrow inset).
Figure Chondroblasticosteosarcoma of jaw. (1) Day 0, administration of Amphinex, (2)
Day 4 Immediately after light delivery, (3) Day 7, 3days after light delivery, (4) Day 14,
10 days after light delivery.274
Although the patient had moderate pain in the first 24 hours after treatment, this soon
settled. Tests of skin sensitivity to simulated sunlight showed no evidence of any effect.
As a “first in man” procedure, the treatment conditions had been chosen to be gentle, so
it was a surprise to see such a dramatic and beneficial effect on the tumour with
minimal effect on normal skin. This trial is on-going, but augurs well for the future of
PCI as a clinical therapy.
I thank Dr Waseem Jerjes and Mr Colin Hopper from the Department of Oral &
Maxillo-Facial Surgery, UCH, for permission to include this brief report in my thesis.275
Appendix III Conference Presentations
13
th Congress of the European Society of Photobiology, Wroclaw, Poland
(September 5
th-10
th ,2009)
 Tzu-wen (Julie) Wang, Alexander J. MacRobert, Kristian Berg, Anders
Høgset, Stephen G. Bown. Photodynamic therapy and photochemical
internalisation on a transplanted rat fibrosarcoma using TPCS2a (Oral
presentation)
12
th World Congress of the International Photodynamic Association, Seattle, USA
(June 11
th-15
th, 2009)
 Tzu-wen (Julie) Wang, Josephine Woodhams, Alexander J. MacRobert,
Kristian Berg, Anders Høgset, Stephen G. Bown. Investigation of PDT and
photochemical internalisation using a sulfonated chlorin TPCS2a
photosensitiser in combination with anti-cancer drugs in vivo (Oral
presentation)
 Tzu-wen (Julie) Wang, Francesca Giuntini, Ian M. Eggleston, Stephen G.
Bown, Alexander J. MacRobert. Investigation of a Tat peptide-
photosensitiser bioconjugate for photodynamic therapy and photochemical
internalisation. (Oral presentation)
1
st Scientific Meeting of Head and Neck Optical Diagnosis Society, London, UK
(March 14
th, 2009)
 Tzu-wen (Julie) Wang, Alexander J. MacRobert, Stephen G. Bown.
Investigation of photochemical internalisation in HN5 head and neck
carcinoma cells and in an in vivo rat model. (Poster presentation)
7
th International Symposium on Photodynamic Therapy and Photodiagnosis in
Clinical Practice, Brixen, Italy (October 7
th-11
th, 2008)
 Tzu-wen (Julie) Wang, Alexander J. MacRobert, Stephen G. Bown.
Investigation of the effect of TPCS2a PCI in combination with saporin in
vitro and in vivo. (Poster presentation)276
12
th Congress of the European Society of Photobiology, Bath, UK (September 1
st-
6
th,2007)
 Tzu-wen (Julie) Wang, Stephen G. Bown, Alexander J. MacRobert.
Photochemical internalisation can enhance the cytotoxicity of bleomycin
and saporin in the A431 cell line. (Oral presentation)
11
th World Congress of the International Photodynamic Association, Shanghai,
China (March 28
th-31
rd, 2007)
 Tzu-wen (Julie) Wang, Kristian Berg, Stephen G. Bown, Alexander. J
MacRobert. Enhanced cytotoxicity of bleomycin and saporin in the A431
cell line using photochemical internalisation (PCI) (Oral presentation)
Tetrapyrrole Disscussion Group Meeting, London, UK (January 5
th 2007)
 Tzu-wen (Julie) Wang, Stephen G. Bown, Alexander J. MacRobert.
Enhanced cytotoxicity of bleomycin and saporin using photochemical
internalization with a phthalocyanine sensitiser. (Poster presentation)277
Appendix IV Publications
Papers have been submitted:
 Julie T-W Wang, Francesca Giuntini, Ian M. Eggleston, Stephen G. Bown, Alexander
J. MacRobert. Investigation of a Tat peptide-photosensitiser bioconjugate for
Photodynamic therapy and photochemical internalisation.
Articles currently being prepared for submission:
 Julie T-W Wang, Alexander J. MacRobert, Stephen G. Bown, Kristian Berg. Review
of PCI. The 3rd issue of the CRC Handbook of Organic Photochemistry and
Photobiology.
 Julie T-W Wang, Anders Høgset, Kristian Berg, Stephen G. Bown, Alexander. J
MacRobert. Investigation of the effect of PCI using a sulfonated chlorin
photosensitiser Amphinex in combination with saporin in vitro.
 Julie T-W Wang, Kristian Berg, Anders Høgset, Alexander J. MacRobert, Stephen G.
Bown. Investigation of PDT and photochemical internalisation using a sulfonated
chlorin photosensitiser Amphinex in combination with anti-cancer drugs in vivo.
 Julie T-W Wang, Kristian Berg, Anders Høgset, Alexander J. MacRobert, Stephen G.
Bown. Photodynamic therapy and photochemical internalisation on a transplanted rat
fibrosarcoma using a sulfonated chlorin photosensitiser Amphinex.278
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